Title (News Shots) ,ID,Date
Celyad Announces Successful Dosing of CYAD-01 IV in P-I THINK Trial for the Treatment of mCRC,578,05-09-2018
Dynavax Reports Preclinical Study Publication of TLR9 Agonist for Treatment of Lung Cancer,579,05-09-2018
Janssen Files NDA for Esketamine Nasal Spray to the US for treatment-resistant depression,580,05-09-2018
Merck's Keytruda sBLA Receives FDA Priority Review for Treatment of Locally Advance or mMCC,581,04-09-2018
Redx Pharma Receives MHRA's Positive Response for Restarting its P-I/IIa RXC004 study,582,04-09-2018
"NMPA, China Accepts NDA for BeiGene &amp; Boehringer BioChina's Tislelizumab for the treatment of r/r cHL",583,04-09-2018
NovellusDx collaborates with Primetech as an Exclusive Supplier in Japan,584,04-09-2018
Sanofi's Cablivi Receives EU Marketing Approval for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP),585,03-09-2018
Group of Dutch Doctors &amp; Advocates Stand up Against Leadiant Biosciences' 500 Times Drug Price Rise,586,03-09-2018
Novartis Plans to Align its Production with Expected Lower Prices in the US,588,03-09-2018
Pfizer Terminates Domagrozumab trial for the treatment of Duchenne muscular dystrophy,589,31-08-2018
MedImmune (AZ) reports results of TULIP 1 P-III for anifrolumab in systemic lupus erythematosus,590,31-08-2018
FDA Reports Newly Added Guidelines for Drug and Device Makers,591,31-08-2018
Vertex and Genomics plc forms a three-year collaboration extendable up to five years for Precision Medicines,592,31-08-2018
BMS's Sprycel (dasatinib) sBLA Receives Positive Response from the US FDA,593,30-08-2018
AstraZeneca's Bydureon BCise Receives EU approval Once-Weekly Prefilled Syringe for Type2 Diabetes,594,30-08-2018
Roche's Hemlibra P-III Positive results for Haemophilia A without factor VIII being published in NEJM,595,30-08-2018
"Amgen's BLINCYTO (blinatumomab, BiTE) Receives EU Expanded approval for pediatric 2L+ B-cell-ALL",596,30-08-2018
Xenon Pharmaceutical Reports Positive Results of XEN1101 P-1b TMS (transcranial magnetic stimulation) study,597,29-08-2018
Emergent BioSolutions to Acquire Adapt Pharma with Narcan (naloxone HCl) Nasal Spray,598,29-08-2018
Alcon Announces Global Removal of CyPass Micro-Stent for Surgical Glaucoma,599,29-08-2018
"NICE, UK Rejects Gilead's Yescarta for Being Too Expensive",600,29-08-2018
Biogen and Eisai Reports Results of Long-Term Extension P-Ib study for aducanumab,601,28-08-2018
Affimed Formed a Research Collaboration with Genentech for Novel NK Cells,602,28-08-2018
Pfizer Announces Tafamidis P-III Transthyretin Cardiomyopathy (ATTR-ACT) study results,603,28-08-2018
AbbVie Receives US FDA Approval for Imbruvica plus Rituximab for the treatment of WaldenstrÃ¶m's macroglobulinemia (WM),604,28-08-2018
Novartis's Kymriah Receives EU Approval,605,27-08-2018
Abbott India Plans to Launch 100 products in next 5 years,606,27-08-2018
Kite's Yescarta Receives EU Marketing Approval,607,27-08-2018
Eisai's and Merck Announces EU's Marketing Approval of Lenvima (lenvatinib mesylate) for Hepatocellular carcinoma,609,25-08-2018
"Novartis's Solar-1 trial BYL719 (PI3Ki, alpelisib) meets primary endpoints in advanced or mBC patients",610,24-08-2018
AstraZeneca announces Results of AERISTO P-IIIb trial for Bevespi Aerosphere in COPD patients,611,24-08-2018
Shire's Takhzyro (lanadelumab-flyo) Receives FDA Approval Novel Hereditary Angioedema (HAE) in Age â‰¥12yrs,612,24-08-2018
Bluebird Bio and Gritstone Oncology signs a Research Collaboration,613,23-08-2018
Pfizer to co-promote Exact Sciences' Cologuard,614,23-08-2018
AbbVie Exercises Exclusive Option to License Argenx's ARGX-115,615,23-08-2018
Pfizer and Astellas Amends Clinical Research Protocols of Xtandi for 2 Phase III to treat Hormone-Sensitive Prostate Cancer (HSPC),616,23-08-2018
Sierra Oncology Acquires Gilead's Momelotinib to Treat Myelofibrosis for ~$198M,617,22-08-2018
"Congo Approves Experimental Ebola Treatments by Gilead, Mapp, Toyama Chemical and Regeneron",618,22-08-2018
Evotec and Novo Nordisk forms collaboration to develop novel small molecule therapies,619,22-08-2018
GSK Looking to Sell its Indian Consumer Health Unit for ~$4B,620,22-08-2018
Kyowa Annouces Ph IIa Results of KW-6356 for Parkinson's Disorder at IAPRD,621,21-08-2018
Bio-Thera Announces BLA Acceptance of Humira's Biosimilar (BAT1406) by China National Drug Administration (CNDA),622,21-08-2018
Harbour Annouces Global Partnership with Kelun-Biotech to Develop and Commercialize A167 (Anti-PD-L1 mAb),623,21-08-2018
Roche's AlecensaÂ® (alectinib) Receives CFDA Priority Review for 1L ALK +ve mNSCLC,624,21-08-2018
"Merck's Keytruda (pembrolizumab) Receives Expanded Label Approval for 1L nonsq. mNSCLC, with No EGFR and ALK Genomic Tumor",625,21-08-2018
Organogenesis Reverse Merges with Avista Healthcare Public Acquisition Corp. (AHPAC),626,20-08-2018
Principia Biopharma files for Initial Public Offering in the US,627,20-08-2018
Bristol-Myers's Opdivo (nivolumab) Receives FDA Priority Review for 2L+ Patients with SCLC in ~20 yrs,628,17-08-2018
Eisai and Merck Annouces the US FDA Approval of Lenvima for Unresectable 1L Hepatocellular Carcinoma (HCC),629,17-08-2018
Nordisk Acquires Ziylo's Glucose Binding Platform to Expand its Glucose Responsive Insulins,630,17-08-2018
Teva Receives US FDA Approval for Generic Version of Epipen Auto-Injector,631,17-08-2018
Pfizer partners with BioNTech to develop vaccine for Influenza for $425M,632,16-08-2018
Depomed changes name to Assertio Therapeutics,633,16-08-2018
Mylan quietly acquired undisclosed WW rights of a product for $463mn in July'18,634,16-08-2018
Inova Diagnostic's HMGCR Antibody detection test Approved by the US FDA,635,14-08-2018
Medtronic Launches Inner Circle Patient Engagement Program using Gamification to Motivate and Engage Diabetic Patients,636,14-08-2018
Mustang Bio Licenses Gene Therapy from St. Jude Children Hospital to treat X-SCID (bubble boy) in newborns,637,14-08-2018
Amicus's Galafold (migalastat) Receives FDA Approval for Treating Fabry Disease after 15 yrs,638,13-08-2018
"FDA Approves Onpattro, a Novel RNAi Therapeutic to Treat Polyneuropathy in Adults",639,13-08-2018
Genentech's Xolair Receives FDA's Breakthrough Therapy Designation for Food Allergies,640,13-08-2018
Astellas Announces Acquisition of Quethera's Ophthalmic Gene Therapy Program,641,13-08-2018
Celltrion's Bevacizumab Biosimilar (CT-P16) Enters into Global Phase III Clinical trial for Treating Colorectal Cancer,642,10-08-2018
JHL Biotech's Trastuzumab Biosimilar (JHL1188) Receives CHMP Positive Scientific Advice to Treat Breast Cancer,643,10-08-2018
Perrigo to Separate its Prescription Pharmaceutical Business,644,09-08-2018
60 Degree Pharma Receives U.S. FDA Approval for ARAKODA (tafenoquine) tablets for Treating Malaria,645,09-08-2018
UCB Partners with MyHealth Teams to boost up Spondyloarthritis social network,646,08-08-2018
FDA approves IV Poteligeo for Treating Two Rare types of Cutaneous T cell lymphoma (CTCL),647,08-08-2018
First Generic approved by FDA using Competitive Generic Pathway (CGT) to Foster Competition for sole source drugs,648,08-08-2018
Ironwood Terminated Rights of Zurampic lesinurad and Duzallo lesinurad/allopurinol Deal with AZ,649,07-08-2018
BioLineRx Annouces Positive Results for Phase 3 GENESIS Trial in Stem-Cell Mobilization,650,07-08-2018
Mallinckrodt forms 5yrs Collaboration with Washington University for Rare Disease,651,07-08-2018
J&amp;J acquired global co-development and Commercialization rights of experimental myeloma gene therapy from a Chinese Start-up Nanjing Legend Biotechnology,652,06-08-2018
Bluebird bio and Regeneron Announce R&amp;D and Commercialization Collaboration for Novel Cancer Immune Cell Therapies,653,06-08-2018
PharmaMar's Lurbinectedin Granted as Orphan drug designation by U.S. FDA for Small Cell Lung Cancer(SCLC),654,03-08-2018
Celltrion's Herzuma (Herceptin biosimilar) Receives Marketing Approval in Australia,655,03-08-2018
CHMP issues positive opinion to expand INVOKANA &amp; VOKANAMET labels to include positive data on cardiovascular(CV) &amp; renal outcomes,656,03-08-2018
Lilly's spinoff Elanco Animal Health files IPO,657,03-08-2018
MYALEPTAÂ® (metreleptin) receives marketing approval by EU for leptin deficiency in lipodystrophy (LD) Patients,658,02-08-2018
Laekna Acquires Exclusive WW Rights of Two Oncology Clinical Stage Candidates from Novartis,659,02-08-2018
Novo Nordisk launches Ozempic DTC campaign for type 2 Diabetes,660,02-08-2018
"Pfizer Receives EU Approval for Xeljanz (tofacitinib citrate, JAK3i) for Moderate to Severe UC Patients",661,01-08-2018
Leo Pharma is acquiring Bayer's dermatology unit with 450 employees,662,01-08-2018
Shionogi's Mulpleta (lusutrombopag) Receives FDA Approval for Chronic Liver Patients in Adults,663,31-07-2018
"Pfizer receives EU approval for Trazimera(Trastuzumab), the First Oncology Biosimilar",664,31-07-2018
Pernix Therapeutics Buys Orexigen's Contrave for $73.5Mn,665,30-07-2018
"Progenies Receives FDA approval of first-and-only Azerda (iobenguane I 131) to treat Unresectable, LA/M Pheochromocytoma/Paraganglioma",666,30-07-2018
Novartis Announces the EU Approval of first-in-class AimovigÂ®ï¸(erenumab) for Migraine Prevention,667,30-07-2018
BioLineRx Annouces Expansion of 2016 Collaboration with Merck&amp;Co. in Immuno-Oncology in pancreatic cancer,668,30-07-2018
Lilly Announces an Extension to 2015 Research Collaboration deal with Dana Farber Cancer Institute,669,30-07-2018
Sun Pharma to Recall 2500 bottles of Riomet from Arizona,670,30-07-2018
ChemBio Annouces the Collaboration with FIND Moving to Development of HCV Point-Of-Care Diagnostic-Test,671,28-07-2018
Imfinzi (durvalumab) Receives Positive CHMP Opinion in EU for PD-L1 expressing LA NSCLC patients,672,27-07-2018
Immunotherapy Keytruda Exceeds Opdivo in Q2 sales,673,27-07-2018
Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India,674,26-07-2018
AstraZeneca Fails to Prove the Drug Selumetinib for Thyroid cancer,675,26-07-2018
GSK Signed a Multiyear Exclusive Collaborative Agreement with 23andMe to use Genetic Databases to Develop Novel Therapies.,676,25-07-2018
J&amp;J India to Pay Compensation of ~$28K per Patient for Faulty Hip Implant,713,05-09-2018
Novartis divests part of Sandoz US Genercis as well as US dermatology business to Aurobindo Pharma for $0.9B,727,06-09-2018
Gilead and Galapagos NV's Filgotinib (JAK1i) Achieves Primary Endpoints for P-II TORTUGA study in AS patients,739,06-09-2018
With Continuous Failure Active Biotech Regains Global Rights for Laquinimod from Teva,790,06-09-2018
Shire Announces Acquisition of Sanaplasma AG to Expand its Immunology business,807,06-09-2018
Pharmacosmos' Monoferric 1000 mg IV Receives Health Canada Marketing Approval,823,07-09-2018
AstraZeneca's Tezepelumab (thymic stromal lymphopoietin antagonist) Receives FDA BT Designation for the Treatment of Severe Asthma with irrespective T2 biomarker status,826,07-09-2018
BeiGene and SpringWorks Globally Signs Clinical Agreement to Target Advanced Solid Tumours,830,07-09-2018
Mylan Discloses its Previous Acquisition of Worldwide Rights to Commercialize Novartis' Products for $463M,833,07-09-2018
Exelixis' Cabometyx (cabozantinib) Recommended by the NCCN in its Clinical Practice Guidelines for advanced RCC despite of patient risk status,1196,10-09-2018
Xspray Pharma Reports Positive P-I Trial Results of HyNap-Dasa for the Treatment of Chronic Myeloid Leukemia (CML),1199,10-09-2018
Merck's (KEYTRUDA in combination with ALIMTA and Pt CT) Receives EU Approval for 1L mNonsq NSCLC with no EGFR or ALK Genomic Tumour,1205,10-09-2018
GSK's Nucala Proves to be Superior than AZ's Fasenra and Teva's Cinqair for the Treatment of Severe Eosinophilic Asthma,1283,11-09-2018
Elevian's Launch to Develop Medicines for Longevity and Age-Related Disorders,1286,11-09-2018
Medtronic Announces Onset of Onyx ONE Clear study in High Bleeding Risk Patients with Resolute Onyx DES,1317,11-09-2018
Merck's ZERBAXA Achieves 1EP of Non-Inferiority in P-III ASPECT-NP study for the Treatment of HABP or VABP in adults,1329,11-09-2018
Gilead and Galapagos NV Reports Filgotinib (JAK1i) achieve 1EP and 2EP in FINCH-2 P-III study for the Treatment of RA,1355,12-09-2018
Novartis Reports Real World Evidence from Psoriasis patients indicating Treatment to Exceed Beyond Clear Skin and safety,1358,12-09-2018
Regeneron and Sanofi Announces Acceptance of sBLA for PRALUENT's by the US for the Treatment of Reduction in MACE,1364,12-09-2018
Shire Receives EU's MAA for VEYVONDI for the Treatment of von Willebrand disease in adults,1369,12-09-2018
Gilead and Precision Biosciences Collaborates to Develop and Commercialize therapies for the Treatment of HBV using ARCUS Technology,1372,13-09-2018
Boehringer Ingelheim Acquires Vira Therapeutics Stakes for Development of Immuno- Oncology Viral Therapies,1378,13-09-2018
Celgene Reports Improvement in Patients with Moderate-to-Severe Plaque Psoriasis with OTEZLA in P-III ESTEEM trial,1381,13-09-2018
Regeneron Announces FDA Review Acceptance of EYLEA's sBLA for the treatment of Diabetic Retinopathy,1390,13-09-2018
VistaGen Therapeutics Acquires WW Rights for Pherin's PH94B nasal spray for the Treatment of Social Anxiety Disorder,1426,14-09-2018
Moleculin Reports Dosing of Novel Brain Cancer Drug WP1066 in P-I trial for the treatment of Brain Tumor,1446,14-09-2018
Allergen Announces Acquisition of Bonti for its Two Aesthetic and Therapeutic Products,1614,17-09-2018
Teva's AJOVY Receives FDA Approval for the Treatment of Migraine in Adults with Monthly and Quarterly Dosing,1631,17-09-2018
Institut Curie Announces formation of Honing Biosciences for the Development of Cell Therapies in Cancer and Chronic Diseases,1638,17-09-2018
"Leo Pharma and MorphoSys Expands Their Existing Collaboration of Antibody-Based Therapies in Dermatology, to Peptide-Derived Therapeutics",1644,18-09-2018
AstraZeneca Reports Results of Fasenra in BORA P-III Extension trial for the Treatment of Severe Eosinophilic Asthma,1659,18-09-2018
Pfizer and Atomwise Signs an Evaluation Agreement to Identify Potential Drug for Target Proteins Using AI Technology,1682,18-09-2018
Cipher Pharmaceuticals Signs Exclusive License Agreement with Moberg Pharma for Commercialization of MOB-015 for Canada,1693,18-09-2018
Almirall's Ilumetri Receives EU Approval for the Treatment of Moderate-To-Severe Chronic Plaque Psoriasis in Adults,1708,19-09-2018
Novo Nordisk Launches a 24/7 Online Chatbot Specifically for People with Diabetes,1723,19-09-2018
Cancer Genetics Announces Acquisition of NovellusDx to Expand its Oncology Platform,1760,19-09-2018
LEO Science &amp; Tech Hub Announces Collaboration with Epicore to Explore the Use of Wearable Sweat Sensors,1783,19-09-2018
Takeda signs a Co-Development Agreement with Molecular Templates for CD38-Targeted Engineered Toxin Bodies(ETBs) for Multiple Myeloma,1813,20-09-2018
Hironic Receives US FDA Approval for AFit Laser Acne Device to Treat Acne,1827,20-09-2018
Mylan Receives EU Marketing Approval for Adalimumab Biosimilar â€œHulioâ€,1872,20-09-2018
Medtronic Acquires Mazor Robotics for $1.64B or $1.34B to Transform Spinal Technologies and Improve Outcomes,1930,21-09-2018
Amicus Therapeutics Acquires Celenex for its Ten Gene Therapy Programs,1934,21-09-2018
Sandoz's Biosimilar Pegfilgrastim Receives CHMP Approval for Febrile Neutropenia,1950,21-09-2018
Bayer's BAY94-9027 Receives CHMP Approval for the Treatment of Haemophilia A aged â‰¥12yrs.,2082,24-09-2018
Sun Pharma's Ilumya Receives Australian Therapeutic Goods Administration (TGA) Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis,2100,24-09-2018
Enesi Pharma Signs a Cooperative R&amp;D Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR) for Shigella's vaccine development,2107,24-09-2018
Gilead's subsidiary Asegua Therapeutics Plans to Launch Authorized Generic Versions in the US of Epclusa &amp; Harvoni for the Treatment of Chronic Hepatitis C,2143,24-09-2018
Mylan Collaborated with Atomo Diagnostics for Commercialization of HIV Rapid Diagnostic tests for Low and Middle-Income Countries,2150,25-09-2018
"Amgen and Astellas' Blincyto (blinatumomab, BiTE) Receives Japanese Marketing Approval for Treatment of R/R B-cell Acute Lymphoblastic Leukemia(ALL)",2157,25-09-2018
"Immuntep, Collaborates with Merck KGaA and Pfizer for Clinical Trial and Supply Agreement for Eftilagimod Alpha with Avelumab",2175,25-09-2018
Stemcell Technologies and Brigham and Women's Hospital Signs Exclusive License Agreement for Kidney Organoid Technology,2182,25-09-2018
Tris Pharma Acquires Pfizer's NextWave Pharmaceuticals for its Two ADHD Treatments,2220,26-09-2018
CSPC Pharmaceutical Signs Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra in China,2228,26-09-2018
Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities in Cell Analysis,2233,26-09-2018
Alexion to Acquire Syntimmune for antibody therapeutics targeting the neonatal Fc receptor (FcRn),2241,27-09-2018
Lyra Therapeutics (Formally 480 Biomedicals) Developing Innovative Therapeutics for ENT Diseases Raises $29.5mn in Series B,2249,27-09-2018
Samsung Bioepis' BLA for SB5 Adalimumab Biosimilar Accepted for Review by the US FDA,2258,27-09-2018
Lilly Receives FDA Approval for Emgality (galcanezumab-gnlm) for Preventive Treatment of Migraine in Adults,2265,28-09-2018
Novartis Signs a License and Collaboration Agreement with Cellular Biomedicine Group (CBMG) for CAR-T Cell Therapy in China,2270,28-09-2018
Janssen Terminates Development and Commercialization Agreement with Geron for Imetelstat,2289,28-09-2018
Salix Signs an Exclusive Co-Promotion Agreement for Dova's Doptelet in the US,2297,28-09-2018
Pfizer's Vizimpro (Dacomitinib) Receives the US FDA Approval for 1L Treatment of mNSCLC with Epidermal Growth Factor Receptor (EGFR),2300,28-09-2018
Roche Acquires Tusk Therapeutics for $81. 24 M (â‚¬70M) for Its Novel Antibody,2317,01-10-2018
Teva Launches Exclusive First-to-File Generic Version of Cialis in the US,2327,01-10-2018
Taro Terminates License and Co-Development Agreement with NovaBiotics for Novexatin,2348,01-10-2018
Hologic Acquires Focal Therapeutics for $125M to Strengthen its Breast Surgery Platform,2363,03-10-2018
GSK and Hitachi Chemical Signs a Three-year Agreement for T-cell Therapy,2367,03-10-2018
Insmed Receives FDA Approval of Arikayce to Treat Mycobacterium Avium Complex (MAC) Lung Disease in Adults,2368,03-10-2018
Merck Partnered with Dragonfly for Development and Commercialization of Immunotherapies for $695M,2369,03-10-2018
Alnylam Launches Novel RNAi Therapeutic Onpattro (patisiran) in Germany,2381,03-10-2018
Novartis Signs License and Equity Investment Agreement with Boston Pharmaceuticals,2398,03-10-2018
Gilead Reports Results of Biktarvy for the Treatment of HIV-1 in Adults (Treatment Naive),2411,04-10-2018
Celyad Signs an Exclusive License Agreement with Horizon Discovery for its shRNA Technology,2421,04-10-2018
Lilly Reports Results of Dual GIP and GIP-1 Receptor Agonist with Reduction in HbA1c and Body Weight,2432,04-10-2018
Roche's Hemlibra Receives the US FDA Approval for Haemophilia A Without Factor VIII Inhibitors,2465,05-10-2018
Janssen Signs Exclusive Worldwide Agreement with Arrowhead for $3.7B,2476,05-10-2018
Novartis Announces Acceptance of its Novel Siponimod (BAF312) by the US FDA and EMA,2515,08-10-2018
AbbVie's Orilissa (elagolix) Receives Health Canada Approval to Treat Moderate-to-Severe Pain Associated with Endometriosis,2523,08-10-2018
Merck's Gardasil 9 Receives FDA's Expanded Label Approval for Prevention of HPV Related Disorders,2536,08-10-2018
Regeneron to Present Results of Libtayo (cemiplimab) for Six Tumor Indications at ESMO 2018,2546,09-10-2018
Celgene Reports Otezla (apremilast) Achieve 1EP in P-III STYLE Study to Treat Moderate-to-Severe Scalp Psoriasis,2551,09-10-2018
Roche to Present Positive Results of Cancer Immunotherapy Programmes at ESMO 2018,2560,09-10-2018
"MVP and Daiichi Signs Exclusive Distribution and License Agreement for Penthrox in China, Thailand, Vietnam",2578,09-10-2018
Roche to Present Results of P-III Trial for Ocrevus (ocrelizumab) at ECTRIMS 2018,2586,10-10-2018
Novartis Reports Positive Results of P-II SUSTAIN study for Crizanlizumab (SEG101) to Treat Sickle Cell Disease (SCD),2593,10-10-2018
Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio,2601,10-10-2018
Eli Lily and Boehringer Ingelheim's (BI) Jardiance (empagliflozin) Shows to Increase Life Span in Adults withT2D and Cardiovascular Disorders ,2620,10-10-2018
"Celltrion and Teva Announces Approval Recommendations for CT-P10's (rituximab, biosimilar) BLA from the US FDA ODAC",2627,11-10-2018
Roche and Ionis Collaborates to Develop Ionis's IONIS-FB-LRx to Treat Complement-Mediated Diseases for $760M,2635,11-10-2018
Mundipharma Acquires Cinfa Biotech for Expansion of its Biosimilar Portfolio,2653,12-10-2018
Sandoz Signs a Non-Exclusive License Agreement with AbbVie for IPR of its Humira (adalimumab) for Major EU Countries,2663,12-10-2018
Lilly and Metastatic Breast Cancer Advocates Reports a RWE and Launches 'Thriver Movement' #MoreforMBC,2667,12-10-2018
Roche Global Launch NGS AVENIO Tumor Tissue Analysis Kits,2678,15-10-2018
Merck Terminates Development and Commercialization Deal with Samsung Bioepis for Lusduna Nexvue (insulin glargine),2682,15-10-2018
Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP in P-III KATHERINE study,2692,15-10-2018
Sarepta Signs an Exclusive Global (Except EU) License Agreement with Lysogene for LYS-SAF302 to Treat MPS IIIA,2699,16-10-2018
"Amgen Launches Amgevita (adalimumab, biosimilar) in EU to Treat Inflammatory Diseases post EMA Approval in Feb 2017",2703,16-10-2018
Novartis Reports Results of Five-year P-III MEASURE 1 and FUTURE 1 study for AS and PsA,2707,16-10-2018
Google Developed AI System for Easy Detection of Last Stage Breast Cancer with 99% Accuracy,2711,16-10-2018
AstraZeneca's Lynparza (olaparib) Receives Fourth FDA's Orphan Drug Designation to Treat Pancreatic Cancer,2715,16-10-2018
Regeneron's Dupixent (Dupilumab) Achieves 1EP &amp; 2EP in two P-III trial for Inadequately-Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),2719,16-10-2018
Ferring Signs a Research Colllaboration with Evotec to Develop Novel Small Molecule Therapies,2724,17-10-2018
Voyager to Present Preclinical Data of VY-HTT01 &amp; VY-SOD102 at ESGCT 2018,2728,17-10-2018
"Samsung Biogen Launches Imraldi (adalimumab, biosimilar) in EU for 14 Autoimmune Conditions",2734,17-10-2018
Novartis to Acquire Endocyte for Expansion of its Investigational Radioligand Therapy (RLT) Platform,2748,18-10-2018
Axsome Therapeutics Receives FDA's Orphan Drug Designation for AXS-12 (reboxetine) to Treat Narcolepsy,2752,18-10-2018
Allergan Announces Completion of UBR-MD-04 &amp; 3110-105-002 Study for Treatment of Migrane,2756,18-10-2018
Eiger Pharmaceuticals Reports Results of Lambda in P-II LIMT (Lambda MonoTx) Study in Hepatitis Delta Virus (HDV) Infection,2760,18-10-2018
Janssen Pharmaceuticals (J&amp;J) Receives Health Canada's Approval for Invokana (canagliflozin) in MACE Reduction,2764,18-10-2018
Mylan Launches MPA Injectable Suspension for Prevention of Pregnancy in the US,2768,20-10-2018
Abbott Receives FDA's Approval for its HeartMate 3 Left Ventricular Assist Device (LVAD) in Patients with Advance Heart Failure,2795,22-10-2018
Roche Reports Results of P-III IMpower130 study of Tecentriq (atezolizumab) for 1L Treatment in Advance NSCLC,2800,22-10-2018
AstraZeneca &amp; Merck Reports P-III SOLO-1 Trial Results of Lynparza (olaparib) for 1L+ Treatement in Advance BRCAm Ovarian Cancer at ESMO18,2808,22-10-2018
Biogen and UCB Reports Results of Dapirolizumab Pegol (DZP) in A P-IIb study for Systemic Lupus Erythematosus (SLE),2816,23-10-2018
Novartis Reports Publication of P-IIIb LIBERTY study's Results of Aimovig (erenumab) in The Lancet,2821,23-10-2018
Astrazeneca Expands Existing Deal with Innate Pharma to Strengthen its Oncology Pipeline,2825,23-10-2018
Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-V and COAST-W trials for Ankylosing Spondylitis (AS),2829,23-10-2018
Alcon (Novartis Division) Plans to Develop SMART Suite Equipment for Improved Cataract Surgery,2833,23-10-2018
Omeros' OMS721 Receives FDA's ODD to Treat Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA),2839,24-10-2018
"Takeda Globally Signs Licensing, Co-Development &amp; Co-Promotion Agreement with Enterome for its EB8018 Candidate",2844,24-10-2018
LEO Pharma Signs License and Research Collaboration with Zymeworks to Develop Novel Bispecific Abs,2850,24-10-2018
"Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab, biosimilar) in Finland",2862,25-10-2018
Orion's Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC),2866,25-10-2018
Pfizer Reports Improved Results of P-III OA (A4091056) Study of Tanezumab in Patients with Osteoarthritis (OA),2870,25-10-2018
"Axovant Reports Dosing of its First Patient in AXO-Lenti-PD study for Parkinson's Disease at NIHR, UCLH",2874,25-10-2018
AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-III HARMONIZE trial in Patients with Hyperkalaemia,2882,26-10-2018
"Seattle Genetics Reports Multiple Results of Adcetris (Brentuximab Vedotin) in P-III ECHELON-1, P-I/II, P-II and P-III AETHERA study in Patients with Hodgkin Lymphoma at ISHL 2018",2898,26-10-2018
Esperion Reports Results of Bempedoic Acid in P-III Study 2 or 1002-047 for Patients with ASCVD or HeFH,2909,29-10-2018
Novartis &amp; Pfizer Enter into a Clinical Development Collaboration to Treat Non-Alcoholic Steatohepatitis (NASH),2923,29-10-2018
ProQR Signs Exclusive Worldwide License Agreement with Ionis for IONIS-RHO-2.5 Candidate (now QR-1123),2932,30-10-2018
Jazz Receives FDA Approval for Xyrem's (sodium oxybate) sNDA to Treat Cataplexy or Excessive Daytime Sleepiness in Pediatric Patients with Narcolepsy,2943,30-10-2018
AstraZeneca Divests Rights of its Nexium and Vimovo Product to Grunenthal,2949,30-10-2018
Astellas' Xtandi (enzalutamide) Receives EU's Approval for Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC),2953,30-10-2018
"Gilead Reports Results of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) in P-III Study 1490 for Patients with HIV-1",2964,30-10-2018
Mirati Therapeutics Announces IND Submission of MRTX849 to Treat NSCLC &amp; CRC,2971,31-10-2018
Roche Licenses Halozyme's ENHANZE Technology for ~$190M for the Development of Therapeutic Targets,2975,31-10-2018
Janssen's (J&amp;J) Invokana (canagliflozin) Receives FDA Approval for MACE events in Adults with T2D,2979,31-10-2018
"Biocardia, CellProThera &amp; SlngXpand Collaborates to Develop and Commercialize CD34+ Stem Cells in Singapore for Myocardial Infarction",2987,31-10-2018
"Lupin Recalls its 6,752 Testosterone Bottles from the US market",3046,05-11-2018
Coherus' Udenyca (pegfilgrastim-cbqv) Receives the US FDA Approval for Patients Receiving Myelosuppressive Chemotherapy,3051,05-11-2018
"Boehringer Ingelheim (BI) &amp; Eli Lilly Reports RWE Results of Jardiance (empagliflozin) in EMPRISE study, Presented at AHA 2018",3061,05-11-2018
Abeona Signs Exclusive License Agreement with Regenxbio to Develop and Commercialize NAV AAV9 vector,3069,06-11-2018
"Merck Signs a Clinical Trial Collaboration with FLX Bio, for a Combination Therapy",3083,06-11-2018
"Regeneron and Sanofi Reports Results of Praluent (alirocumab) in ODYSSEY OUTCOMES study in Patients with MACE events, Presented at AHA 2018",3091,12-11-2018
AstraZeneca Announces Acceptance of Priority Review of Lynparza's (olaparib) sNDA by FDA in Patients with BRAC-Mutated Advance Ovarian Cancer,3098,12-11-2018
Merck's Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC),3107,12-11-2018
Roche Reports Acceptance of sBLA from FDA for its Tecentriq (atezolizumab) + Abraxane (nab-paclitaxel) for 1L Metastatic Triple- Negative Breast Cancer (TNBC),3116,13-11-2018
BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates,3123,15-11-2018
Merck Reports Initiation of BLA Filling for V920 (rVSVâˆ†G-ZEBOV-GP) Under FDA for Ebola Zaire,3137,14-11-2018
Ferring Signs an Exclusive License Agreement with Invo for its INVOcell Intravaginal Culture (IVC) System in the US,3142,14-11-2018
Wugen Enters into License Agreement with Washington University for its CAR-T Therapy Technologies,3146,14-11-2018
Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study,3150,15-11-2018
"Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product, Qutenza (capsaicin)",3160,15-11-2018
Lilly Files Lasmiditan to FDA for Acute Treatment of Migrane,3165,15-11-2018
Bristol-Myers Squibb Receives CHMP Recommendation for Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) in 1L RCC Based in P-III CheckMate-214 study,3173,16-11-2018
"Ipsen's Cabometyx (cabozantinib, as monothx) Receives EU Approval for the Treatment of 2L Advance HCC",3182,16-11-2018
"Pfizer to Raise Prices of its 41 Drugs in the US, in January 2019",3219,19-11-2018
Novartis' Kisqali (ribociclib) (as a Combination Therapy) Receives CHMP's Expanded Label Recommendation for HR+/HER2- Locally Advanced or Metastatic Breast Cancer,3227,19-11-2018
"Gilead's Vemlidy (Tenofovir Alafenamide) Receives NMPA (CFDA) Approval for Chronic Hepatitis B Virus (HBV) Infection""",3235,19-11-2018
AstraZeneca Reports Results of Imfinzi (durvalumab) &amp; Tremelimumab in Global P-III MYSTIC Trial for Stage IV Non-Small Cell Lung Cancer (NSCLC),3246,19-11-2018
Genentech Collaborates with Immunocore to Co-develop IMC-C103C for MAGE-A4 (Melanoma-Associated Antigen A4),3264,20-11-2018
Leidos Collaborates with GeoVax for the Development of Immunotherapies for Cancer,3272,20-11-2018
"Sandoz and Pear Therapeutics Launches reSET Medical Mobile APP, for Patients with Substance Use Disorder (SUD)",3277,20-11-2018
Verily (Alphabet's Division) Holds its Smart Lens Project,3288,20-11-2018
Boston Scientific Acquires BTG with its Interventional Medicine Portfolio,3301,21-11-2018
OrthroXel's Apex Femoral Nailing System Receives CE Mark Clearance in EU,3308,21-11-2018
"Mylan Recalls 15 Batches of Valsartan Globally, for the Treatment of Hypertension",3321,21-11-2018
Leo Pharma Collaborates with PellePharm for the Development of Drug Candidate for Gorlin Syndrome and Basal Cell Carcinoma (BCC),3327,21-11-2018
Genentech's Venclexta (venetoclax) Receives FDA's Accelerated Approval for Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML),3334,22-11-2018
Pfizer and Zenith Epigenetics Collaborates to Evaluate ZEN-3694 &amp; Talazoparib for TNBC,3339,22-11-2018
Evotec and Immuneering Collaborates to Develop Novel Candidates for Rare Hereditary Metabolic Diseases,3344,22-11-2018
Medtronic to Acquire Nutrino Health Along with its AI-Based Continuous Glucose Monitoring (CGM) Technology,3351,22-11-2018
Indivior Receives Health Canada Approval for Sublocade (SC) (Buprenorphine Extended-Release) in Patients with Moderate to Severe Opioid Use Disorder(OUD),3368,26-11-2018
"Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim, Biosimilar)",3383,26-11-2018
Novartis Receives EU Approval for Gene Therapy Luxturna (voretigene neparvovec) in Patients with Rare Inherited Retinal Disease,3466,26-11-2018
Bristol-Myers' Opdivo and Yervoy Combination Couldn't Meet OS as Maintenance Therapy in esSCLC Patients Post 1L Chemo,3473,27-11-2018
RegenxBio and Rocket Signs Exclusive Worldwide License Agreement for NAV AAV9 Vector,3484,27-11-2018
Sandoz's Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration of Neutropenia,3489,27-11-2018
"Genentech's ACTpen Receives FDA's Approval for Actemra (tocilizumab) to Treat Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA) and Two Forms of Juvenile Arthritis",3494,27-11-2018
Loxo's Vitrakvi (larotrectinib) Receives the US FDA Approval for the Treatment of Solid Tumors in Adults and Pediatric Patients,3501,28-11-2018
Novo Nordisk Reports Improved Results of Oral Semaglutide in PIONEER 9 Study in Patients with Type-2 Diabetes (T2D),3506,28-11-2018
Beigene Signs Exclusive License and Development Agreement with Zymeworks (ZW),3510,28-11-2018
Mesa Biotech's Accula RSV Test Receives FDA's 510(K) Clearance and CLIA Waiver for Respiratory Infections,3519,28-11-2018
Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors,3529,29-11-2018
Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) &amp; Pifeltro (doravirine) Receives EU's Approval for the Treatment of HIV-1 Infection,3533,29-11-2018
Q BioMed Acquires Rights of Metastron from GE Healthcare,3537,29-11-2018
"ElectroCore's gammaCore (nVNS) Receives FDA's 510(k) Approval, a Novel Therapy for Cluster Headache in Adults",3542,29-11-2018
Astellas' Xospata (gilteritinib) Receives FDA â€˜s Approval for 1L R/R Acute Myeloid Leukemia (AML) in Adults,3550,30-11-2018
Vertex's Kalydeco (ivacaftor) Receives FDA's Expanded Label Approval for Cystic Fibrosis (CF) Aged 12 to &lt; 24 Months,3554,30-11-2018
NTU SingaporeTTSH Develops AI based Smart Medical Device for Early Detection of Congestive Heart Failure,3560,30-11-2018
Shire's Takhzyro IV (lanadelumab) Receives EU's Approval for Hereditary Angioedema,3586,03-12-2018
Bluebird Bio and Celgene Reports Results of bb21217 in P-I (CRB-402) study for 3L+ r/r Multiple Myeloma,3617,03-12-2018
Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06 study for CD20-Positive Non-Hodgkin Lymphoma,3625,03-12-2018
GSK to Acquire Tesaro for its Zejula (niraparib) for $5.1B (Â£4.0 billion),3629,03-12-2018
Cilag Acquires Exclusive Worldwide Rights of Argenx's Cusatuzumab (ARGX-110) for $1.6B,3646,04-12-2018
"Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial for Refractory Large B-Cell, Lymphoma, Presented at ASH 2018",3685,04-12-2018
Crown Laboratories Acquires Rights for GSK's Five OTC Drugs,3698,04-12-2018
Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE Study for HER2-positive Early Breast Cancer (eBC),3705,06-12-2018
Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim (BI) for G-Protein Coupled Receptors (GPCRs),3710,05-12-2018
Roche Collaborates with Icagen for the Development of Drug Candidates for Neurological Disorders,3718,06-12-2018
Subtle an AI based Medical Device SubtlePET Receives FDA's 510(K) Clearance,3729,06-12-2018
Novartis Reports Results of BYL719 (alpelisib) + fulvestrant in P-III SOLAR-1 trial for HR+/HER2- Advanced Breast Cancer,3742,07-12-2018
Biogen Exercises Exclusive Worldwide Option to Develop &amp; Commercialize Ionis's BIIB067 (IONIS-SOD1RX) for Amyotrophic Lateral Sclerosis (ALS),3749,07-12-2018
Novartis Expands its Cell Therapy Collaboration with Intellia Therapeutics for CRISPR/Cas9-Based Therapy,3757,07-12-2018
"Gilead's Descovy (Emtricitabine, Tenofovir Alafenamide) Receives NMPA â€˜s (CFDA) Approval for HIV-1 Infection",3764,05-12-2018
Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for Alcoholic Liver Disease,3776,05-12-2018
"Celltrion Reports Results of CT-P10 (rituximab, biosimilar) in P-III for Advance Follicular Lymphoma (AFL)",3788,05-12-2018
NeuroPace Reports Positive Results of Next-Gen RNS System for Refractory Epilepsy in the US,3793,05-12-2018
"Genentech's Tecentriq Receives FDA Approval a Combination Therapy, for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations",3798,07-12-2018
Daiichi Reports Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in P-I study for HER2 Low Expressing Metastatic Breast Cancer,3815,10-12-2018
Merck Licenses Cyclica's In-Silico Artificial Intelligence (AI) based Ligand Express Platform,3824,10-12-2018
AstraZeneca Reports Imfinzi (durvalumab) &amp; tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer,3830,10-12-2018
Bristol-Myers (BMS) Collaborates with Vedanta Biosciences to Develop Combination Therapy for Advanced or Metastatic Cancers,3850,11-12-2018
Novartis Reports Results of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA trials for (HR+/HER2-) Advanced Breast Cancer,3857,11-12-2018
Shionogi Signs a Research Collaboration with UBE Industries for the Development of Anti-RS Virus Drug Candidates,3875,11-12-2018
"Sandoz Receives FDA's Clearance for reSET-O, a Medical Mobile App for Opioid Use Disorder (OUD)",3886,11-12-2018
"Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation, in the US",3894,12-12-2018
Circassia Plans to Exercise Option for the US Commercialization Rights for Tudorza (aclidinium) From AstraZeneca,3909,12-12-2018
Johnson&amp;Johnson (J&amp;J) Signs a Research Collaboration with Apple for Atrial Fibrillation (AFib),3922,18-01-2019
BioMed X and Boehringer Ingelheim (BI) Collaborates for Neurology Disorders,3930,18-01-2019
Ironwood Pharmaceuticals' Linzess (linaclotide) Receives NMPA (CMPA) Approval for Irritable Bowel Syndrome with Constipation (IBS-C),3943,16-01-2019
"FitBit and National Institutes of Health (NIH) Launches a Digital Health Project, Fitbit Bring-Your-Own-Device (BYOD)",3950,17-01-2019
AstraZeneca Signs an Exclusive Promotion Agreement with Luye Pharma for its Xuezhikang in China,3966,17-01-2019
"Roche Launches uPath Enterprise Software, a Digital PathologyTechnology",3967,17-01-2019
Abbott Exercises its Option to Acquire Cephea Valve Technologie,3968,17-01-2019
Boehringer Ingelheim (BI) and Bioharmony Therapeutics Collaborates to Develop Bacteriophage Lysins,3969,16-01-2019
Beigene's Zanubrutinib (BGB-3111) Receives the US FDA's Breakthrough Therapy Designation for Mantle Cell Lymphoma (MCL),3970,16-01-2019
Sanofi Licenses Biomunex Pharmaceuticals' BiXAb Technology to Develop Bi- and Multi-Specific Antibodies,3972,16-01-2019
"Abbott's Amplatzer Piccolo Occluder Receives FDA Approval, a Medical Device for Premature and Newborns with Patent Ductus Arteriosus (PDA)",3973,15-01-2019
"Cipla Signs an Exclusive License Agreement with Bio-Thera for its BAT1706 (bevacizumab, biosimilar)",3974,15-01-2019
Array Biopharma Reports Results of Triplet Combination Therapy in P-III BEACON CRC Trial for BRAF-Mutant Metastatic Colorectal Cancer (mCRC),3975,15-01-2019
Exelixis' Cabometyx (cabozantinib) Receives FDA Approval for Previously Treated Hepatocellular Carcinoma (HCC),3976,15-01-2019
Bristol-Myers Squibb's (BMS) Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Receives EU Approval for 1L Intermediate- and Poor-Risk Advanced RCC,3977,15-01-2019
Ascletis Signs an Exclusive License Agreement with Alphamab for its KN035,3978,14-01-2019
Chiesi Farmaceutici Licenses Tum Bio's NCE401 for $74M,3979,14-01-2019
Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib),3980,14-01-2019
RFPi's iCertainty Receives FDA 510(k) Clearance Approval for Blood Flow in Surgeries,3982,11-01-2019
Rafael Pharmaceuticals' Devimistat (CPI-613) Receives EMA's ODD for R/R Acute Myeloid Leukemia (AML) and Metastatic Pancreatic Cancer (mPC),3983,11-01-2019
Yuhan Signs an Exclusive License Agreement with Glenmark for its Ryaltris,3984,11-01-2019
Sumitomo Dainippon Reports Results of Lurasidone Hydrochloride (lurasidone) in P-III JEWEL Study in Patients with Schizophrenia,3985,11-01-2019
Empatica's Embrace an AI Smartwatch Receives FDA's 510(K) Clearance Approval in Pediatric Patients Aged â‰¥6 yrs.,3986,10-01-2019
Elevian and Insilico Medicine Collaborates to Develop Therapies Targeting Aging,3988,10-01-2019
"Sanofi Reports Results of Cablivi (caplacizumab) in P-III HERCULES Study in Patients with Rare Blood Clotting Disorder, Published in NEJM",3989,10-01-2019
ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine) to OMERS,3990,09-01-2019
Janssen (J&amp;J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severely Active Ulcerative Colitis (UC),3991,09-01-2019
Exelixis and Daiichi Sankyo's Minnebro (Esaxerenone) Receives MHLW Marketing Approval In Patients With Hypertension In Japan,3992,09-01-2019
Astellas and Amgen Astellas' Evenity (romosozumab) Receives MHLW Approval for Patients with Osteoporosis at High Risk of Fracture in Japan,3993,09-01-2019
3SBio Signs a License Agreement with Samsung Bioepis for its Biosimilars,3995,08-01-2019
Eli Lilly to Acquire Loxo Oncology for $8B,3996,08-01-2019
Novartis's SEG101(crizanlizumab) Receives FDA's Breakthrough Therapy(BT) Designation for Sickle Cell Disease,3997,08-01-2019
Merck Exercises its Option to License NGM's NGM313 (MK-3655) for NASH and Type 2 Diabetics,3998,04-01-2019
Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) to Collaborate with Boehringer Ingelheim(BI) for Neuropsychiatric Disorders,3999,04-01-2019
"Daiichi Signs an Exclusive License Agreement with Esperion, for $1.2B",4000,04-01-2019
"Merck's Keytruda(pembrolizumab) Receives 5 Approvals from PMDA, Japan across 3 Indications",4001,03-01-2019
Bristol-Myers Squibb (BMS) to Acquire Celgene for $74B,4002,03-01-2019
Progenics Signs Exclusive License Agreement with Curium for the Development of PyL in EU,4003,03-01-2019
"Celgene Licenses Aprinoia's APN-1607 an Imaging Tracer, for Neurodegenerative Diseases",4004,03-01-2019
Bristol-Myers Squibb Receives FDA's Approval for Sprycel (dasatinib) + CT in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL),4005,03-01-2019
Teva's ProAir Digihaler (Albuterol Sulfate 117 mcg) Inhalation Powder Receives FDA Approval for Asthma &amp; COPD Patients Aged 4 Years or Older,4007,31-12-2018
Betta Pharma Licenses Inventisbio's D-0316 to Treat Non-Small Cell Lung Cancer (NSCLC),4008,31-12-2018
"FDA Approves Elzonris (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy",4009,31-12-2018
Sanofi and Merck Receives FDA Approval for Vaxelis in Pediatric Patients,4010,29-12-2018
Horizon Pharma's Ravitchi (Glycerol Phenylbutyrate) Receives FDA Approval for Expansion of Age Range for in Patients with Urea Cycle Disorder (UCD),4011,28-12-2018
Innovent Biologics and Eli Lilly's Tyvyt (Sintilimab injection) Receives NMPA (CFDA) Approval for Classical Hodgkin's Lymphoma (cHL) Patients,4012,28-12-2018
JHL Biotech Reports Randomization of Patients in P-III Study of JHL1101 for Diffuse Large B-Cell Lymphoma,4013,28-12-2018
Merck and Pfizer Reports Results of Avelumab in P-III JAVELIN Ovarian 100 study for Previously Untreated Advanced Ovarian Cancer,4014,28-12-2018
"AbbVie Licenses Lupin's MALT1 Inhibitor Program, for $977M",4015,27-12-2018
Alexion's Ultomiris (Ravulizumab-Cwvz) Receives FDA Approval in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH),4016,27-12-2018
Zydus' Doxycycline Hyclate Delayed-Release Tablets USP and Febuxostat Tablets Receives FDA's Approval,4017,27-12-2018
Merck's Keytruda (pembrolizumab) Receives FDA's Approval for LA or Metastatic Merkel cell carcinoma (MCC),4018,20-12-2018
Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho,4019,20-12-2018
AstraZeneca and Merck's Lynparza (olaparib) Receives FDA's Approval for 1L BRCA-Mutated Advanced Ovarian Cancer,4020,20-12-2018
Albireo's A4250 Receives EU Orphan Drug Designation (ODD) for Biliary Atresia,4021,19-12-2018
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer,4022,19-12-2018
Alcon to Acquire Tear Film Innovations for its iLux Medical Device,4023,19-12-2018
Eli Lilly Collaborates with Aduro Biotech for its cGAS-STING Pathway Inhibitor Program to Develop Immunotherapies,4024,19-12-2018
Amgen Signs an Immuno-Oncology Agreement with Molecular Partners' for its MP0310,4025,19-12-2018
Bristol-Myers' Sprycel (dasatinib) Receives CHMP Recommendation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL),4026,18-12-2018
Ligand Purchases Palvella's Royalty Rights and Milestone Payments of PTX-022 for Pachyonychia Congenita,4027,18-12-2018
Merck's Keytruda (pembrolizumab) Receives EU Approval for Resected Stage III Melanoma in Adults,4028,18-12-2018
Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes,4029,17-12-2018
Merck Acquires Antelliq Group with its Digital Animal Health Technology,4030,17-12-2018
Amgen's Nplate (Romiplostim) Receives FDA's Approval for Immune Thrombocytopenia Aged 1 year and Older,4031,17-12-2018
Novartis' Xolair (omalizumab) Receives EU's Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU),4033,14-12-2018
Vertex's Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic Fibrosis (CF) Aged 2 to 5 yrs.,4034,14-12-2018
Axovant Sciences Licenses Two Gene Therapy Programs from University of Massachusetts for Rare and Fatal Neurodegenerative Genetic Disorders,4035,14-12-2018
Eli Lilly's Olumiant (baricitinib) Receives FDA's Fast Track Designation for Systemic Lupus Erythematosus (SLE),4036,14-12-2018
AstraZeneca and AVEO Oncology Enter into an Immuno-Oncology Clinical Collaboration,4037,13-12-2018
Lilly Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative Diseases,4038,13-12-2018
Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue,4039,13-12-2018
Oxford BioTherapeutics Licenses WuXi Biologics' WuXiBody Platform for Five Bispecific Antibodies,4040,13-12-2018
CorMedix Reports Results of Neutrolin in P-III LOCK-IT-100 Study for Patients with Hemodialysis,5276,18-01-2019
Thyas Signs an Exclusive License Agreement with iPS Academia Japan (iPS-AJ) to Develop Autologous Immunotherapies,5363,18-01-2019
"Samsung Bioepis' Biosimilar Transtuzumab Ontruzant (transtuzumab,dttb), Receives US FDA Approval for Oncology Indications",5479,21-01-2019
Vertex Pharmaceuticals' Orkambi (lumacaftor+ivacaftor) Receives EU Approval for Cystic Fibrosis (CF) with Mutation in CFTR gene in Children Aged 2 to 5,5503,21-01-2019
Celgene Signs an Exclusive WW License Option with Obsidian for DDs Technology,5511,21-01-2019
"Sandoz's Erelzi (etanercept, biosimilar) Receives Health Canada Approval for Psoriatic Arthritis (PsA) in Adults",5589,22-01-2019
Verilyâ€˜s Study Watch Receives FDA's 510 (k) Clearance for Cardiovascular Disorders,5622,22-01-2019
"Eli Lilly Reports Results of Cyramza (ramucirumab) in P-III REACH 2 study for 2L AFP-High HCC, Published in The Lancet",5652,22-01-2019
ProBioGen and CRISPR Therapeutics Signs a Multi-Year Research Collaboration for In Vivo Delivery Therapies,5660,22-01-2019
Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III Study for Advanced or Metastatic Soft Tissue Sarcoma (STS),5663,22-01-2019
Amgen's Blincyto (blinatumomab) Receives EU Expanded Indication Approval for Ph- CD19 Positive B-cell Precursor Acute Lymphoblastic Leukemia (ALL),5688,23-01-2019
Albireo's A4250 Receives FDA's Orphan Drug Designation (ODD) for Biliary Atresia,5702,23-01-2019
Purdue Pharma Signs Exclusive License Agreement with Klaria for its KL-01401,5709,23-01-2019
Taiwan Liposome's TLC178 Receives EMA's ODD for Soft Tissue Sarcoma (STS),5721,23-01-2019
Abbott's TactiCath Contact Force Ablation Catheter Receives FDA's Approval for Atrial Fibrillation (AFib),5729,23-01-2019
B-MoGen Biotechnologies and CytoSen Therapeutics Sign an Agreement for the Development of Gene-Modified Therapies,5756,24-01-2019
Athersys Reports Results of Multistem Cell Therapy (IV) in Patients with Acute Respiratory Distress Syndrome (ARDS),5765,24-01-2019
Grifols Signs a License and Commercialization Agreement with Rigel Pharmaceuticals for Fostamatinib,5791,24-01-2019
23andMe's MAP Report Receives FDA's 510(k) Clearance for Hereditary Colorectal Cancers,5802,24-01-2019
"Philogen Collaborates with Johnson&amp;Johnson (J&amp;J), Novartis and Celgene",5812,24-01-2019
"Indian Government to Set Trade Margins of 50 Orphan Drugs, Treatments for Cancer and Rare Diseases",5842,25-01-2019
Mannin Research Signs a Collaboration with Mcmaster University for MAN-01,5843,28-01-2019
Vertex Signs an Exclusive License Agreement with Merck KGaA for its Two DNA-PK Inhibitor,5852,28-01-2019
Medtronic to Acquire EPIX Therapeutics for its Cardiovascular Technologies,5863,28-01-2019
Clovis Oncology's Rubraca (Rucaparib) Receives EU Approval for Maintenance Treatment of Relapsed Ovarian Cancer (OC) in Adults,5868,25-01-2019
Dr. Reddy's Tosymra (sumatriptan nasal spray) 10mg Receives the US FDA Approval for Acute Treatment of Migraine,5873,28-01-2019
Amgen's Repatha (evolocumab) Receives NMPA (CFDA) Approval for Reduction of Cardiovascular Risks in China,5880,24-01-2019
Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Cancer (UC),5888,25-01-2019
"Amgen and Allergan Report Results of ABP 798 (rituximab, biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Arthritis (RA)",5893,24-01-2019
Zimber Biomet's Rosa Knee System Receives the US FDA's 510(k) Clearance for Robotically-Assisted Surgeries,5903,28-01-2019
"AbbVie's Imbruvica (ibrutinib) + Gazyva (obinutuzumab) Receives FDA's Approval, First CT Free Treatment for 1L+ CLL/SLL",5917,28-01-2019
Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in Patients with Atypical Hemolytic Uremic Syndrome (AHUS),5938,29-01-2019
Purdue Pharma Signs an Agreement with Alivio Therapeutics for its ALV-107,5951,29-01-2019
"Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab, biosimilar) from NMPA (CFDA) to Treat NSCLC",5963,29-01-2019
Vertex's Kalydeco (ivacaftor) Receives Health Canada's Approval for Cystic Fibrosis (CF) with CFTR Gene Mutation in Children Aged 12 to,5969,29-01-2019
Medtronic Launches Mazor X Stealth Edition for Spine Surgery in the US,5976,29-01-2019
"Zai Lab Receives Priority Review for Zejula's (niraparib) NDA from NMPA (CFDA), in China",5980,29-01-2019
Pfizer and Eli Lilly Report Results of Tanezumab in P-III OA study (A4091057) for Moderate-To-Severe Osteoarthritis (OA) Pain,5994,30-01-2019
Takeda Reports Results of TAK-003 in P-III TIDES (DEN-301) Trial for Dengue,6001,30-01-2019
Sumitomo Dainippon's Latuda (lurasidone HCl) Receives NMPA's (CFDA) Approval for Schizophrenia,6008,30-01-2019
"EMA Shifts its Headquarters from London to Amsterdam, The Netherlands",6016,30-01-2019
Neurocrine and Voyager Collaborate to Develop and Commercialize VY-AADC &amp; VY-FXN01 for Parkinson's &amp; Friedreich's Ataxia Disease,6019,30-01-2019
Roche Discontinues P-III CREAD-1 and 2 Trials of Crenezumab in Patients with Early Alzheimer's Disease (AD),6037,31-01-2019
AstraZeneca's Lumoxiti Receives FDA approval for the Treatment of R/R 2L+ Hairy Cell Leukemia in patients,6055,14-09-2018
Genentech Receives FDA approval for Actemra SC for the Treatment of Active Systemic JIA in patients aged â‰¥2 yrs.,6056,14-09-2018
Ipsen's Cabometyx Receives Health Canada's Approval for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults,6057,20-09-2018
Merck's Delstrigo and Pifeltro Receives CHMP Approval for the Treatment of HIV-1 Infection in EU,6058,21-09-2018
Coherus Biosciences' Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for Febrile Neutropenia,6059,26-09-2018
Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor Drugs Using i-DPS Technology,6060,26-09-2018
I-Mab Biopharma Expands Collaboration with Wuxi Biologics for three more Antibody Programs,6061,27-09-2018
Sanofi's Libtayo Receives the US FDA approval for Metastatic Cutaneous Squamous Cell Carcinoma (mCSCC),6062,01-10-2018
Kite and HiFiBio Signs a Research &amp; License Agreement for Neoantigen-Reactive T Cell Receptors (TCRs),6063,03-10-2018
Novo Nordisk's Tresiba Receives Health Canada Approval for Type 1 Diabetes in patients Aged â‰¥2 years,6064,03-10-2018
Eagle Pharmaceuticals and USAMRICD Signs an Agreement for Ryanodex (dantrolene sodium),6065,04-10-2018
Xbrane Biopharma Reports Results of Xlucane Compared to Lucentis from In-Vivo Study,6066,04-10-2018
MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio,6067,10-10-2018
Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018,6068,11-10-2018
Myriad and Pfizer Signs a Service Agreement for Testing of BRCA-Mutated Triple Negative Breast Cancer,6069,12-10-2018
"Therapiva Private Acquires Dr. Reddy's API Manufacturing Unit Jeedimetla, Hyderabad",6070,15-10-2018
Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for Oncolytic Virotherapies,6071,15-10-2018
AbbVie Announces FDA's Acceptance of sNDA for PR for Imbruvica (ibrutinib) + Gazyva (Obinutuzumab),6072,17-10-2018
"Mylan Launches Hulio (adalimumab, biosimilar) in EU for Autoimmune Diseases",6073,22-10-2018
"Mylan &amp; Biocon Receive CHMP Recommendation to Ogivri (trastuzumab, biosimilar) for HER-2 Breast Cancer",6074,22-10-2018
"At ESMO'18, Pfizer Presents Results of PALOMA-3 Trial Results of Ibrance and Fulvestrant",6075,22-10-2018
Novartis Reports Results of Extended Follow-up P-III COMBI-AD Trial of Tafinlar (dabrafenib) + Mekinist (trametinib) during ESMO18,6076,22-10-2018
UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients,6077,24-10-2018
Roche's Xofluza (baloxavir marboxil) Receives FDA Approval for Influenza in Patients Aged â‰¥12 yrs.,6078,25-10-2018
Medtronic's Valiant Navion(TM) Thoracic Stent Graft System Receives FDA Approval for Aortic Diseases,6079,26-10-2018
Regeneron's Eylea (aflibercept) Achieves 1EP &amp; 2EP in P-III PANORAMA trial in Patients with Non-Proliferative Diabetic Retinopathy (NPDR),6080,26-10-2018
Esperion Reports Completion of Bempedoic Acid in Global P-III LDL-C Development Program for Patients with ASCVD or HeFH,6081,29-10-2018
Lilly Signs a Global Research and License Collaboration with Dicerna for ~$550M,6082,29-10-2018
Henry Ford Health System Signs Development and Commercialization Agreement with G3 Pharma for its Galectin-3 inhibitors,6083,31-10-2018
Gilead Signs Global Research Collaboration with Tango to Develop &amp; Commercialize Targeted Immuno-Oncology Therapies,6084,01-11-2018
Sandoz's Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases,6085,01-11-2018
Roche Reports Results of Venclexta/Venclyxto plus Gazyva/Gazyvaro in P-III CLL-14 study for CLL patients,6086,01-11-2018
Roche Receives EU Approval for Venclyxto (venetoclax) plus MabThera (rituximab) to Treat Adults with CLL,6087,01-11-2018
Sanofi and Denali Therapeutics Collaborates to Develop &amp; Commercialize Clinical Candidates for Neurology and Inflammatory Disorders,6088,01-11-2018
Vertex Receives EU's MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged â‰¥12yrs. with Mutations in CFTR gene,6089,02-11-2018
Aileron Therapeutics &amp; Dana-Farber/Boston Children's Cancer and Blood Disorders Center Enters into a Clinical Collaboration to Treat Pediatric Patients with Cancer,6090,02-11-2018
"AbbVie Exercises its Option to License Agreement for BioArctic's Alpha-Synuclein Antibody Portfolio, Signed in 2016",6091,02-11-2018
Illumina Acquires Pacific Biosciences for ~$1.2B with its Sequel SMRT Technology,6092,02-11-2018
Sage Reports Voting Results from FDA Advisory Committees for Zulresso (brexanolone) to Treat Postpartum Depression (PPD),6093,05-11-2018
Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immuno-Oncology Therapies,6094,06-11-2018
"Amgen to Present Long-Term Safety-Efficacy Data of Repatha (evolocumab) in Multiple studies, at AHA 2018",6095,06-11-2018
Amgen Out-Licenses its AMG 714 (PRO-015) Candidate to Provention to Treat Celiac Disease,6096,05-11-2018
Eisai Reports Results of Lenvima (Lenvatinib) + Keytruda (pembrolizumab) to Treat Metastatic NSCLC Metastatic Melanoma and Metastatic Urothelial Carcinoma,6097,12-11-2018
Amgen Reports Safety &amp; Efficacy Results of Repatha (evolocumab) in OSLER-1 Five-Year Extension Study,6098,13-11-2018
Novartis' Gilenya (fingolimod) Receives EU's Approval for Relapsing-Remitting Forms of Multiple Sclerosis (RRMS),6099,30-11-2018
Janssen (J&amp;J) Reports Results of Erleada (apalutamide) in P-III TITAN Study for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) #ASCO2019,6156,31-01-2019
Merck's V114 Receives FDA's Breakthrough Therapy Designation to Prevent Invasive Pneumococcal Disease,6157,31-01-2019
Columbia's Zuckerman Institute Develops an AI-based Brain-Computer Interface (BCI) for People with Aphasia &amp; Amyotrophic Lateral Sclerosis (ALS),6159,31-01-2019
Eli Lilly's Alimta (pemetrexed) + Keytruda (pembrolizumab) Receives FDA's Expanded Label Approval for 1L Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC),6178,31-01-2019
Janssen(J&amp;J) Signs an Exclusive Worldwide License Agreement with MeiraGTx for its Gene Therapy Candidates,6193,01-02-2019
Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders,6194,01-02-2019
Alexion Collaborates with Caelum Biosciences for its CAEL-101 to Treat Light Chain (AL) Amyloidosis,6198,01-02-2019
Audentes Reports Next Phase Development of AT132 for X-linked Myotubular Myopathy (XLMTM) with RMAT Designation,6206,01-02-2019
ONO Signs a Research Collaboration with Repare Therapeutics for its PolÎ¸ Inhibitor Program,6207,01-02-2019
ï»¿Roche Recalls Lots of Coaguchek Xs Pt Test Strips with FDA's Class I Warning,6285,04-02-2019
Evolus' Jeuveau (prabotulinumtoxinA-xvfs) Receives FDA Approval for Moderate-to-Severe Glabellar Lines in Adults,6361,04-02-2019
ï»¿Novartis' Kymriah Receives NICE Approval for R/R Diffuse Large B-cell lymphoma (DLBCL) in Adults,6409,04-02-2019
Merck's KEYTRUDA (pembrolizumab) Receives CHMP Recommendation for 1L Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC),6500,04-02-2019
Argenx Signs a Worldwide License Agreement with Halozyme for its ENHANZE Technology,6560,05-02-2019
Eli Lilly Reports Results of Olumiant (baricitinib) in P-III BREEZE-AD1 and BREEZE-AD2 study for Moderate-to-Severe Atopic Dermatitis (AD),6631,05-02-2019
ï»¿BioLineRX's BL-8040 Receives FDA's Orphan Drug Designation (ODD) for Pancreatic Cancer,6838,05-02-2019
ï»¿Eisai and Purdue Report Result of Lemborexant in P-III SUNRISE 2 Study for Insomnia in Adults,6861,05-02-2019
AstraZeneca's MEDI8897 Receives FDA's Breakthrough Therapy Designation (BTD) &amp; EMA's PRIME Designation for Lower Respiratory Tract Infection (LRTI) in Infants,6879,05-02-2019
Novartis to Acquire AveXis with its Gene Therapy Clinical Candidates,6936,09-04-2018
Celgene to Acquire Juno for its Cellular Immunotherapy &amp; Hematology Portfolio,6940,06-02-2018
ï»¿Sanofi to Acquire Bioverativ to Treat Hemophilia,6946,22-01-2018
FDA to Refuse Celgene for Filling Ozanimod's NDA for the Treatment of Relapsing Multiple Sclerosis,6951,27-02-2018
"GSK to Acquire 36.5% Stake in Consumer Healthcare Joint Venture, Established with Novartis",6957,22-04-2018
Genentech Signs a Development and Commercialization Agreement with Xencor for its IL-15 &amp; XmAb24306 Programs,6969,06-02-2019
ï»¿Lilly Reports Negative Results of Solanezumab in P-III EXPEDITION Studies in Patients with Alzheimer Disease,6980,06-12-2018
"Novo Nordisk, Genentech and Sanofi to cut off jobs in 2018",6986,03-11-2018
ï»¿Kyowa Kirin Signs an Exclusive Commercialization Agreement with Hisamitsu for its HP-3000,6997,06-02-2019
ï»¿Top Pharma Companies Appointed Their New CEOs in 2018,7016,06-09-2018
ï»¿Merck Reports Acceptance of NDA from FDA for Its (Imipenem/Cilastatin) + (Relebactam) for Complicated Urinary Tract and Intra-Abdominal Infections in Adults,7018,06-02-2019
ï»¿GSK to Collaborate with Pfizer to Build a Consumer Healthcare Joint Venture,7041,19-12-2018
Sanofi Report Results of Isatuximab in P-III ICARIA-MM Study for Patients with Relapsed/Refractory Multiple Myeloma (MM),7044,06-02-2019
"Pfizer's Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for Anemia ï»¿",7052,15-05-2018
"Pfizer's Nivestym (filgrastim-aafi, biosmilar) Receives the US FDA Approval for Neutropenia",7074,15-07-2018
Celltrion's Truxima (rituximab-abbs) Receives FDA's Approval for Three on-Hodgkin's Lymphoma Indications,7082,29-11-2018
"ï»¿Celltrion and Teva's Herzuma (trastuzumab-pkrb, Herceptin biosimilar) Receives FDA's Approval for HER2-Overexpressing Breast Cancer",7095,14-12-2018
"Amgen and Allergan's Mvasi (bevacizumab, biosimilar) + Combination Therapy Receives EU's MAA Approval for Treatment of Certain Types of Cancer",7109,18-01-2019
"Celltrion's Herzuma (Trastuzumab Biosimilar, CT-P6) Receives EMA Approval for Breast Cancer, Metastatic Breast Cancer and Metastatic Gastric Cancer",7118,14-02-2018
"Amgen and Allergan's ABP 980 (biosimilar, Herceptin) Receives CHMP Recommendation for Three Types of Cancerï»¿",7131,23-03-2018
"Sandoz's Zessly (infliximab) Receives EU Approval for Gastroenterological, Rheumatological And Dermatological Diseases",7138,24-05-2018
Sandoz's Hyrimoz (adalimumab) Receives EU Approval for Autoimmune Disorders,7147,27-07-2018
"Biocon and Mylan Fulphila (pegfilgrastim, Neulasta biosimilar) Receives CHMP (EMA) Recommendation for Neutropenia",7152,21-09-2018
Mylan and Biocon's Semglee Receives EU Approval for Patients with Diabetes,7161,28-03-2018
"GSK Signs a Worldwide Development &amp; Commercialization Collaboration with Merck KGaA, for $4.2B",7178,06-02-2019
ï»¿Sanofi's Cablivi (caplacizumab-yhdp) Receives FDA's Approval for Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in Adults,7224,07-02-2019
"ï»¿Paratek's Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults, Published in NEJM",7243,07-02-2019
Recordati Licenses Exclusive Commercialization Rights of Juxtapid (lomitapide) from Aegerion Pharmaceuticals ï»¿,7314,07-02-2019
AstraZeneca's Fasenra Receives Orphan Drug Designation (ODD) For Hypereosinophilic Syndrome (HES),7375,07-02-2019
"P&amp;G to Acquire ""This is L."" for its Feminine Care Products in the US ï»¿",7405,07-02-2019
ï»¿Medtronic's Pipeline Flex Embolization Device Receives FDA's Expanded Indication Approval for Intracranial Aneurysms (IAs),7525,08-02-2019
BioMarin Reports Results of Brineura (cerliponase alfa) for Patients with CLN2 Disease Aged 3 to 16 yrs.,7539,08-02-2019
ï»¿Genagon Signs a Worldwide License Agreement with Ligand for its Omniab Technology,7670,08-02-2019
Orthofix Medical's M6-C Artificial Cervical Disc Receives FDA's Approval for Cervical Disc Degeneration,7721,08-02-2019
Galapagos Signs a Worldwide Development &amp; Commercialization Agreement with Evotec for Fibrotic Diseases,7822,08-02-2019
C-Bridge Capital Signs a Development &amp; Commercialization Agreement with Samsung Bioepis for Biosimilars in China,7834,11-02-2019
Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Trial for Diabetic Retinopathy (DR),7859,11-02-2019
Pfizer Recalls Lots of Ambaro (valsartan and amlodipine besylate salt) for its Carcinogenic Effects in Japan,7877,11-02-2019
Finch Therapeutics' CP101 Receives FDA's Breakthrough Therapy Designation (BT) for Recurrent Clostridium Difficile (C. difficile) Infection,8013,11-02-2019
ï»¿Bristol-Myers Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate-214 study in Patients with Advanced or Metastatic RCC,8085,12-02-2019
Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Men,8117,12-02-2019
ï»¿Bayer Signs an Exclusive License Agreement with Moberg Pharma for MOB-015 in EU,8223,12-02-2019
Takeda's Adcetris (brentuximab vedotin) + AVD Receives EU Approval for CD30+ Stage IV Hodgkin Lymphoma (HL) in Adults,8333,12-02-2019
Genmab's Darzalex (daratumumab) Split Dosing Regimen Receives the US FDA Approval for Multiple Myeloma,8454,12-02-2019
ï»¿Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH),8575,13-02-2019
ï»¿AbbVie Signs a Partner and Option to Acquire Agreement with TeneoOne for its TNB-383B,8606,13-02-2019
Janssen (J&amp;J) Reports Voting Results from FDA Advisory Committees for Spravato (esketamine) in Adults with Resistant Depression,8677,13-02-2019
Almirall Signs an Option to License Agreement with Dermira to Develop and Commercialize Lebrikizumab in EU for Atopic Dermatitis ï»¿,8757,13-02-2019
ITROM Pharmaceutical Signs an Exclusive License &amp; Commercialization Agreement with Mithra for 20 years,8802,13-02-2019
Novartis' Egaten (triclabendazole) Receives FDA's Approval for Fascioliasis in the US,8887,14-02-2019
ï»¿Johnson &amp; Johnson to Acquire Auris Health for its Monarch Technology for $5.7B,8900,14-02-2019
Clinigen Licenses Commercialization Rights for Proleukin from Novartis in the US,8906,14-02-2019
ï»¿Amgen Signs a Multi-Target Collaboration with Abilita Bio for Enabled Membrane Proteins (EMPs),9013,14-02-2019
ï»¿Roche Signs a Clinical Program Agreement with Vaccibody to Evaluate VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer,9056,14-02-2019
Bayer Reports Results of Darolutamide in P-III ARAMIS trial for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC),9196,15-02-2019
Nestle Health Science (NHSc) Exercises its Exclusive WorldWide Option to License CDX-6114 from Codexis,9201,15-02-2019
Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC),9250,15-02-2019
Novartis Signs a Multi-Target Agreement with AbCellera for its Ab-Based Technology,9341,15-02-2019
Arvelle Therapeutics Licenses Exclusive Development &amp; Commercialization Rights for Cenobamate from SK Biopharmaceuticals in EUï»¿,9448,15-02-2019
Merck Reports Results of Keytruda (pembrolizumab) + Inlyta (axitinib) in P-III KEYNOTE-426 Study in Patients with 1L Advanced Renal Cell Carcinoma (RCC),9472,18-02-2019
Bayer Exercises its Exclusive WW Option to License Vitrakvi &amp; BAY 2731954 with Change-In-Control Clause from Loxo Oncology,9685,18-02-2019
Medtronic to Recall its Dual Chamber Implantable Pulse Generators (IPGs) in the US,10001,18-02-2019
Medtronic Reports Results of PRODIGY Study in Patients with Opioid-Induced Respiratory Depression (OIRD)ï»¿,10007,18-02-2019
ï»¿Pfizer Reports Results of Bavencio (avelumab) + Inlyta (axitinib) in P-III JAVELIN Renal 101 trial for 1L Advanced Renal Cell Carcinoma (RCC),10018,19-02-2019
Japan Ministry of Health Approves Use of Induced Pluripotent Stem Cells (iPSCs) for Spinal Injuries,10126,19-02-2019
Roche's Polatuzumab Vedotin as Combination Therapy &amp; Entrectinib Receives FDA's Priority Review for r/r Diffuse DLBCL &amp; NTRK Fusion-Positive Solid Tumors,10273,19-02-2019
Innovent Biosciences Collaborates with ï»¿Chipscreen to Evaluate Chidamide in Combination with Sintilimab &amp; IBI305 in China,10280,19-02-2019
ï»¿AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3 Study for Refractory Advanced or Metastatic Renal Cell Carcinoma (RCC),10288,19-02-2019
ï»¿Merck's Keytruda (pembrolizumab) Receives FDA's Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node,10304,20-02-2019
"Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol, N8-GP) for Patients with Haemophilia A",10310,20-02-2019
Alkermes Signs a Research Collaboration with Clovis Oncology to Evaluate ALKS 4230 in Combination with Rucaparib &amp; Lucitanib,10316,20-02-2019
ï»¿Pfizer and Lilly Report Result of Tanezumab in P-III A4091059 Study for Chronic Low Back Pain (CLBP),10324,20-02-2019
Bausch + Lomb Licenses US Commercial Rights for Eton Pharmaceuticals' EM-100 to Treat Ocular Itching,10329,20-02-2019
ï»¿Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study for 1L Advanced Hepatocellular Carcinoma (HCC),10338,21-02-2019
ï»¿Mustang Bio Signs an Exclusive Worldwide Collaboration with Nationwide Children's Hospital for Glioblastoma Multiforme,10346,21-02-2019
ï»¿Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App,10357,21-02-2019
AbbVie's Humira (adalimumab) Receives Health Canada Approval for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients,10374,21-02-2019
Merck to Acquire Immune Design for its Technologies for $300M,10379,21-02-2019
AbbVie &amp; Eisai's Humira (adalimumab) Receives Approval for Hidradenitis Suppurativa in Japan,10387,22-02-2019
Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv Mecarbil for Patients with Heart Failure,10394,22-02-2019
Janssen (J&amp;J) Signs an Exclusive WW Research Collaboration with Morphic to Develop Human Integrins Therapiesï»¿,10400,22-02-2019
Eurofarma Signs an Exclusive Development and Commercialization Agreement with NLS-1 Pharma for its Nalazol Therapy,10406,22-02-2019
Mallinckrodt Reports Results of Therakos Photopheresis Therapy in P-III study for Steroid-Refractory Acute Graft-Versus-Host Disease (aGvHD),10416,22-02-2019
ï»¿AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Trial for Patients with Coronary Artery Disease (CAD) and Type-2 Diabetes (T2D),10431,25-02-2019
ï»¿ Roche to Acquire Spark Therapeutics for $4.3B,10441,25-02-2019
Santhera Reports Results of Raxone (Idebenone) in P-III DELOS trial for Patients with Duchenne Muscular Dystrophy (DMD)ï»¿,10448,25-02-2019
AbbVie Signs an Exclusive Worldwide Research Collaboration with Voyager Therapeutics for Vectorized Abs,10456,25-02-2019
ï»¿Danaher to Acquire Biopharma Unit of GE LifeScience for $21.4B,10471,26-02-2019
Novartis Exercises its Option to License AKCEA-APO(a)-LRx from Akcea,10480,26-02-2019
ï»¿Ipsen to Acquire Clementia Pharmaceuticals for $1.31B to Expand its Rare Disease Portfolio,10488,26-02-2019
ï»¿Amgen Reports In-Favor Uphold of its Two Patents for Repatha from Delaware Jury,10499,26-02-2019
ï»¿Genmab Reports Results of Darzalex (daratumumab) in P-III COLUMBA Study for Patients with R/R Multiple Myeloma,10504,26-02-2019
ï»¿AstraZeneca and Merck Report Result of Lynparza (olaparib) in P-III POLO Trial for BRCA-Mutated Metastatic Pancreatic Cancer #ASCO2019,10520,27-02-2019
ï»¿Roche and Immatics Collaborate to Evaluate IMA101 + Tecentriq (atezolizumab) for Solid Cancers,10526,27-02-2019
ï»¿Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology,10532,27-02-2019
ï»¿Medtronic Resolute Drug-Eluting Stent (DES) Platform Receives FDA's Approval for Expanded Indication for Chronic Total Occlusion (CTO),10540,27-02-2019
Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for $165M,10551,27-02-2019
AstraZeneca's Farxiga and Xigduo XR Receives FDA's Expanded Label Approval for Type 2 Diabetes (T2D) and Moderate Renal Impairment,10559,28-02-2019
Janssen's Tremfya (guselkumab) Receives FDA's Approval for Moderate-to-Severe Plaque Psoriasis in Adults,10564,28-02-2019
Novartis Signs a Research Agreement with Target PharmaSolutions for Conducting TARGET-DERM Studyï»¿,10575,28-02-2019
ï»¿Novartis and Blackstone Life Sciences Collaborate to Launch Anthos Therapeutics for Cardiovascular Disorders,10587,28-02-2019
ï»¿Amicus Therapeutics' Galafold (migalastat) Receives FDA Approval for Fabry Disease in Adult Patients,10598,10-08-2018
AbCellera and Denali Therapeutics Expand Collaboration to Develop Abs for Neurological Disorders,10602,28-02-2019
ï»¿Servier's Asparlas (calaspargase pegol-mknl) Receives FDA's Approval for Acute Lymphoblastic Leukemia (ALL),10609,20-12-2018
Shire's Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation (CIC) in Adults,10630,17-12-2018
ï»¿Catalyst's Firdapse (amifampridine) Receives FDA's Approval for Lambert-Eaton Myasthenic Syndrome,10634,20-10-2018
Roche's Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Receives FDA's Approval for Patients with HER2-Positive Breast Cancers,10642,01-03-2019
Biogen's Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.ï»¿,10648,01-03-2019
ï»¿Pfizer's Daurismo (glasdegib) Receives FDA Approval for Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML),10653,11-10-2018
Sobi's Gamifant (emapalumab) Receives FDA Approval for Primary Haemophagocytic Lymphohistiocytosis (HLH),10660,20-11-2018
Pfizer's Lorbrena (lorlatinib) Receives FDA Approval for Patients with 1L ALK- Positive Metastatic NSCLC,10666,20-11-2018
"Alvogen Expands Development and Commercialization Collaboration with Pfenex for PF708 in EU, MENA and ROW",10669,01-03-2019
"Pfizer's Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated, HER2-Negative LA or MBC",10676,11-10-2018
ï»¿Ionis' Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults,10687,05-10-2018
Johnson &amp; Johnson Collaborates with AdoRx Therapeutics to Develop Therapies for Lung Cancer,10688,01-03-2019
Leadiant Biosciences Revcovi's (elapegademase-lvlr) Receives FDA Approval for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID) in Pediatric and Adult Patients,10696,05-10-2018
Paratek Pharmaceuticals' Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) in Adults,10704,02-10-2018
TaiMed Biologics' Trogarzo (ibalizumab-uiyk) Receives Approval for Multidrug Resistant (MDR)-HIV,10706,06-03-2018
Paratek's Seysara (sarecycline) Receives FDA's Approval for Treatment of Moderate to Severe Acne,10714,02-10-2018
ï»¿Verastem Oncology's Copiktra (duvelisib) Receives FDA Approval for r/r 2L+ Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),10720,24-09-2018
Rigel Pharmaceuticals' Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for Chronic Immune Thrombocytopenia (ITP) in Adults,10722,06-03-2018
Merck's Pifeltro (doravirine) Receives FDA Approval for Patients with HIV-1 in Appropriate Patients,10728,30-08-2018
Therapeutics MD's Annovera (Segesterone Acetate/Ethinyl Estradiol) Receives FDA Approval for the Prevention of Pregnancyï»¿,10734,10-08-2018
ï»¿Tetraphase Pharmaceuticals' Xerava (eravacycline) Receives FDA's Approval for Complicated Intra-Abdominal Infections (CIAI),10738,27-08-2018
ï»¿Eli Lilly's Olumiant (baricitinib) Receives FDA Approval for Moderately-to-Severely Active Rheumatoid Arthritis (RA) in Adults,10753,06-06-2018
GSK's Krintafel (tafenoquine) Receives FDA Approval Preventing the Relapse of P.vivax Malariaï»¿,10756,20-07-2018
AstraZeneca's Lokelma Receives FDA's Approval for Patients with Hyperkalaemia in Adults,10759,18-05-2018
Amgen's Aimovig (erenumab-aooe) Receives FDA's Approval for Prevention of Migraine in Adults,10765,17-05-2018
Agios Pharmaceuticals' Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutationï»¿,10771,20-07-2018
Janssen's Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC),10774,14-02-2018
ï»¿Helsinn's (fosnetupitant + palonosetron) Receives FDA Approval for Managing Chemotherapy-Induced Nausea and Vomiting (CINV),10779,20-04-2018
ï»¿SIGA Technologies' TPOXX (tecovirimat) Receives FDA Approval for Smallpox,10783,13-07-2018
BioMarin's Palynziq (pegvaliase-pqpz) Receives FDA Approval for Phenylketonuria (PKU) in Adults,10789,24-05-2018
Achaogen's Zemdri (plazomicin) Receives FDA Approval for Complicated Urinary Tract Infection (cUTI),10794,26-06-2018
GW Pharmaceuticals' Epidiolex (cannabidiol) Receives FDA Approval for Epilepsy for 2yrs. or older,10803,25-06-2018
Medicines Development for Global Health's (MDGH) Moxidectin Receives FDA Approval for Onchocerciasis (River Blindness),10806,13-06-2018
ï»¿Novavax Reports Results of ResVax in P-III PREPARE Trial for Prevention of RSV Disease in Infants via Maternal Immunization,10823,01-03-2019
Biocodex's Diacomit (stiripentol) Receives FDA Approval for Seizures Associated with Dravet Syndrome (DS) in Patients Aged 2 Years or Older,10872,02-08-2018
Sanofi's Zynquista (sotagliflozin) and Dupixent (dupilumab) Receives CHMP Recommendation for Type 1 Diabetes and Asthmaï»¿,10897,04-03-2019
Novartis Reports Results of Cosentyx (secukinumab) in P-III Study in Patients with Moderate to Severe Plaque Psoriasis in Chinaï»¿,10904,04-03-2019
ï»¿Lupus Therapeutics Signs a Research Agreement with Takeda for its TAK-079,10910,04-03-2019
ï»¿Biogen to Acquire Nightstar Therapeutics for $800M,10916,04-03-2019
ï»¿Verastem Oncology Reports Results of Copiktra (Duvelisib) in P-III DUO Study in Patients with R/R CLL/SLL,10930,05-03-2019
ï»¿Clovis Oncology Launches Rubraca (rucaparib) for Women with Relapsed Ovarian Cancer in Germany,10938,05-03-2019
ï»¿Ascendis Pharma Reports Results of TransCon Growth Hormone in P-III Height Study for Growth Hormone Deficiency (GHD) in Children,10945,05-03-2019
"Bioxcel, Nektar and Merck KGaA in a Triple Collaboration for Pancreatic Cancer",10955,05-03-2019
ProMab Biotechnologies Signs Worldwide License Agreement with NantKwest to Develop Ab for Multiple Myeloma,10963,05-03-2019
ï»¿Celgene's Fedratinib Receives FDA's Priority Review to NDA Filing for Myelofibrosis,10971,06-03-2019
Genentech Announces FDA's Acceptance of sNDA for Xofluza (baloxavir marboxil) in Patients with Influenza,10976,06-03-2019
ï»¿Pacira to Acquire MyoScience to Expand its Post-Surgical Portfolio,10981,06-03-2019
Acceleron's ACE-083 Receives FDA's ODD for Charcot Marie Tooth Disease (CMT),10987,06-03-2019
Pfizer Exercised its Option to License AnTolRx's Immune Tolerance Therapy for Type 1 Diabetes (T1D),10993,06-03-2019
ï»¿Allergan Reports Results of Rapastinel in Four P-III RAP-MD Studies for Major Depressive Disorders (MDD),11004,07-03-2019
ï»¿BeiGene and Ambrx Enters into a Worldwide Research and Development Collaboration to Develop Novel Biologics,11010,07-03-2019
Vertex Reports Positive Results of Triple Combination Therapy in P-III Studies for Cystic Fibrosisï»¿,11016,07-03-2019
ï»¿Alnylam Reports Positive Result of Givosiran in P-III ENVISION Study for Acute Hepatic Porphyria (AHP),11022,07-03-2019
ï»¿Baxter's Eptifibatide Receives the US FDA's Approval for Cardiovascular Diseases,11029,07-03-2019
ï»¿Shionogi Signs Development &amp; Commercialization Agreement with Akili for its AKL-T01 and AKL-T02 for ADHD &amp; ASD,11042,08-03-2019
ï»¿Oncternal Therapeutics Reverse Merges with GTx,11047,08-03-2019
ï»¿Janssen (J&amp;J) Reports Positive Results of Rilpivirine + Cabotegravir in P-III ATLAS and FLAIR Studies for HIV,11058,08-03-2019
Zeiss' CIRRUS HD-OCT Receives FDA's 510 (k) Clearance for Epithelial Thickness Mapping (ETM),11063,08-03-2019
ï»¿Bayer Submits EU's Marketing Authorization Application to EMA for Darolutamide,11069,08-03-2019
Roche's Ventana PD-L1 (SP142) Receives FDA's Approval for Identifying Triple-Negative Breast Cancer (TNBC) as CDxï»¿,11091,11-03-2019
ï»¿MSD Signs a License Agreement with King's College London &amp; Wellcome's Innovations to Develop Chronic Neuropathic Pain Therapies,11098,11-03-2019
Almirall's Ilumetri (tildrakizumab) Receives NICE's Provisional Approval for Moderate-To-Severe Plaque Psoriasisï»¿,11135,11-03-2019
ï»¿Roche's Tecentriq + Abraxane Receive FDA's Accelerated Approval for mTNBC,11149,11-03-2019
ï»¿AstraZeneca and Seres Therapeutics Enters into Research Collaboration for 3yrs.,11156,12-03-2019
Pfizer's Trazimera (trastuzumab-biosimilar) Receives FDA's Approval for HER-2+ Breast Cancer and m-Gastric/GEJ Cancerï»¿,11162,12-03-2019
Allergan Reports Acceptance of NDA from FDA for its Ubrogepant for Migraine,11167,12-03-2019
ï»¿Fujifilm to Acquire Biogen's Danish Biologics Manufacturing Facility for $890M,11176,12-03-2019
ï»¿Paige.AI Receives FDA's Breakthrough Designation for its Artificial Intelligence in Pathology,11183,12-03-2019
Eli Lilly Reports Positive Results of Cyramza (ramucirumab) in P-III RELAY Study for mNSCLCï»¿,11189,12-03-2019
Vertex's Symdeko (tezacaftor/ivacaftor and ivacaftor) Receives TGA's Approval for Cystic Fibrosis with CFTR Gene Mutation in Australiaï»¿,11198,13-03-2019
ï»¿Secura Bio Acquires WW Commercialization Rights to Novartis' Farydak for R/R Multiple Myeloma,11209,13-03-2019
ï»¿Akebia Therapeutics Reports Positive Results of Vadadustat in P-III J01 &amp; J03 Studies for Anemia Due to Chronic Kidney Disease (CKD) in Japan,11215,13-03-2019
ï»¿Exactech to Acquire XpandOrtho for its Ligament-Balancing Technology,11234,13-03-2019
ï»¿Sun Pharma's SPARC Signs a Research Collaboration with HitGen to Develop Therapies,11237,13-03-2019
ï»¿Retrotope's RT001 Receives EMA's Orphan Drug Designation for Infantile Neuroaxonal Dystrophy (INAD),11246,14-03-2019
ï»¿Smith &amp; Nephew to Acquire Osiris Therapeutics for $660M,11253,14-03-2019
ï»¿Roche's Hemlibra Receives EU's Approval for Severe Haemophilia A without Factor VIII Inhibitors,11259,14-03-2019
ï»¿Hoth Therapeutics Signs a License Agreement with UMB and Isoprene Pharmaceuticals,11276,14-03-2019
ï»¿Merck's Keytruda + Chemotherapy Receive EU's Approval for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC),11279,14-03-2019
ï»¿Merck KGaA Collaborates with Iktos for its Artificial Intelligence (AI) Technology,11294,15-03-2019
ï»¿Bayer Reports Results of Nifurtimox in P-III CHICO Study for Chagas Disease in Pediatric Patients,11297,15-03-2019
Roche's MabThera (rituximab) Receives EU's Approval for Rare Autoimmune Disease Pemphigus Vulgaris (PV),11303,15-03-2019
ï»¿Abbott's MitraClip Device Receives FDA's Expanded Indication Approval for Secondary Mitral Regurgitation (MR),11308,15-03-2019
AbCellera ï»¿Signs a Research Agreement with Bill &amp; Melinda Gates Foundation to Accelerate Global Health Research,11314,15-03-2019
BMS Reports Positive Results of Eliquis (apixaban) in P-IV AUGUSTUS Study for NVAF/ACS/PCI,11325,18-03-2019
Alcon to Acquire PowerVision for $285M,11336,18-03-2019
ï»¿Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure,11341,18-03-2019
ï»¿Cellesce Signs a License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Organoids,11345,18-03-2019
AstraZeneca Reports Positive Results of Farxiga in P-III DECLARE-TIMI 58 Study for Type-2 Diabetes (T2D),11352,19-03-2019
ï»¿Baxter and BioMerieux Collaborates to Develop Biomarkers for Acute Kidney Injury (AKI),11359,19-03-2019
Jazz Pharmaceuticals' Sunosi (solriamfetol) Receives FDA's Approval for the Treatment of Sleep Disordersï»¿,11364,22-03-2019
Mylan Voluntary Globally Recalls 2 Lots of Levoleucovorin (250mg/25ml) Injection Used to Prevent Harmful Effects of Methotrexate,11370,19-03-2019
Merck Extends its Strategic Collaboration with NGM Biopharmaceuticals,11375,22-03-2019
Roche's Tecentriq (atezolizumab) + Chemotherapy (carboplatin and etoposide) Receive FDA's Approval for Extensive-Stage Small Cell Lung Cancer (ES-SCLC),11382,19-03-2019
ï»¿Biogen and Eisai Terminate P-III ENGAGE and EMERGE Study for Alzheimer's Disease,11388,22-03-2019
Thea and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD,11390,19-03-2019
Merck KGaA and Pfizer Terminates P-III JAVELIN Ovarian PARP 100 Study for Advanced Ovarian Cancer,11398,20-03-2019
ï»¿Celgene Collaborates with Exscientia for its AI Drug Discovery Platform,11408,22-03-2019
"ï»¿Novartis Announces Spin-Off of Alcon Eye Care Business on April 9, 2019",11420,22-03-2019
AbbVie Reports FDA's Hold on All Clinical Trials Evaluating Venclexta/Venclyxto (venetoclax) for Multiple Myeloma,11422,20-03-2019
ï»¿Merck KGaA Collaborates with GenScript for the Expansion of Cell and Gene Therapies in China,11433,20-03-2019
ï»¿Sage Therapeutics' Zulresso (brexanolone) Receives FDA's Approval for Postpartum Depression (PPD),11434,20-03-2019
Evotec and GARDP Collaborates to Develop Novel Antibiotics for Antimicrobial Resistance (AMR)ï»¿,11440,20-03-2019
AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)ï»¿,11443,26-03-2019
ï»¿Thermo Fischer to Acquire Brammer Bio for $1.7B,11460,25-03-2019
ï»¿Almirall Signs a Research Collaboration with HitGen for its DNA-Encoded Technology,11467,26-03-2019
ï»¿Lupin and YL Biologics' Etanercept Biosimilar (YLB113) Receive PMDA's Approval for Moderate-to-Severe Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA) in Japan,11474,26-03-2019
"AbbVie's Skyrizi (risankizumab) Receives Japanese Ministry of Health, Labour and Welfare (MHLW) Approval to Treat Plaque Psoriasis, Generalized Pustular Psoriasis, Erythrodermic Psoriasis and Psoriatic Arthritis in Adults",11487,26-03-2019
ï»¿Celgene Files NDA for Ozanimod to the US FDA for Relapsing Forms of Multiple Sclerosis (RMS),11497,26-03-2019
Novartis' Mayzent (siponimod) Receives FDA's Approval for Patients with Secondary Progressive Multiple Sclerosis (SPMS)ï»¿,11520,27-03-2019
ï»¿Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext to Develop Therapies for Autoimmune Disorders,11589,27-03-2019
ï»¿AstraZeneca's Forxiga (dapagliflozin) Receives MHLW's Approval for Type-1 Diabetes (T1D) in Japan,11596,27-03-2019
"ï»¿Gilead's Biktarvy (Bictegravir, Emtricitabine and Tenofovir Alafenamide) Receives MHLW's Approval for HIV-1 Infection in Japan",11604,27-03-2019
ï»¿Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness,11611,27-03-2019
Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates in Immuno-Oncology,11628,25-03-2019
ï»¿Eisai Signs a Research Agreement with Cerveau Technologies for its Novel Tau Imaging Agent,11635,25-03-2019
AstraZeneca's Forxiga (dapagliflozin) Receives EU's Approval for Type-1 Diabetes (T1D) in Adults,11644,25-03-2019
ï»¿BioLineRx Reports Engraftment Data of BL-8040 in P-III GENESIS Trial for Patients with Multiple Myeloma,11652,28-03-2019
ï»¿Chugai's Risdiplam Receives MHLW's Orphan Drug Designation for Spinal Muscular Atrophy (SMA),11657,28-03-2019
ï»¿Ono Pharmaceutical Signs a Multi-Year Collaboration with LifeArc and Cancer Research UK to Develop Immuno-Therapies for Cancer,11669,28-03-2019
ï»¿Apple Launches its Watch Series 4 Enabled with ECG App and Irregular Rhythm Notification in Europe and Hong Kong,11678,28-03-2019
ï»¿Johnson &amp; Johnson (J&amp;J) Vision Launches Acuvue Oasys with Transitions Light Intelligent Technology in the US,11689,28-03-2019
ï»¿Bayer Signs a Non-Exclusive Licensing Agreement with ProteoNic Biotechnology for its 2G UNic Technology,11708,29-03-2019
ï»¿Gilead and Galapagos' Report Results of Filgotinib in P-III FINCH 3 Trial for Moderate-To-Severe Active Rheumatoid Arthritis (RA),11716,29-03-2019
ï»¿AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi Sankyo for $6.9B,11726,29-03-2019
ï»¿Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH) for ALS Biomarker Study,11741,29-03-2019
Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders,11747,29-03-2019
ï»¿Bluebird Bio's Zynteglo Receives CHMP's Positive Opinion for Conditional Marketing for Patients with Transfusion-Dependent Î²-Thalassemia (TDT) without Î²0/Î²0 Genotype,11851,01-04-2019
ï»¿Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B,11913,01-04-2019
ï»¿Boehringer Ingelheim (BI) to Acquire ICD Therapeutics for its MacroDel Delivery Technology,11940,01-04-2019
ï»¿Roche Reports Result of Ipatasertib + Tecentriq (atezolizumab) in P-Ib Study for 1L Patients with Advanced Triple-Negative Breast Cancer (TNBC),11944,01-04-2019
ï»¿VistaGen Therapeutics Reports Positive Results of PH94B in P-III study for Social Anxiety Disorder (SAD),11956,02-04-2019
AveXis to Purchase Biologics Manufacturing Facility in Colorado,11968,02-04-2019
ï»¿Merck's Keytruda (pembrolizumab) + Chemotherapy Receive NMPA's (CFDA) Approval for 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC),12006,02-04-2019
Novartis' Cosentyx (secukinumab) Receives NMPA's (CFDA) Approval for Patients with Plaque Psoriasis in Adults,12045,02-04-2019
Sangamo Therapeutics Signs an Option Agreement with Brammer Bio for its AAV Manufacturing Facility,12054,02-04-2019
Allergan and Molecular Partners Report Result of Abicipar pegol in P-III MAPLE Study for Neovascular Macular Degeneration (nAMD)ï»¿,12066,03-04-2019
ï»¿Astellas Signs a Research and License Agreement with Xencor for Bispecific Antibody Program in Oncology,12076,03-04-2019
ï»¿Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy's Three Dermatology Products,12088,03-04-2019
ï»¿Dermelix Collaborates with EspeRare to Co-develop and Commercialize DMX-101 for XLHED,12098,03-04-2019
ï»¿Channel Medsystems' Cerene Cryotherapy Device Receives FDA's Approval for Heavy Menstrual Bleeding,12104,03-04-2019
ï»¿Liquidia Reports Results of LIQ861 in P-III INSPIRE Trial in Patients with Pulmonary Arterial Hypertension (PAH),12117,04-04-2019
"ï»¿Fresenius Kabi's Idacio (adalimumab, biosimilar) Receives EU's Marketing Approval in Rheumatology, Gastroenterology and Dermatology",12124,04-04-2019
ï»¿Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies,12132,04-04-2019
ï»¿Genmab and Janssen Biotech Report Initiation of P-III MMY3021 Study for Darzalex (daratumumab) in Multiple Myeloma,12145,04-04-2019
AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES),12171,04-04-2019
ï»¿Oncology Venture Signs an Exclusive Option Agreement to In-License Commercialization Rights for R-Pharm's Ixempra (ixabepilone) in EU,12176,05-04-2019
ï»¿Myriad Expands its Companion Diagnostic Collaboration with AstraZeneca and Merck,12184,05-04-2019
ï»¿Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers,12196,05-04-2019
ï»¿Roivant Launches Cytovant Sciences to Collaborates with Medigene for the Development of Cellular Therapies in Asia,12208,05-04-2019
ï»¿Amazon Launches Alexa's Health Services for Managing Health and Handling Patients Data,12216,05-04-2019
ï»¿Novartis' Kisqali + Aromatase Inhibitor Receive FDA's Breakthrough Therapy Designation for HR+/HER2- Advanced Breast Cancer,12227,03-01-2018
ï»¿Roche's Hemlibra Receives FDA's Breakthrough Therapy Designation for Hemophilia A without Factor VIII Inhibitors,12231,17-04-2018
Roche's Tecentriq + Avastin Receive FDA's Breakthrough Designation as 1L Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC),12237,18-07-2018
Proteostasis' PTI-428 Receives FDA's Breakthrough Therapy Designation for Cystic Fibrosis (CF),12242,12-03-2018
Novartis' Promacta Receives FDA's Breakthrough Therapy Designation for Severe Aplastic Anemia (SAA),12248,04-01-2018
Seattle Genetics' Adcetris (brentuximab vedotin) Receives FDA's Breakthrough Designation for Frontline Peripheral T-Cell Lymphomasï»¿,12253,15-11-2018
ï»¿Compass Pathways' Psilocybin Therapy Receives FDA's Breakthrough Therapy Designation for Treatment-Resistant Depression,12259,23-10-2018
Sage Therapeutics' SAGE-217 Receives FDA's Breakthrough Designation for CNS Disorders,12264,07-02-2018
ï»¿Avita Medical Reports Results of RECELL System in Investigational Device Exemption (IDE) Compassionate Use and Continued Access Studies for Third-Degree Burns in Pediatric Patients,12352,08-04-2019
ï»¿Celgene and Acceleron Pharma Submit Biologics License Application (BLA) to the US FDA for Luspatercept,12378,08-04-2019
ï»¿Sanofi and Alnylam Exercise Research and Option Phase Collaboration for its 2014 Deal,12388,08-04-2019
Xoma Purchases Royalty Rights for Aronora's Five Preclinical and Clinical Hematology Candidates,12403,08-04-2019
"ï»¿Regeneron Collaborates with Alnylam to Discover, Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders",12423,09-04-2019
ViiV Healthcare's Dovato (dolutegravir/lamivudine) Receives FDA's Approval to Treat HIV-1 Infection in Adultsï»¿,12432,09-04-2019
ï»¿uniQure's AMT-130 Receives FDA's Fast Track Designation for Huntington's Disease,12443,09-04-2019
ï»¿Audentes Signs an Exclusive License Agreement with Nationwide Children's Hospital (NCH) for the Expansion of its AAV Technology and Pipeline,12454,09-04-2019
ï»¿BeiGene Signs a Worldwide Co-Development and Commercialization Agreement with BioAtla for BA3071 and Tislelizumab,12467,09-04-2019
Amgen's Evenity (romosozumab-aqqg) Receives FDA's Approval for Osteoporosis in Postmenopausal Women at High Risk for Fracture,12489,10-04-2019
ï»¿Xinhua Healthcare Signs an Exclusive License Agreement with ArcDia for its mariPOC Technology in China,12496,10-04-2019
ï»¿AstraZeneca and Merck's Lynparza (olaparib) Receive EU's Approval as a Monotherapy to Treat Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer,12506,10-04-2019
ï»¿Â­Alkermes' Reports Results of Aristada (aripiprazole lauroxil) and Invega Sustenna (paliperidone palmitate) in P-IIIb ALPINE Study to Treat Schizophrenia,12513,10-04-2019
Shanghai Fosun Signs an Exclusive License Agreement with ReNeuron for its CTX and hRPC Cell Therapy in China,12520,10-04-2019
ï»¿Astellas Collaborates with Concerto HealthAI on Real-World Evidence (RWE) Initiative for Acute Myeloid Leukemia (AML),12531,11-04-2019
ï»¿Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies,12536,11-04-2019
Sandoz Signs a Commercialization Agreement with Shionogi for Rizmoic (naldemedine) in Europe,12545,11-04-2019
Cognoa Signs an Exclusive License Agreement with Stanford for its Google Glass-based Technology for Children with Autism Spectrum Disorder (ASD),12553,11-04-2019
ï»¿BioDelivery Sciences (BDSI) Signs a License Agreement with Shionogi to Commercialize Symproic (naldemedine) in the US,12559,11-04-2019
Merck's Keytruda (pembrolizumab) Receives FDA's Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell Lung Cancer (NSCLC),12569,12-04-2019
Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC),12576,12-04-2019
Moleculin Signs a Clinical Research Agreement with Emory University for Brain Tumor in Pediatric Patients,12581,12-04-2019
Gilead and Novo Nordisk Collaborate to Conduct a Combination Therapy Trial in NASH,12589,12-04-2019
Omron Healthcare Receives FDA's Approval for Complete a Blood Pressure Monitoring Device with ECG Facility,12603,12-04-2019
ï»¿Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria,12620,15-04-2019
ï»¿Tracon Terminates its P-III TAPPAS Trial of TRC105 (carotuximab) + Votrient (pazopanib) for Advanced or Metastatic Angiosarcoma,12629,15-04-2019
ï»¿Dr. Reddy's to Acquire a Portfolio of 42 Abbreviated New Drug Applications (ANDA) in the US,12637,15-04-2019
Santhera to Present Result of DELOS &amp; SYROS Study at the 2019 MDA Clinical and Scientific Conference ï»¿,12643,15-04-2019
ï»¿Generium and Selexis Launch Eculizumab Biosimilar for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Hemolytic Uremic Syndrome (aHUS) in Russia,12662,09-04-2019
Novartis Reports FDA's Acceptance of BLA for Brolucizumab (RTH258) to Treat Wet AMD,12670,16-04-2019
ï»¿Castle Creek Collaborates with Fibrocell to Develop and Commercialize FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB),12681,16-04-2019
Eagle Restructured its Licensing Agreement with Teva for Bendeka (bendamustine hydrochloride),12690,16-04-2019
Janssen Expands Clinical Development for Tremfya(R) (guselkumab) in Familial Adenomatous Polyposis (FAP)ï»¿,12699,16-04-2019
Alnylam Initiates P-III ILLUMINATE-B Study of Lumasiran for Primary Hyperoxaluria Type 1 (PH1) in Pediatric Patients,12707,16-04-2019
Tessa Collaborates with Merck to Evaluate a Combination Therapy for Metastatic or Recurrent Cervical Cancerï»¿,12718,17-04-2019
ï»¿Novartis Reports Results of Zolgensma (onasemnogene abeparvovec-xioi) in P-III STR1VE Study for Spinal Muscular Atrophy (SMA) Type 1,12741,17-04-2019
ï»¿FDA Orders Immediate Stop on Commercialization of Surgical Mesh for Women with Pelvic Collapse in the US,12748,17-04-2019
Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays for Adverse Pregnancy Outcomes,12749,17-04-2019
ï»¿Gilead Collaborates with Insitro to Discover and Develop Novel Therapies in Nonalcoholic Steatohepatitis (NASH) for 3yrs.,12763,17-04-2019
ï»¿Boehringer Ingelheim Collaborates with PureTech to Develop Immuno-Oncology Candidates for Immune Modulation,12776,18-04-2019
ï»¿CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program,12783,18-04-2019
Medtronic Reports Results of VenaSeal Closure System in VeClose Extension Study for Chronic Venous Diseases,12792,18-04-2019
ï»¿OncoSec Signs Research Agreement with Duke University School of Medicine to Evaluate the Combination of TAVOPLUS with a HER2-Plasmid Vaccine,12801,18-04-2019
World Health Organization (WHO) Reports 10 Guidelines on Digital Health Interventions,12806,18-04-2019
Pfizer &amp; Eli Lilly Report Results of Tanezumab in Long-Term P-III Study for Osteoarthritis,12815,19-04-2019
ï»¿AbbVie's Skyrizi (risankizumab) Receives Health Canada's Approval for Moderate to Severe Plaque Psoriasis,12821,19-04-2019
ï»¿Mylan and TB Alliance Collaborate to Commercialize Pretomanid in Two Combination Regimens for Tuberculosis,12836,19-04-2019
ï»¿NICE Publishes Final Recommendation for Almirall's Ilumetri (tildrakizumab) to Treat Moderate-To-Severe Plaque Psoriasis in Adults,12844,19-04-2019
ï»¿Almac Diagnostic Collaborates with Queen's University to Bring Personalized Chemotherapy for Esophageal Cancer,12851,19-04-2019
ï»¿Alvogen Voluntary Recalls Nationwide Two Lots of Fentanyl Transdermal System Due to Product Mislabeling,12874,22-04-2019
ï»¿TELA Bio's Restella Reconstructive BioScaffolds Receives FDA's 510(k) Clearance for Reconstructive Surgery,12889,22-04-2019
ï»¿Lilly Signs a Global Research and Licensing Agreement with Avidity Biosciences to Develop Therapies in Immunology,12893,22-04-2019
Merck's Keytruda (pembrolizumab) + Inlyta (axitinib) Receive FDA's Approval as 1L Treatment for Advanced Renal Cell Carcinoma,12899,22-04-2019
ï»¿Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study for Non-Radiographic Axial Spondyloarthritis,12904,23-04-2019
ï»¿Roche Launches Ventana HER2 Dual ISH CDx for the Identification of Breast and Gastric Cancer,12913,23-04-2019
ï»¿Eli Lilly to Sell Rights for its Two Antibiotics and a Manufacturing Facility to Eddingpharm in China for $375M,12924,23-04-2019
ï»¿Alder BioPharmaceuticals Reports FDA's Acceptance of BLA for Eptinezumab to Prevent Migraine,12943,23-04-2019
NuVasive Reports Results of Cohere Porous PEEK Implants for Degenerative Cervical Disc,12947,23-04-2019
BAROnova's TransPyloric Shuttle Device Receives FDA's Approval for the Treatment of Obesity in Adults,12961,24-04-2019
Teva Discontinues its P-III ENFORCE Study of Fremanezumab for Episodic Cluster Headache,12972,24-04-2019
ï»¿OncoSec Initiates a Triple Combination Immunotherapy Trial for Squamous Cell Head and Neck Cancer,12994,24-04-2019
AbbVie's Skyrizi (risankizumab-rzaa) Receives FDA's Approval for Moderate to Severe Plaque Psoriasis,13019,24-04-2019
Fulcrum Therapeutics ï»¿Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy,13025,24-04-2019
ï»¿Takeda Signs a Licensing Option Agreement with Emendo Biotherapeutics for its OMNI Nuclease Program,13052,25-04-2019
Perelman School of Medicine Signs a Research and Development Agreement with Sensus Healthcare for its Sculptura Intraoperative Radiation Therapy System,13114,24-04-2019
ADC Therapeutics Signs a License Agreement with Adagene for its SAFEbody Technology,13237,25-04-2019
Eli Lilly Facilitates the Withdrawal of Lartruvo (olaratumab) from the Global Market for Advanced Soft Tissue Sarcoma,13326,25-04-2019
ï»¿B. Braun Launches its Heparin Sodium Prefilled Syringe in the US,13377,25-04-2019
Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi Tanabe for its MT-1303 (amiselimod),13397,26-04-2019
Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062 Study as a Monotherapy for 1L Treatment of Advanced Gastric Cancer,13444,26-04-2019
Takeda Files NDA for Cabometyx (cabozantinib) to MHLW for Advanced Renal Cell Carcinoma in Japan,13511,26-04-2019
ï»¿Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study for Bridging Fibrosis (F3) due to NASH,13528,26-04-2019
Novo Nordisk Files MAA for Semaglutide to the EMA for Type 2 Diabetesï»¿,13533,26-04-2019
ï»¿AstraZeneca and Merck's Lynparza (olaparib) Receive CHMP's Positive Opinion for 1L Maintenance Treatment of BRCA-Mutated Advanced Ovarian Cancer,13566,29-04-2019
Sanofi and Lexicon's Zynquista (sotagliflozin) Receive EU's MAA to Treat Type-1 Diabetes in Adults,13664,29-04-2019
Acutus Medical's AcQMap Contact Mapping Software Receives CE Mark Approval,13674,29-04-2019
"ï»¿Novo Nordisk's Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP's Positive Opinion to Treat Hemophilia A in Adolescents and Adults",13683,29-04-2019
Sandoz Signs an Agreement with EirGenix to Commercialize Proposed Trastuzumab Biosimilar for HER2+ Cancer Tumors,13707,30-04-2019
ViiV Healthcare Files NDA for Cabotegravir + Edurant (rilpivirine) to the US FDA to Treat HIV-1 Infection in Adultsï»¿,13722,30-04-2019
ï»¿Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology,13776,30-04-2019
ï»¿AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis,13824,30-04-2019
Abbott Reports Results of High Sensitive Troponin-I Blood Test for Risk Assessment of Heart Diseases,13827,30-04-2019
Vertex's Kalydeco (ivacaftor) Receives FDA's Approval for Cystic Fibrosis in Eligible Infants Aged 6 to Less than 12 Months,13852,01-05-2019
ï»¿AbbVie's Mavyret (glecaprevir and pibrentasvir) Receives FDA's Approval for All Genotypes of Hepatitis C in Pediatric Patients,13872,01-05-2019
ï»¿Roche Spin-Off Nimble Therapeutics to Commercialize its Drug Development Technology,13886,01-05-2019
ï»¿AbbVie's Skyrizi (risankizumab) Receives European Commission's Approval for Moderate to Severe Plaque Psoriasis,13929,01-05-2019
ï»¿Medtronic Launches Solitaire X Revascularization Device for Acute Ischemic Stroke in the US,13943,01-05-2019
ï»¿Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for Advanced Renal Cell Carcinoma,13961,02-05-2019
Medtronic's Attain Stability Quad MRI SureScan Left Heart Lead Receives FDA's Approval for Heart Failureï»¿,13967,02-05-2019
ï»¿Eisai Terminates its Worldwide Development &amp; Commercialization Agreement with Purdue Pharma for Lemborexant,13973,02-05-2019
ï»¿Tmunity Signs an Exclusive Research Agreement with the University of California to Advance TCR Therapies for Pediatric Cancers,13979,02-05-2019
Sanofi's Dengvaxia Receives FDA's Approval to Prevent Dengue in Endemic Region in the US,13985,02-05-2019
ï»¿AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies,13998,03-05-2019
ï»¿GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma,14012,03-05-2019
ï»¿Boehringer Ingelheim Signs a Clinical Research Agreement with Amal for the Evaluation of Combination Therapy to Treat Stage IV colorectal cancer,14020,03-05-2019
ï»¿Celgene Collaborates with Presage to Evaluate Therapies with its CIVO Technology for Multiple Cancers,14027,03-05-2019
"ï»¿AstraZeneca's Qternmet XR (dapagliflozin, saxagliptin, metformin hydrochloride) Receives FDA's Approval for Type-2 Diabetes in the US",14038,03-05-2019
ï»¿Roche's Kadcyla (trastuzumab emtansine) Receives FDA's Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in the US,14066,06-05-2019
ï»¿Lundbeck to Acquire Abide Therapeutics for $400M,14074,06-05-2019
ï»¿Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men,14082,06-05-2019
ï»¿Pfizer's Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) Receive FDA's Approval for Transthyretin Amyloid Cardiomyopathy,14090,06-05-2019
ï»¿Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine,14120,07-05-2019
ï»¿Roche Reports Results of Risdiplam in FIREFISH and SUNFISH Studies for Spinal Muscular Atrophy,14147,07-05-2019
ï»¿BioMarin's Palynziq (pegvaliase injection) Receives European Commission's MAA Approval for Phenylketonuria,14154,07-05-2019
Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers for Neurodegenerative Diseases,14164,07-05-2019
ï»¿Novartis Reports Results of MS Progression Discussion Tool in a Validation Study for Patients with Multiple Sclerosis,14171,07-05-2019
ï»¿AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukaemia,14186,08-05-2019
ï»¿Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies for Relapsing and Primary Progressive Multiple Sclerosis,14193,08-05-2019
ï»¿Sanofi's Dupixent (dupilumab) Receives European Commission Approval for Severe Asthma with Type 2 Inflammation,14197,08-05-2019
ï»¿AstraZeneca and Daiichi Report Results of Trastuzumab Deruxtecan (DS-8201) in P-II DESTINY-Breast01 Study for Refractory HER2+ Metastatic Breast Cancer,14220,08-05-2019
ï»¿FDA Issues an Alert on Medtronic's Pacemaker or Cardiac Resynchronization Therapy Pacemaker for its Premature Battery Depletion,14226,08-05-2019
Pfizer to Acquire Therachon for the Expansion of its Rare Disease Portfolio,14241,08-05-2019
ï»¿Novartis Acquires Worldwide Rights of Takeda's Xiidra (lifitegrast ophthalmic solution) for $5.3B,14252,09-05-2019
ï»¿Medtronic Reports Results of MiniMed 640G System in the SMILE Study for Reducing Hypoglycemia in Patients with Type 1 Diabetes,14263,09-05-2019
ï»¿Janssen (J&amp;J) Expands its PTG-200 Collaboration with Protagonist for Second Generation Oral IL-23 Receptor Antagonists,14270,09-05-2019
Gilead Collaborates with Goldfinch Bio to Develop and Commercialize Therapies for Kidney Disorders,14278,09-05-2019
Takeda Signs a Licensing Agreement with Curadev for Stimulator of Interferon Genes (STING) Agonist,14285,09-05-2019
ï»¿Ethicon Acquires Rights of Takeda's TachoSil Fibrin Sealant Patch for ~$400M,14295,09-05-2019
ï»¿BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme,14301,10-05-2019
ï»¿Medtronic To Acquire Titan Spine for its Portfolio of Implants and nanoLock Surface Technology,14311,10-05-2019
ï»¿Takeda Reports FDA's Acceptance of BLA for Entyvio (Vedolizumab SC) as a Maintenance Therapy in Moderate to Severe Active Ulcerative Colitis,14325,10-05-2019
ï»¿Boston Scientific to Acquire Vertiflex for its Superion Indirect Decompression System,14334,10-05-2019
AstraZeneca Reports Results of Roxadustat in Global Phase III Programme for Cardiovascular Safety in Patients with Chronic Kidney Disease,14342,10-05-2019
ï»¿Eli Lilly's Cyramza (ramucirumab) Receives FDA's Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carcinoma,14369,13-05-2019
"ï»¿Novartis Voluntary Nationwide Recalls Three Lots of Promacta (eltrombopag, 12.5 mg) Oral Suspension Due to Peanut Contamination",14375,13-05-2019
ï»¿Boston Scientific Reports Results of Emblem S-ICD System in UNTOUCHED Study to Prevent Sudden Cardiac Death,14390,13-05-2019
The US FDA Issues Final Guidance on Interchangeable Biosimilars,14395,13-05-2019
ï»¿Roche Launches Cobas MTB-RIF/INH Test for the Detection of Antimicrobial Resistance in Tuberculosis,14404,14-05-2019
ï»¿Regeneron's Eylea (aflibercept) Injection Receives FDA's Approval for Diabetic Retinopathy,14411,14-05-2019
ï»¿Exelixis and Daiichi Report Launch of Minnebro (Esaxerenone) Tablets for Hypertension in Japan,14419,14-05-2019
ï»¿AliveCor's KardiaMobile 6L Receives FDA's Clearance as Six-Lead Personal ECG Device,14422,14-05-2019
ï»¿HanX Biopharmaceuticals Signs a License Agreement with Onconova to Develop and Commercialize Rigosertib in Greater China,14428,14-05-2019
ï»¿Myovant Sciences Reports Results of Relugolix Combination Therapy in P-III LIBERTY 1 Study for Uterine Fibroids in Women,14440,15-05-2019
ï»¿Merck KGaA and Pfizer's Bavencio (avelumab) + Inlyta (axitinib) Receive FDA's Approval as 1L Treatment for Advanced Renal Cell Carcinoma,14447,15-05-2019
ï»¿Abbott Collaborates with NIH on Brain Initiative for Advancing Research on Neurological Disorders,14460,15-05-2019
ï»¿Progenics Signs an Exclusive Agreement with ROTOP Pharmaka to Develop and Commercialize Imaging Agent 1404 for Prostate Cancer in Europe,14466,15-05-2019
ï»¿REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based on NAV-Technology,14472,15-05-2019
ï»¿Roche and AbbVie's Venclexta (venetoclax) + Gazyva (obinutuzumab) Receive FDA's Approval for Untreated Chronic Lymphocytic Leukemia,14485,16-05-2019
Vertex Signs a 4 Years Agreement with Kymera to Discover and Develop Protein Degradation Therapies,14493,16-05-2019
ï»¿Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders,14507,16-05-2019
"ï»¿NeuClone to Initiate P-I Clinical Study of Stelara (ustekinumab, biosimilar) in Australia",14516,16-05-2019
ï»¿GSK Expands its License Agreement with Zymework to Develop and Commercialize Bi-Specific Antibodies,14528,16-05-2019
ï»¿Sanofi and Regeneron Report Updated Results of Libtayo (cemiplimab-rwlc) in P-II EMPOWER-CSCC-1 Study for Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma,14539,17-05-2019
ï»¿Thermo Fisher to Acquire Manufacturing Facility from GSK for ~$100M,14555,17-05-2019
ï»¿Pfizer's Fragmin (dalteparin sodium) Receives FDA's Approval for Symptomatic Venous Thromboembolism in Pediatric Patients,14559,17-05-2019
ï»¿Exelixis Signs an Exclusive Option and License Agreement with Iconic Therapeutics for Advancing ADC Program,14580,17-05-2019
Roche Signs a Worldwide License Agreement with Parvus Therapeutics to Develop and Commercialize Navacim Platform for Autoimmune Diseases,14587,17-05-2019
ï»¿AbbVie Reports Results of Depatux-M (depatuxizumab mafodotin) in P-III INTELLANCE-1 Study for Glioblastoma,14622,20-05-2019
ï»¿Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study for Ulcerative Colitis,14638,20-05-2019
ï»¿Ethicon (J&amp;J) Recalls Endo-Surgery Intraluminal Staplers Due to Complete Staple Line Failure,14643,20-05-2019
Takeda's Gattex (teduglutide) Receives the US FDA's Approval for Short Bowel Syndrome in Children,14653,20-05-2019
ï»¿UCB's Nayzilam (midazolam) Receives FDA's Approval for the Treatment of Seizure Cluster in Epilepsy in the US,14678,21-05-2019
ï»¿Santhera Signs a Pre-Clinical Research Agreement with Biozentrum to Advance Gene Therapy for Congenital Muscular Dystrophy,14693,21-05-2019
ï»¿Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-119 Study for Metastatic Triple-Negative Breast Cancer,14696,21-05-2019
AstraZeneca Reports Results of Symbicort Turbuhaler (budesonide/formoterol) in Novel START Study for Mild Asthma,14702,21-05-2019
ï»¿Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer,14711,21-05-2019
ï»¿Merck to Acquire Peloton Therapeutics for $2.2B,14721,22-05-2019
Verily Collaborates with Global Pharma Companies to Develop Clinical Research Program,14734,22-05-2019
ï»¿Array BioPharma Reports Results of Combination Therapy in P-III BEACON CRC Study for BRAF(V600E)- Mutant Metastatic Colorectal Cancer,14742,22-05-2019
ï»¿Abbott Reports Results of Minimally Invasive Device in TRILUMINATE Study for Tricuspid Heart Valve Leaks,14750,22-05-2019
Medtronic Reports Results of Symplicity Renal Denervation System in Two Studies for Hypertensive Heart Diseases,14759,22-05-2019
"Biocon and Mylan's Ogivri (trastuzumab, biosimilar) Receives Health Canada's Approval for HER2-Positive Breast and Gastric Cancers",14763,22-05-2019
ï»¿Takeda's Entyvio (vedolizumab) Receives MHLW's Approval for Moderate to Severely Active Crohn's Disease in Japan,14778,23-05-2019
Santhera Signs an Exclusive License Agreement with Chiesi to Develop and Commercialize Raxone for Leber's Hereditary Optic Neuropathy,14786,23-05-2019
ï»¿OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer,14795,23-05-2019
ï»¿Synlogic Collaborates with Roche to Evaluate the Combination of SYNB1891 and Tecentriq (atezolizumab) for Advanced Solid Tumors,14801,23-05-2019
ï»¿Boston Scientific Initiates OPTION Study of Watchman FLX Device for Stroke Risk Reduction Post-AF Ablation,14807,23-05-2019
ï»¿GSK's Shingrix Receives NMPA's Approval for the Prevention of Shingles in China,14817,24-05-2019
"ï»¿Celltrion's Herzuma (trastuzumab, biosimilar) Receives ANVISA's Approval for Breast and Gastric Cancer in Brazil",14825,24-05-2019
ï»¿Hologic &amp; Cepheid's Diagnostic Tests Receive 510(k) Clearance for Extragenital Testing in Chlamydia and Gonorrhea,14835,24-05-2019
ï»¿Roche's Cobas TV/MG Test Receives FDA's 510 (k) Clearance for the Detection of Sexually Transmitted Diseases,14842,24-05-2019
ï»¿BrightInsight Launches a CE-Marked Dosing Calculator for Emicizumab to Treat Patients with Hemophilia A,14853,24-05-2019
ï»¿Novartis' Piqray (alpelisib) + Fulvestrant Receive FDA's Approval for Patients with a PIK3CA Mutation in HR+/HER2- Advanced/Metastatic Breast Cancer,14872,27-05-2019
ï»¿Pfizer Reports Results of Lyrica (pregabalin) in P-III Study for Primary Generalized Tonic-Clonic Seizures,14883,27-05-2019
ï»¿Novartis' Zolgensma (onasemnogene abeparvovec-xioi) Receives FDA's Approval for Spinal Muscular Atrophy in Pediatric Patients,14891,27-05-2019
ï»¿Calecim Collaborates with Menarini Asia-Pacific to Expand the Worldwide Sales of its Product,14898,27-05-2019
ï»¿Santhera Reports Submission of Marketing Authorization Application to the EMA for Puldysa (Idebenone) in Duchenne Muscular Dystrophy,14905,28-05-2019
ï»¿Matas to Acquire Kosmolet for its Make-up Brand Nilens Jord,14913,28-05-2019
ï»¿Nanobiotix Launches Curadigm Facility with Nanoprimer Technology in France and the US,14918,28-05-2019
BioMarin Reports Results of Valoctocogene Roxaparvovec in P-III GENEr8-1 Study for Hemophilia A,14925,28-05-2019
Eli ï»¿Lilly Signs an Exclusive Worldwide License Agreement with Centrexion Therapeutics for its CNTX-0290,14931,28-05-2019
ï»¿Celgene's Revlimid (Lenalidomide) + Rituximab Receive FDA's Approval for Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma in Adults,14944,29-05-2019
"Prestige BioPharma Reports EMA's Acceptance of Marketing Authorization Application for its Tuznue (trastuzumab, biosimilar)ï»¿",14953,29-05-2019
ï»¿Bayer Signs a License Agreement with Sensible Medical for its ReDS Technology in Europe,14961,29-05-2019
ï»¿Arvinas' ARV-110 Receives the US FDA's Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer in Men,14969,29-05-2019
ï»¿Ziopharm Signs an Exclusive License Agreement with NIH to Develop and Commercialize TCRs Targeting Neoantigen for Cancer,14977,29-05-2019
Bayer Signs a Worldwide Agreement with Roche's Foundation Medicine to Develop and Commercialize CDx for Cancer,14985,29-05-2019
ï»¿Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate) in P-III QUARTZ Study for Inadequately Controlled Asthma,15002,30-05-2019
ï»¿Roche's Tecentriq (atezolizumab) Combination Therapy Receives Health Canada's Approval for Metastatic Non-Squamous Non-Small Cell Lung Cancer in Adults,15007,30-05-2019
ï»¿Philips Reports Results of Stellarex .035 Low-Dose Drug-Coated Balloon in Two Clinical Studies for Peripheral Arterial Disease,15017,30-05-2019
ï»¿Medtronic's SelectSite C304-HIS Deflectable Catheter System Receives FDA's Clearance for HIS Bundle Pacing,15024,30-05-2019
ï»¿Janssen Reports Results of Darzalex (daratumumab) in P-III MAIA Study for Patients with Multiple Myeloma Ineligible for ASCT,15035,30-05-2019
ï»¿Sumitomo Dainippon Pharma Signs a Co-Promotion &amp; Commercialization Agreement with Novartis for Diabetes in Japan,15043,31-05-2019
ï»¿Roche and GE Healthcare Launch NAVIFY Tumor Board 2.0 for Personalized Treatment Decision in Cancer Care,15050,31-05-2019
"ï»¿Pfenex and Alvogen Report EMA's Acceptance of MAA for PF708 (biosimilar, teriparatide)",15057,01-06-2019
ï»¿Merck Reports Result of Keytruda (pembrolizumab) in P-III KEYNOTE-048 Study as a 1L Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,15071,31-05-2019
Genmab's Darzalex (daratumumab) + Bortezomib + Thalidomide and Dexamethasone (VTd) Receive FDA's Priority Review to sBLA Filing for Frontline Multiple Myelomaï»¿,15076,31-05-2019
Novartis Reports Results of Xolair (omalizumab) in Two P-III Studies for Chronic Rhinosinusitis with Nasal Polyps in Adults,15137,03-06-2019
ï»¿Sanofi Reports Results of Isatuximab Combination Therapy in P-III ICARIA-MM Study for Relapsed/Refractory Multiple Myeloma #ASCO2019,15141,03-06-2019
ï»¿Novartis Reports Result of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA-7 Study for HR+/HER2- Advanced Breast Cancer #ASCO2019,15164,03-06-2019
Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation #ASCO2019,15176,04-06-2019
ï»¿AstraZeneca and Merck Report Results of Lynparza (olaparib) in P-III SOLO3 Study for Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer #ASCO2019,15183,04-06-2019
Merck's Zerbaxa (ceftolozane and tazobactam) Receives FDA's Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults,15196,04-06-2019
"Fresenius Kabi Launches its Idacio (adalimumab, biosimilar) in Germany",15206,03-05-2019
British Columbia Expands Use of Biosimilars to Explore Treatment Options,15212,27-05-2019
The US FDA Releases Drafts Guidance Recommending on Comparative Analytical Assessment for Biosimilars,15227,21-05-2019
UnitedHealthcare to Use Brand-Name for Pegfilgrastim from July'19,15230,21-05-2019
AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim,15235,14-05-2019
Roche Reports Results of Xofluza (baloxavir marboxil) in P-III BLOCKSTONE Study for the Prevention of Influenza,15243,04-06-2019
Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks,15253,04-06-2019
Celgene and Acceleron Report FDA's Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia,15267,04-06-2019
Astellas and Seattle Genetics Report Results of Enfortumab Vedotin in P-II EV-201 Study for Patients with Locally Advanced or Metastatic Urothelial Cancer #ASCO2019,15272,04-06-2019
ï»¿Eli Lilly's Emgality (galcanezumab-gnlm) Receives FDA's Approval for Episodic Cluster Headache in Adults,15290,05-06-2019
Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for Chronic Lymphocytic Leukemia #ASCO2019,15298,05-06-2019
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019,15314,05-06-2019
ï»¿BioMarin's Vimizim (elosulfase alfa) Receives NMPA's (CFDA) Approval for Treatment of Morquio A Syndrome,15326,05-06-2019
ï»¿Bayer Signs a Research and Development Collaboration with Arvinas for its PROTAC Technology,15340,05-06-2019
IBM Watson Health Reports Real-World Progress of AI in Oncology in #ASCO2019,15347,05-06-2019
ï»¿Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-AL1 Study in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis,15356,06-06-2019
Enzyvant Reports FDA's Acceptance of BLA for RVT-802 to Treat Pediatric Congenital Athymia,15369,06-06-2019
Oncolytics Biotech Signs a Clinical Trial Collaboration with Merck KGaA and Pfizer,15421,06-06-2019
Celgene Reports FDA and EMA's Acceptance of NDA for Ozanimod to Treat Relapsing Forms of Multiple Sclerosis,15432,06-06-2019
AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE-TN Trial for Patients with Previously Untreated Chronic Lymphocytic Leukemia,15441,06-06-2019
GSK's Nucala (mepolizumab) Receives FDA's Approval for its Two New Self-Administered Methods for Patients with SEA and EGPA,15516,07-06-2019
Novartis Reports Histology Data of CFZ533 (iscalimab) in Kidney Transplantation for Extended Survival of Transplanted Organs,15526,07-06-2019
Novartis' LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP's Positive Opinion for Reduction of Kidney Exposure to Radiation During PPRT with Lutathera,15539,07-06-2019
Vertex to Expand its Collaboration with CRISPR Therapeutics to Develop Therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1,15565,07-06-2019
STADA to Acquire GSK's OTC Portfolio for the Expansion of its Consumer Health Business in Europe,15573,07-06-2019
Eli Lilly Reports Results of Ultra Rapid Lispro (URLi) in Two P-III Studies for Type 1 And Type 2 Diabetes,15617,10-06-2019
ï»¿Theramex Signs an Exclusive License Agreement with Therapeutics MD to Commercialize Bijuva and Imvexxy Outside the US,15626,10-06-2019
ï»¿Merck To Acquire Tilos Therapeutics for ~ $773M,15633,10-06-2019
ï»¿Medtronic and Tidepool Collaborates to Develop Interoperable Automated Insulin Pump System for Diabetes Management,15640,10-06-2019
Innovate Biopharmaceuticals Initiates P-III Clinical Study for Celiac Diseaseï»¿,15647,10-06-2019
ï»¿Roche's Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA's Accelerated Approval for Relapsed/Refractory Lymphoma,15656,11-06-2019
Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years P-III Study for Plaque Psoriasis #WCD2019ï»¿,15662,11-06-2019
ï»¿Innovative Health Solution's IB-Stim Receives FDA's Clearance for the Treatment of Functional Abdominal Pain in Irritable Bowel Syndrome,15672,11-06-2019
ï»¿Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019,15681,11-06-2019
Eli Lilly and Boehringer Ingelheim Report Cardiovascular Outcomes of Tradjenta (linagliptin) in CAROLINA Study for Type 2 Diabetes,15688,11-06-2019
ï»¿Merck's Keytruda (pembrolizumab) Receives FDA's Approval for 1L Treatment of Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma,15696,11-06-2019
Janssen Reports Cardiovascular Outcomes of Invokana (canagliflozin) in P-III CREDENCE Study for Type 2 Diabetes and Chronic Kidney Disease,15708,12-06-2019
Janssen Signs an Exclusive Worldwide License and Option Agreement with Genmab for its HexaBody-CD38,15717,12-06-2019
ï»¿Biogen To Report New Data of its Biosimilar Anti-TNF Portfolio at European Congress of Rheumatology (EULAR) 2019,15726,12-06-2019
ï»¿Genentech Reports Acceptance of sBLA for Rituxan (rituximab) to Treat Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in Children with 2 Years and Older,15736,12-06-2019
ï»¿Novo Nordisk Reports Cardiovascular Outcomes of Oral Semaglutide in PIONEER 6 Study for Type 2 Diabetes,15742,12-06-2019
ï»¿AbbVie Reports Results of Upadacitinib in Two P-III Studies for Rheumatoid Arthritis #EULAR2019,15756,13-06-2019
ï»¿Genentech Reports Positive Results of Rituxan (rituximab) in P-III PEMPHIX Study to Treat Patients with Moderate to Severe Pemphigus Vulgaris,15770,13-06-2019
ï»¿Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV ORAL Shift Study for Moderate to Severe Rheumatoid Arthritis #EULAR2019,15778,13-06-2019
"ï»¿Celltrion Reports Results of CT-P13 SC (biosimilar, infliximab) in a Clinical Study for Rheumatoid Arthritis #EULAR2019",15789,13-06-2019
ï»¿Sobi Acquires Novimmune's Emapalumab with its All Related Assets to Strengthen its Focus in Hematology and Immunology,15805,13-06-2019
"ï»¿Amgen and Allergan's Kanjinti (biosimilar, trastuzumab) Receive the US FDA's Approval for All Approved Indications of Herceptin",15824,14-06-2019
ï»¿BMS Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019,15833,14-06-2019
ï»¿BeiGene Reports Updated Results of Tislelizumab in P-II Study in Chinese Patients with R/R Classical Hodgkin Lymphoma #EHA2019,15846,14-06-2019
ï»¿Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019,15858,14-06-2019
ï»¿Upsher-Smith Signs an Agreement with Dr. Reddy's Laboratories to Acquire its Two Neurology Products,15885,14-06-2019
ï»¿AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-IIIb DIALIZE Study to Treat Hyperkalaemia in Patients with End-Stage Renal Disease,15895,14-06-2019
ï»¿Janssen Reports Results of Tremfya (guselkumab) in Two P-III DISCOVER Studies for Psoriatic Arthritis,15924,17-06-2019
ï»¿Immunophotonics Signs a Research Agreement with Clinical Laserthermia Clinical Laserthermia Systems for Cancer Patients with Solid Tumors,15934,17-06-2019
ï»¿Pfizer to Acquire Array Biopharma for ~$11.4B,15944,17-06-2019
ï»¿AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukemia #EHA2019,15952,17-06-2019
ï»¿Novo Nordisk's Victoza (liraglutide) Receives FDA's Approval for Type 2 Diabetes in Children and Adolescents,15967,18-06-2019
BeiGene Terminates its Worldwide Development and Commercialization Agreement with Celgene for Tislelizumab,15974,18-06-2019
ï»¿Roche's Rozlytrek (entrectinib) Receives MHLW's Approval for NTRK Fusion-Positive Advanced Recurrent Solid Tumors in Adult and Pediatric Patients in Japan,15981,18-06-2019
ï»¿AstraZeneca and MSD's Lynparza (olaparib) Receive European Commission's Approval as 1L Maintenance Treatment for BRCA-Mutated Advanced Ovarian Cancer,16001,18-06-2019
ï»¿Abbott Launches Afinion HbA1c Dx (Rapid Point-Of-Care Test) to Aid the Diagnosis of Diabetes,16009,18-06-2019
ï»¿Merck's Keytruda (pembrolizumab) Receives FDA's Accelerated Approval as a Monotherapy for Metastatic Small Cell Lung Cancer,16030,19-06-2019
ï»¿Ironwood and Allergan Report Positive Results of Inzess (linaclotide) in P-IIIb Trial for Patients with Irritable Bowel Syndrome with Constipation,16045,19-06-2019
ï»¿AstraZeneca's Breztri Aerosphere (PT010) and Bevespi Aerosphere Receive MHLW's Approval for Chronic Obstructive Pulmonary Disease in Japan,16062,19-06-2019
Roche's Hemlibra (emicizumab injection) Receives Health Canada Approval for Patients with Hemophilia A Without Factor VIII Inhibitors ï»¿,16091,19-06-2019
"ï»¿Bristol-Myers Squibb to Sell its Manufacturing Facility to Catalent in Anagni, Italy",16098,19-06-2019
ï»¿Sanofi Signs an Agreement with Google to Develop Virtual Innovation Lab for Transforming Healthcare Services,16105,19-06-2019
Gilead Signs an Agreement with Nurix to Develop and Commercialize Protein Degradation Therapies for Cancer and Other Disease,16115,20-06-2019
ï»¿Amgen Signs a Research Agreement with the University of Washington's IPD for the Development of Protein-Based Therapies,16125,20-06-2019
Alexa to Detect Cardiac Arrest with AI-Enabled Tool for Smart Speakers and Smartphones,16134,20-06-2019
ï»¿Resolution Bioscience Collaborates with Janssen to Develop Cell-Free DNA CDx for Niraparib to Treat Prostate Cancer,16146,20-06-2019
ï»¿Alexion's Ultomiris (ravulizumab) Receives MHLW's Marketing Authorization to Treat Paroxysmal Nocturnal Hemoglobinuria in Adults,16163,20-06-2019
"ï»¿Novo Nordisk's Esperoct (turoctocog alfa pegol, N8-GP) Receives European Commission Approval for the Treatment of Hemophilia A",16181,21-06-2019
IBRI Signs a License Agreement with Eli Lilly to Access its Fab Phage Display Library,16188,21-06-2019
ï»¿Valneva Terminates its Agreement with GSK for Regaining Control of Research and Development Assets,16196,21-06-2019
ï»¿Bayer Initiates P-III Study of Aflibercept for the Prevention of Blindness in Premature Infants with Retinopathy of Prematurity,16202,21-06-2019
Sanofi and Regeneron Report Results of REGN3500 in P-II Study for Asthma,16209,21-06-2019
Allergan's BOTOX (onabotulinumtoxinA) Receives FDA's Approval for Upper Limb Spasticity in Pediatric Patients,16227,24-06-2019
Pfizer's Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Breast Cancerï»¿,16235,24-06-2019
"Henlius Reports EMA's Acceptance of Marketing Authorization Application for HLX02 (biosimilar, trastuzumab)",16242,24-06-2019
ï»¿Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459 Study as 1L Treatment for Patients with Unresectable Hepatocellular Carcinoma,16248,24-06-2019
"ï»¿Allergan's CoolTone Device Receives FDA's Clearance to Strengthen, Tone and Firm Abdominal Muscles",16259,24-06-2019
ï»¿Gilead Signs an Agreement with Carna Biosciences to Develop and Commercialize Immuno-Oncology Therapies,16268,25-06-2019
"Novartis to Collaborate with Glenmark to Promote, Commercialize and Distribute Three Respiratory Therapies for COPD in Brazilï»¿",16277,25-06-2019
ï»¿AbbVie to Acquire Allergan for $63B,16288,25-06-2019
Bristol-Myers Squibb to Divest Celgene's Otezla (apremilast) to Gain the US FTC's Approval on Celgene Acquisitionï»¿,16296,25-06-2019
C4X Discovery Signs a Neurodegeneration Drug Discovery Agreement with PhoreMost for Parkinson's Disease,16305,25-06-2019
ï»¿Almirall Exercises its Option to License Dermira's Lebrikizumab for Atopic Dermatitis in Europe,16309,26-06-2019
ï»¿Tilt Biotherapeutics Signs an Agreement with Merck KGaA and Pfizer to Investigate the Dual Combination for Solid Tumors,16318,26-06-2019
ï»¿Eisai Reports Results of Fycompa (perampanel) in P-III FREEDOM Study for Patients with Newly Diagnosed or Untreated Partial Onset Seizures,16324,26-06-2019
ï»¿Lilly Reports Results of Trulicity (dulaglutide) in P-III AWARD-11 Study for Type 2 Diabetes,16331,26-06-2019
ï»¿Boehringer Ingelheim and Eli Lilly's Empagliflozin Receive FDA's Fast Track Designation for Chronic Heart Failure,16344,26-06-2019
ï»¿Daiichi Sankyo to Return Exclusive Development and Commercialization Rights for Four Diagnostic Imaging Agents to GE Healthcare in Japan,16346,26-06-2019
Louisiana Department of Health Launches Innovative Payment Model with Asegua Therapeutics to Eliminate Hepatitis C in Louisiana,16358,27-06-2019
Regeneron and Sanofi's Dupixent (dupilumab) Receives FDA's Approval for Chronic Rhinosinusitis with Nasal Polyposisï»¿,16367,27-06-2019
AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancerï»¿,16377,27-06-2019
ï»¿Sanofi Reports FDA's Acceptance of BLA for MenQuadfi to Prevent Meningococcal Meningitis,16380,27-06-2019
GSK Amends its Development and Commercialization Agreement with Liquidia for Inhaled Therapies,16386,27-06-2019
ï»¿Janssen's Darzalex (daratumumab) in Combination with Lenalidomide + Dexamethasone Receive FDA's Approval for Transplant Ineligible Patients with Multiple Myeloma,16394,28-06-2019
ï»¿Alexion's Soliris (eculizumab) Receives FDA's Approval for Anti-Aquaporin-4 Antibody Positive Patients with Neuromyelitis Optica Spectrum Disorder,16403,28-06-2019
ï»¿Apple Disrupting the Healthcare with the Availability of One Drop Blood Glucose Monitor at its Retails Outlets in the US,16413,28-06-2019
Sanofi and Regeneron's Dupixent (dupilumab) Receive CHMP's Positive Opinion for Moderate-To-Severe Atopic Dermatitis in Adolescentsï»¿,16420,28-06-2019
"ï»¿Innovent and Eli Lilly Report NMPA's Acceptance of NDA for IBI301 (rituximab, biosimilar) for Non-Hodgkin's lymphoma",16430,28-06-2019
"ï»¿Pfizer's Zirabev (biosimilar, bevacizumab) Receives the US FDA's Approval for Five Types of Cancer",16442,28-06-2019
ï»¿Pfizer Reports Results of Revatio (sildenafil citrate) in P-III Study for Persistent Pulmonary Hypertension in the Newborns,16460,01-07-2019
ï»¿AstraZeneca's Forxiga and Fasenra (Prefilled Syringe and Pen) Receive EU CHMP's Positive Opinion for CV Outcomes in T2D and Asthma,16469,01-07-2019
ï»¿Janssen's Imbruvica (ibrutinib) Receives CHMP Positive Recommendation for its Expanded Use in Chronic Lymphocytic Leukaemia and Waldenstrom's Macroglobulinemia in Europe,16479,01-07-2019
Roche's Tecentriq (atezolizumab) + Abraxane Receives CHMP's Recommendation for its Approval in Europe,16484,01-07-2019
ï»¿Biogen Reports Results of Spinraza (nusinersen) in P-II NURTURE Study as a Foundation of Care in Spinal Muscular Atrophy,16502,02-07-2019
Regeneron and Sanofi's Libtayo (cemiplimab) Receives European Commission's Approval for Advanced Cutaneous Squamous Cell Carcinoma,16507,02-07-2019
ï»¿Teva Reports Results of Fremanezumab in P-IIIb FOCUS Study for Migraine in Adults,16514,02-07-2019
"ï»¿Egis Pharmaceuticals Signs an Exclusive Distribution Agreement with Mundipharma for Pelmeg (biosimilar, pegfilgrastim) in Central and Eastern Europe",16520,13-06-2019
"ï»¿Amgen to Withdraw the ABP 710 (biosimilar, infliximab) MAA with European Medical Agency",16527,28-06-2019
ï»¿Boehringer Ingelheim Signs a License Agreement with Yuhan Corporation to Develop Dual Agonist for Nonalcoholic Steatohepatitis,16534,02-07-2019
Foundation Medicine's FoundationOne CDx Receives FDA's Approval as a CDx for Lynparza (olaparib),16543,02-07-2019
ï»¿Varian to Acquire Boston Scientific's Oncology Assets for $90M,16553,02-07-2019
ï»¿Genentech Reports Results of Xofluza (baloxavir marboxil) in P-III MINISTONE-2 Study for Influenza in Children,16589,03-07-2019
ï»¿Sandoz Launches Generic Gefitinib for Locally Advanced or Metastatic Non-Small Cell Lung Cancer in 13 European Countries,16596,03-07-2019
ï»¿ViiV Healthcare's Dovato (dolutegravir/lamivudine) Receives European Commission Marketing Authorization for HIV-1 Infection in Adults and Adolescents,16603,03-07-2019
GSK to Initiate P-III ContRAst Studies of Otilimab to Treat Moderate to Severe Rheumatoid Arthritis,16610,03-07-2019
Asieris Signs a Worldwide Development and Commercialization Agreement with Photocure for Cevira,16619,03-07-2019
ï»¿Samsung Bioepis and Genentech Settles Patent Dispute of Trastuzumab Biosimilar-Ontruzant,16626,04-07-2019
Alexion's Ultomiris (Ravulizumab) Receives European Commission's Marketing Authorization for Paroxysmal Nocturnal Hemoglobinuria in Adults,16632,04-07-2019
ï»¿Karyopharm's Xpovio (selinexor) Receives FDA's Accelerated Approval for Relapsed/Refractory Multiple Myeloma,16649,04-07-2019
"Samsung Bioepis Reports EU Label Update with Extended Storage Conditions for Imraldi (biosimilar, adalimumab)",16664,28-06-2019
ï»¿Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics,16665,04-07-2019
ï»¿Janssen Returns its Exclusive Rights to Develop and Commercialize Hanmi's Antidiabetic Obesity Therapy,16685,04-07-2019
ï»¿SIFI Acquires Laboratoire Gifrer Barbezat's Dacudoses and Novoptine for $6.7M in France,16701,05-07-2019
Grifols' Xembify (20% SC Immunoglobulin) Receives FDA's Approval for the Treatment of Primary Immunodeficienciesï»¿,16712,05-07-2019
ï»¿Fraunhofer MEVIS' Experts Develops Intelligent Catheter Navigation System in Germany,16721,05-07-2019
ï»¿SDSC and Moores Cancer Center Collaboratively Work with CureMatch to Develop Machine Learning Model for the Diagnosis of Bladder Cancer,16747,05-07-2019
ï»¿Fresenius Kabi Voluntary Recalls Two Lots of Fluorouracil Injection Due to Potential for Glass Particulate,16756,05-07-2019
ï»¿BeiGene's Tislelizumab Receives NMPA's Priority Review to sNDA for Urothelial Carcinoma in China,16765,08-07-2019
ï»¿Isansys Lifecare Develops Patient Status Engine Wearable Body Patch for the Detection of Sepsis,16768,08-07-2019
ï»¿Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children,16779,08-07-2019
ï»¿Takeda Reports Updated Results of Adynovate in P-IIIb/IV PROPEL Study for Personalized Prophylaxis in Patients with Severe Hemophilia A,16786,08-07-2019
ViiV Healthcare Initiates CUSTOMIZE Study of Dual-Drug Injectable Regimen for the Treatment of HIV,16793,08-07-2019
ï»¿Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism,16802,09-07-2019
Roche Reports Updated Results of Hemlibra (emicizumab) in P-III HAVEN and P-IIIb STASEY Studies for Hemophilia A,16808,09-07-2019
ï»¿The US Department of Defense Awarded Contract to SIGA for Expanded Indication of TPOXX (tecovirimat) for $19.5M,16819,09-07-2019
ï»¿Merck Reports FDA's Acceptance of sBLA of Keytruda (pembrolizumab) with Six-Week Dosing Schedule for Multiple Indications,16828,09-07-2019
ï»¿Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Children,16833,09-07-2019
ï»¿Sanofi Reports FDA's Acceptance of BLA to Review Isatuximab for Relapsed/Refractory Multiple Myeloma,16846,10-07-2019
ï»¿ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection,16852,10-07-2019
ï»¿Mirati Signs a Non-Exclusive Clinical Collaboration with Novartis to Evaluate the Combination of MRTX849 and TNO155 for Solid Tumors,16862,10-07-2019
ï»¿Janssen Signs an Agreement with Celsius Therapeutics to Identify Response Biomarkers for Ulcerative Colitis,16869,10-07-2019
ï»¿Jazz Pharmaceuticals Acquires Redx Pharma's Pre-clinical Pan-RAF Inhibitor Program for RAF and RAS Mutant Tumors,16881,10-07-2019
ï»¿Sandoz Launches Pre-Filled Epinephrine Injection for Type 1 Allergic Reactions in the US,16890,10-07-2019
ï»¿Celgene's Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada's Approval for Multiple Myeloma,16897,11-07-2019
ï»¿Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India,16906,11-07-2019
ï»¿Takeda's Vyvanse (lisexamfetamine dimesylate) Chewable Tablet Receives Health Canada's Approval for the Treatment of Patients with Attention-Deficit/Hyperactivity Disorder Agedâ‰¥ 6yrs.,16912,11-07-2019
ï»¿Amazon's AI-Powered Alexa to Deliver NHS Health Advice in the UK,16917,11-07-2019
ï»¿Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III Study for Episodic Cluster Headache,16927,11-07-2019
ï»¿I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop and Commercialize Enoblituzumab in Greater China,16934,11-07-2019
"ï»¿Novartis, Amgen and Banner Alzheimer's Institute Terminate Two P-II/III Studies of CNP520 (umibecestat) for the Prevention of Alzheimer's Disease",16948,12-07-2019
Abbott's Alinity S System Receives FDA's Approval for Blood and Plasma Screening in the USï»¿,16956,12-07-2019
ï»¿Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven to Develop and Commercialize 5F9 in Selected Asian Countries,16962,12-07-2019
Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson's Disease in Canadaï»¿,16970,12-07-2019
Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine,16988,12-07-2019
ï»¿GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study as 1L Maintenance Therapy for Ovarian Cancer,17052,15-07-2019
ï»¿Gilead to Raise Stake in Galapagos with ~$5.1B Deal,17061,15-07-2019
ï»¿Janssen Reports Submission of BLA to the US FDA for Darzalex (daratumumab) Subcutaneous Formulation for Multiple Myeloma,17076,15-07-2019
ï»¿AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer,17080,15-07-2019
ï»¿Boehringer Ingelheim Acquires AMAL Therapeutics for its KISIMA Immunization Platform,17095,16-07-2019
ï»¿Abbott's MitraClip G4 Receives the US FDA's Approval for the Treatment of Mitral Regurgitation,17103,16-07-2019
ï»¿Bayer's Gadavist (gadobutrol) Injection Receives the US FDA's Approval for use in CMRI in Patients with Coronary Artery Disease,17109,16-07-2019
ï»¿T-CiRA Research Collaboration Initiates Clinical Study of iCART Therapies for the Treatment of Cancer,17118,16-07-2019
ï»¿Novartis Reports FDA's Acceptance of BLA for Crizanlizumab (SEG101) to Treat Sickle Cell Disease,17124,16-07-2019
Genentech Signs an Exclusive Option and License Agreement with Skyhawk to Discover and Develop RNA Splicing Modifiers for Oncology and Neurodegenerative Diseasesï»¿,17137,17-07-2019
Genentech Enters into an Exclusive Worldwide Collaboration and Option to Acquire Agreement with Convelo to Discover Remyelinating Therapies,17145,17-07-2019
ï»¿Knight Therapeutics' Nerlynx (neratinib) Receives Health Canada Approval as Extended Adjuvant Therapy for HR+ and HER2+ Breast Cancer,17150,17-07-2019
ï»¿Merck's Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA's Approval for Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections,17165,17-07-2019
ï»¿Allergan Reports FDA's Acceptance of NDA for Bimatoprost Sustained-Release to Treat Glaucoma or Ocular Hypertension,17172,17-07-2019
Genentech Signs a Research and License Agreement with Sosei Heptares to Develop GPCR Modulating Therapies,17177,17-07-2019
ï»¿MacroGenics Plans to Advance the Development of Flotetuzumab for Acute Myeloid Leukemia,17187,18-07-2019
ï»¿Novartis' Kisqali (ribociclib) + Fulvestrant Receive NICE Approval for Advanced or Metastatic Breast Cancer,17195,18-07-2019
ï»¿Paragon Biosciences Launches a Facility for the Advancement of QuantX Medical Imaging AI System Diagnosing Breast Cancer,17201,18-07-2019
ï»¿Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer,17208,18-07-2019
Astellas Signs a License Agreement with Frequency Therapeutics to Develop and Commercialize FX-322 for Hearing Loss,17211,18-07-2019
Takeda and Chembio Diagnostics Collaborate to Develop Point-of-Care Diagnostic Test,17218,18-07-2019
Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for Diagnosing Thyroid Cancer,17227,19-07-2019
Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics for its BBT-877 for $1.28B,17234,19-07-2019
Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study for Patients with Idiopathic Pulmonary Fibrosis (IPF),17248,19-07-2019
Mallinckrodt Signs an Agreement with Silence Therapeutics to Develop and Commercialize RNAi Therapeutics for Complement-Mediated Diseases,17254,19-07-2019
Amgen and Allergan Report Availability of Mvasi (biosimilar bevacizumab) and Kanjinti (biosimilar trastuzumab) in the US,17274,19-07-2019
Gilead Signs an Exclusive Worldwide License Agreement with Novartis for its Three Preclinical Antiviral Programs,17292,19-07-2019
Sandoz Reports Patient Enrollment in P-I/III ROSALIA Study of Proposed Biosimilar Denosumab for Postmenopausal Osteoporosis,17400,22-07-2019
Celgene's Otezla (apremilast) Receives FDA's Approval for Oral Ulcers Associated with BehÃ§et's Disease,17407,22-07-2019
Takeda Reports Results of Entyvio (vedolizumab SC) in P-III VISIBLE 2 Study for Moderately to Severely Active Crohn's Disease,17418,22-07-2019
Medtronic Collaborates with Viz.ai to Facilitate Adoption of AI Software for Stroke Centers in the US,17424,22-07-2019
Gilead Signs an Exclusive Worldwide License Agreement with Durect for its HIV and Hepatitis B Products,17430,22-07-2019
Baxter's Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA's Approval for Diabetes Mellitusï»¿,17442,23-07-2019
Sanofi Signs an Exclusive Agreement with Roche for OTC Rights of Tamiflu (oseltamivir phosphate) in the US,17450,23-07-2019
ViiV Healthcare Reports Results of Fostemsavir in P-III BRIGHTE Study for HIV-1 infection,17457,23-07-2019
AstraZeneca Reports Inclusion of Overall Survival Data in Labelling of Imfinzi (durvalumab) in the US,17465,23-07-2019
Merck and Eisai's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive FDA's Third Breakthrough Therapy Designation as 1L Therapy for Hepatocellular Carcinoma,17469,23-07-2019
Chiasma Reports Results of Mycapssa (octreotide) in P-III CHIASMA OPTIMAL Study as a Maintenance Therapy for Acromegaly,17476,23-07-2019
"Pfizer's Ruxience (biosimilar, rituximab) Receives FDA's Approval for Cancer and Autoimmune Diseases",17484,24-07-2019
"Samsung Bioepis' Hadlima (biosimilar, adalimumab) Receives FDA's Approval for Autoimmune Diseases",17494,24-07-2019
Ligand to Acquire Ab Initio Biotherapeutics for its Antigen Technology,17499,24-07-2019
Medtronic Solicits the US FDA for Non-Adjunctive Labeling Approval of MiniMed 670G Insulin Pump Sensor,17508,24-07-2019
Gilead Reports Updated Results of Descovy in P-III DISCOVER Study for Pre-Exposure Prophylaxis of H,17518,24-07-2019
Celgene Partners with Multiple Sclerosis Association of America Bringing MS MindShift Brain Bulb Hot Air Balloon to Raise Awareness of Multiple Sclerosis and Brain Health,17524,24-07-2019
Synapse Signs an Agreement with Pfizer in Oncology Precision Medicine,17529,24-07-2019
Eli Lilly's Baqsimi (glucagon 3mg) Nasal Powder Receives FDA's Approval for the Treatment of Severe Hypoglycemia,17541,25-07-2019
BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -227 Part 1a Study for 1L Non-Small Cell Lung Cancer,17553,25-07-2019
Celgene Reports Update on its Collaboration with Jounce Therapeutics,17568,25-07-2019
Allergan Voluntary Recalls Worldwide BIOCELL Textured Breast Implants and Tissue Expandersï»¿,17577,25-07-2019
Regenxbio Signs an Exclusive Development and Commercialization Agreement with Neurimmune for AAV Gene Therapies Targeting Neurodegenerative Diseases,17586,25-07-2019
Sanofi Enter into an Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra (duvelisib) for all Oncology Indications,17596,26-07-2019
Boehringer Ingelheim's Ofev (nintedanib) Receives FDA's Advisory Committee Recommendation for Systemic Sclerosis Associated ILD,17601,26-07-2019
Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis,17615,26-07-2019
BMS' Triple Regimen Receives Positive CHMP Recommendation for its Approval to Treat R/R Multiple Myeloma in Europe,17625,26-07-2019
Roche's Tecentriq Receives EU's CHMP Recommendation for its Approval as 1L Therapy for Extensive-Stage Small Cell Lung Cancer,17632,26-07-2019
Epizyme Reports FDA's Acceptance of NDA for Tazemetostat to Treat Epithelioid Sarcoma,17640,26-07-2019
ViiV Healthcare Reports Submission of MAA to EMA for the Combination of Cabotegravir + Rilpivirine to Treat HIV-1 Infection,17702,29-07-2019
Pfizer in Talks with Mylan to Merge its Off-Patent Drug Business ï»¿,17706,29-07-2019
Pfizer's Upjohn Off-Patent Drug Business to Merge with Mylan to Form a New Pharmaceutical Company,17731,29-07-2019
Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program for Type2 Diabetes and Terminates Its Collaboration with Lexicon,17740,29-07-2019
Baxter Launches PrisMax Acute Care System for Acute Kidney Injury in the US,17756,30-07-2019
Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III KEYNOTE-522 Study for Triple-Negative Breast Cancer,17765,30-07-2019
Exact Sciences to Merge with Genomic Health Forming a New Cancer Diagnostics Company,17774,30-07-2019
Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer,17797,30-07-2019
Merck Receives EU's CHMP Positive Opinion for its Zerbaxa (ceftolozane and tazobactam) and Keytruda (pembrolizumab) + Inlyta (axitinib) Regimen,17805,30-07-2019
Novartis' Lucentis Receive EU's CHMP Positive Opinion for Retinopathy of Prematurity in Preterm Infan,17807,30-07-2019
Bayer's Nubeqa (darolutamide) Receives the US FDA's Approval for Non-Metastatic Castration-Resistant Prostate Cancer in Men,17826,31-07-2019
Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis,17834,31-07-2019
Gates Foundation Grants $13M to Lyndra Therapeutics for the Development of Once-Monthly Oral Contraceptive,17839,31-07-2019
Bayer's Vitrakvi (larotrectinib) Receives Health Canada Approval for Advanced Solid Tumors Harboring NTRK Gene Fusion,17872,31-07-2019
Merck's Keytruda (pembrolizumab) Receives FDA's Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophageal Cancer Expressing PD-L1 (CPS â‰¥10),17877,31-07-2019
Pfizer Signs a License Agreement with Regenxbio for its NAV AAV9 Vector to Treat Friedreich's Ataxia,17885,31-07-2019
Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women,17898,01-08-2019
Chimerix Signs an Exclusive Worldwide License Agreement with Cantex for CX-01 to Treat Acute Myeloid Leukemia,17909,01-08-2019
Exelixis Signs a Research Collaboration and Option to License Agreement with Aurigene to Discover and Develop Therapies for Cancer,17919,01-08-2019
LEO Pharma's Enstilar Foam and Taclonex Topical Suspension Receive the US FDA's Expanded Approval for Plaque Psoriasis,17925,01-08-2019
Sun Pharma Reports Submission of Manufacturing and Marketing Authorization Application of Tildrakizumab in Japan,17935,01-08-2019
GSK's Nucala (mepolizumab) Receives European Commission Approval for Self-Administration in Severe Eosinophilic Asthma,17944,02-08-2019
Nektar and BMS Receive the US FDA's Breakthrough Designation for Bempegaldesleukin (NKTR-214) + Opdivo (nivolumab) to Treat Advanced Melanoma,17952,02-08-2019
Arcellx Signs a Development Evaluation and License Agreement with Pfenex for Advancing SparX Proteins,17961,02-08-2019
"Mylan and Biocon Launch Ogivri (biosimilar, trastuzumab) in Australia",17977,02-08-2019
Voluntis' Oleena Digital Application Receives FDA's Marketing Approval to Self-Manage Cancer Symptoms,17993,02-08-2019
Thermo Fisher Enters into a Collaboration with Genome Canada and OICR to Develop NGS Assays for Cancer,17997,02-08-2019
AbbVie's Maviret (glecaprevir/pibrentasvir) Receives European Commission Approval for Treatment-Naive Patients with Chronic Hepatitis C and Compensated Cirrhosis,18040,02-08-2019
Daiichi Sankyo's Turalio (pexidartinib) Receives the US FDA's Approval for the Symptomatic Tenosynovial Giant Cell Tumor,18119,05-08-2019
Roche Reports Results of Tecentriq in P-III IMvigor130 Study for Previously Untreated Advanced Bladder Cancer,18129,05-08-2019
Takeda Signs an Exclusive Multi-Target Research Agreement with Sosei Heptares to Develop and Commercialize Therapies Modulating GPCR,18137,05-08-2019
AstraZeneca Reports Label Update with Positive Cardiovascular Outcomes and Renal Data for Forxiga (dapagliflozin) in EU,18144,05-08-2019
Pfizer Reports Results of Rivipansel in P-III RESET Study for Sickle Cell Disease with Vaso-Occlusive Crisis,18154,05-08-2019
NUST MISIS Laboratory Develops an Ultrasound Tomography System for the Diagnosis of Cancer,18163,05-08-2019
"Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for AVT02 (biosimilar, adalimumab)",18165,23-07-2019
Coherus Biosciences Reports Winning of Pegfilgrastim Patent Dispute Against Amgen,18180,29-07-2019
"Celltrion to Initiate P-I trial for CT-P39 (biosimilar, omalizumab)",18187,15-07-2019
Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III CONQUER Study for Chronic and Episodic Migraine,18194,05-08-2019
Chong Kun Dang and Dong-A ST Plan to Launch Nesp biosimilar in Japan,18205,21-07-2019
"Mundipharma and Prestige Enters into an Exclusive License and Supply Agreement for Tuznue (biosimilar, trastuzumab, HD201)",18214,02-07-2019
Sanofi and Regeneron's Dupixent Receives European Commission Approval for Moderate-To-Severe Atopic Dermatitis in Adolescents,18250,06-08-2019
LifeOmic Launches AI-Based LIFE Extend App to Expand Healthcare and Enable People to Adopt Five Health Pillarsï»¿,18258,06-08-2019
MannKind Enter into an Agreement with One Drop to Combine Bluetooth-Connected Inhaler with Dose Detection into the One Drop Platform,18265,06-08-2019
Innovent and Shenogen Enter into a Collaboration to Evaluate the Combination of Tyvyt (sintilimab injection) + SNG1005 for Advanced Cancer,18276,06-08-2019
GSK and Sabin Signs an Exclusive Agreement to Advance the Development of Ebola and Marburg Vaccines,18284,06-08-2019
Astellas Initiates P-III BRIGHT SKY Clinical Program for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms,18293,06-08-2019
Allergan Reports the Acceptance of EMA's MAA for Abicipar to Treat Neovascular Age-Related Macular Degeneration,18311,07-08-2019
Spring Bank Signs a Research Agreement with the University of Texas Southwestern Medical School to Evaluate STING Antagonist Compounds,18316,07-08-2019
AstraZeneca and MSD's Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Mutation,18328,07-08-2019
ADC Therapeutics and Sophia Genetics Collaborate to Identify Biomarkers in Clinical Study,18342,07-08-2019
NIH Launches LUCA Biologics to Develop Live Biotherapeutics for Women's Health,18349,07-08-2019
Newsoara Biopharma Signs a Licensing Agreement with Zenith Epigenetics for its ZEN-3694,18357,07-08-2019
Aevi Genomic Medicine Signs an Option and License Agreement with AstraZeneca for its MEDI2338,18363,08-08-2019
Stoke Therapeutics' STK-001 Receives FDA's Orphan Drug Designation for Dravet Syndrome,18369,08-08-2019
Myriad to File sPMA to the US FDA of BRACAnalysis CDx as a Companion Diagnostic for Lynparza (olaparib) to Treat Metastatic Castrate-Resistant Prostate Cancer in Men,18378,08-08-2019
Akcea Therapeutics and Ionis Pharmaceutical Launch Waylivra (volanesorsen) for Familial Chylomicronemia Syndrome in EU,18384,08-08-2019
Gilead Sciences Receives the US FDA Advisory Committee's Recommendation on Approval of Descovy for PrEP,18391,08-08-2019
Mitsubishi Tanabe's Edaravone Receives NMPA's Approval for Amyotrophic Lateral Sclerosis (ALS),18393,08-08-2019
Bayer to Acquire BlueRock Therapeutics for its Cell Therapies,18417,09-08-2019
Eli Lilly with Evidation Health and Apple Report Results of Digital Alzheimer's Study,18429,09-08-2019
Takeda Reports Submission of NDA to MHLW for Vedolizumab SC to Treat Moderately to Severely Active Ulcerative Colitis in Japan,18440,09-08-2019
AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III FLAURA Study for 1L EGFR-Mutated Non-Small Cell Lung Cancer,18445,09-08-2019
Ziopharm Oncology's Controlled IL-12 Platform Receives EMA's COMP Positive Recommendation for Orphan Drug Designation to Treat Glioma,18452,09-08-2019
"Gilead's Biktarvy (Bictegravir, Emtricitabine and Tenofovir Alafenamide) Receives NMPA's Approval for Treatment of HIV-1 Infection",18518,12-08-2019
SMS-Oncology Signs a Clinical Trial Collaboration with Cytovation to Treat Solid Tumors,18529,12-08-2019
Atricure to Acquire SentreHEART for Expansion of Therapies to Treat Atrial Fibrillation,18543,12-08-2019
Oncologie and Merck Collaborate to Evaluate Bavituximab + Keytruda for Treatment of Advanced Gastric or Gastroesophageal Cancer,18554,12-08-2019
ï»¿Zai Lab and Novocure's Optune Receive NMPA's Innovative Medical Device Designation for its Tumor Treating Field Delivery System,18567,12-08-2019
Boehringer Ingelheim Signs a Multi-Year Agreement with University of Texas for the Advancement of Cancer Therapies,18576,13-08-2019
Baxter's PrisMax System Receives Health Canada's Approval for Maximizing Treatment in the Intensive Care Unit,18595,13-08-2019
Pharming Signs an Exclusive Development and Commercialization Agreement with Novartis for its CDZ173 to Treat Activated Phosphoinositide 3-kinase Delta Syndrome,18607,13-08-2019
Jazz Pharmaceutical to Acquire Cavion for the Expansion of its Sleep and Neurology Portfolio,18619,13-08-2019
Eli Lilly Reports Superiority Results of Taltz (ixekizumab) in P-IV IXORA-R Study for Patients with Moderate to Severe Plaque Psoriasis,18634,13-08-2019
Roche's Tecentriq (atezolizumab) Receives Health Canada's Approval for 1L Extensive-Stage Small Cell Lung Cancer in Adults,18643,13-08-2019
Innovate Initiates its Dosing For P-III CeD LA 3001 Trial for Celiac Disease,18656,13-08-2019
Janssen's Imbruvica (ibrutinib) Receives European Commission Approval for Chronic Lymphocytic Leukaemia and Waldenstrom's Macroglobulinemia in Adults,18677,14-08-2019
AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia,18692,14-08-2019
Leo Pharma Enters into a Sub-Licensing Agreement with Bausch Health to Develop and Commercialize Brodalumab for Moderate-to-Severe Psoriasis Outside Europe,18705,14-08-2019
AstraZeneca and MSD Report Results of Lynparza in P-III PAOLA-1 Study as 1L Maintenance Therapy for Advanced Ovarian Cancer,18712,14-08-2019
Regeneron's Eylea (aflibercept) Receives the US FDA's Approval as a Prefilled Syringe,18720,14-08-2019
Regeneron Reports Positive Results of Evinacumab in P-III Study for Homozygous Familial Hypercholesterolemia,18729,14-08-2019
Roche's Rozlytrek (entrectinib) Receives the US FDA Approval for ROS1-Positive Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors,18737,16-08-2019
Ultragenyx Enters into a Partnership and Option to Acquire Agreement with GeneTx to Develop its GTX-102 for Angelman Syndrome,18749,16-08-2019
Gilead and Galapagos Reports the Validation of EMA's MAA for Filgotinib to Treat Rheumatoid Arthritis,18760,16-08-2019
Baxter Collaborates with Cosmed to Commercialize Q-NRG+ Indirect Calorimetry Device to Support Global Clinical Nutrition ï»¿,18768,16-08-2019
Mallinckrodt Reports Positive Results of Terlipressin in P-III CONFIRM Study for Hepatorenal Syndrome Type 1,18780,16-08-2019
Profound Medical's TULSA-PRO Receives the US FDA's 510(k) Clearance for Ablation of Prostate Tissue,18787,16-08-2019
AbbVie's Rinvoq (upadacitinib) Receives the US FDA's Approval for Moderate to Severe Rheumatoid Arthritis,18823,19-08-2019
Celgene's Inrebic (fedratinib) Receives the US FDA's Approval for Myelofibrosis,18835,19-08-2019
Alcon to Launch PRECISION1 Daily Disposable Contact Lenses in the US,18845,19-08-2019
CVRx's Barostim Neo Device Receives the US FDA's Approval as World's First Heart Failure Neuromodulation Device,18856,19-08-2019
Glenmark's Combination Therapy of Remogliflozin Etabonate + Metformin Hydrochloride Receive Approval for Type 2 Diabetes in India,18866,19-08-2019
"Dr. Reddy's Laboratories Launches Versavo (biosimilar, bevacizumab) for Multiple Cancer Indications in India",18875,20-08-2019
AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure,18890,20-08-2019
Boston Scientific's ImageReady MRI For Vercise Gevia Deep Brain Stimulation System Receives FDA's Approval for Parkinson's Disease,18896,20-08-2019
Nabriva's Xenleta (lefamulin) Receives FDA's Approval for the Treatment of Community-Acquired Bacterial Pneumonia in Adults,18907,20-08-2019
Elanco To Acquire Bayer's Animal Health Business for $7.6B,18915,20-08-2019
"Gedeon Richter Launches Terrosa (biosimilar, teriparatide) in Europe",18921,20-08-2019
Biotheus Enters into an Agreement with Alligator Bioscience to Develop Bispecific Molecules in Greater China,18933,21-08-2019
AstraZeneca Reports Results of Imfinzi (durvalumab) + Tremelimumab in P-III NEPTUNE Study for Stage IV Non-Small Cell Lung Cancerï»¿,18945,21-08-2019
GSK Reports Submission of NDA to MHLW for Daprodustat to Treat Patients with Renal Anaemia due to Chronic Kidney Disease in Japan,18955,21-08-2019
BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with Merck's Keytruda (pembrolizumab) for Solid Tumors,18964,21-08-2019
Orexo Enters into an Agreement with GAIA to Develop and Commercialize Digital Therapy for Opioid Use Disorderï»¿,18972,21-08-2019
Vivus Reports Results of Qsymia in Pilot Clinical Study for Patients with Laparoscopic Sleeve Gastrectomy Surgery,18979,21-08-2019
Pfizer to Invest $500M in State-of-the-Art Gene Therapy Facility in North Carolina,18995,22-08-2019
"Biocon Receives EU's GMP Certification for its Semglee (biosimilar, Insulin Glargine) Manufacturing Facility in Malaysia",19045,22-08-2019
Clarus Therapeutics' Jatenzo (Testosterone Undecanoate Capsules for Oral Use) (CIII) Receives FDA'S Approval for Testosterone Replacement Therapy in Certain Adult Men,19062,27-03-2019
EMD Serono's Mavenclad (Cladribine) Receives FDA's Approval for RRMS and SPMS in Adults,19072,29-03-2019
Johnson &amp; Johnson's Balversa (erdafitinib) Receives FDA's Approval for Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alteration,19082,12-04-2019
Amgen's Corlanor (ivabradine) Receives FDA's Approval to Reduce Risk of Hospitalization for Worsening Heart Failure in Patients with Chronic Heart Failure,19087,15-04-2019
Bausch's Duobrii (Halobetasol Propionate and Tazarotene) Receives FDA's Approval for Topical Treatment of Plaque Psoriasis in Adults,19093,25-04-2019
Janssen's Darzalex (daratumumab) Receives MHLW's Approval for Transplant Ineligible Patients with Multiple Myeloma in Japan,19100,22-08-2019
"Samsung Bioepis Eticovo's (etanercept-ykro, biosmilar) Receives FDA's Approval for All Eligible Indication",19111,29-04-2019
Jacobus Pharmaceutical's Ruzurgi (amifampridine) Receives the US FDA's Approval for Lambert-Eaton myasthenic syndrome,19117,06-05-2019
AstraZeneca Signs an Agreement with Sobi to Buy its Priority Review Voucher for $95M,19128,22-08-2019
Exeltis' Slynd Receives the US FDA's Approval for the Prevention of Pregnancy,19133,06-06-2019
Innovent Signs a License Agreement with Eli Lilly to Develop and Commercialize OXM3 in China,19138,22-08-2019
AstraZeneca and FibroGen's Roxadustat Receive NMPA's Approval for the Treatment of Anemia in Non-Dialysis-Dependent Patients with Chronic Kidney Disease in China,19147,22-08-2019
"Palatin Technologies' Vyleesi (bremelanotide injection) Receives FDA's Approval for Premenopausal Women with Acquired, Generalized Hypoactive Sexual Desire Disorder",19154,22-06-2019
MSD Signs an Exclusive License and Research Agreement with Themis Bioscience to Develop Vaccine Therapies,19178,23-08-2019
"Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab) in JASMINE Study for Non-Hodgkin's Lymphoma",19191,23-08-2019
Roche's Tecentriq (atezolizumab) Receives MHLW's Approval as the First Immunotherapy for Extensive-Stage Small Cell Lung Cancer in Japan,19202,23-08-2019
Cantargia Extends Licensing Agreement with BioWa for its POTELLIGENT Technology,19250,23-08-2019
Novartis Signs an Option Agreement with Iconic Therapeutics for its Ophthalmology Program,19263,23-08-2019
OxThera's Oxabact Receives EMA's Positive Decision on Pediatric Investigational Plan to Treat Primary Hyperoxaluria,19279,23-08-2019
Amgen to Acquire Celgene's Otezla (apremilast) for $13.4B,19305,26-08-2019
Miracor's PiCSO Impulse System Receives FDA's Breakthrough Device Designation for Treatment of Patients with STEMI,19314,26-08-2019
Zogenix to Acquire Modis Therapeutics for its MT1621,19321,26-08-2019
Eli Lilly and Incyte Report Results of Olumiant (baricitinib) + Topical Corticosteroids in P-III BREEZE-AD7 Study for Moderate to Severe Atopic Dermatitis,19330,26-08-2019
Laminate Reports Results of VasQ External Support Device in a Clinical Study for Arteriovenous Fistulas in Hemodialysis Patients,19334,26-08-2019
Freenome Signs an Agreement with ADC Therapeutics to Develop Biomarker for its ADCT-402 (loncastuximab tesirine),19350,27-08-2019
Eli Lilly's Taltz (ixekizumab) Receives Third US FDA's Approval for Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)ï»¿,19362,27-08-2019
Alcon's AcrySof IQ PanOptix Receives the US FDA's Approval as the First Trifocal Lens for Patients Undergoing Cataract Surgery in the USï»¿,19371,27-08-2019
Abbott Reports Positive Data of its Blood Test Technology Detecting Traumatic Brain Injury in Patients with Negative CT Scan,19380,27-08-2019
AstraZeneca's Farxiga Receives the US FDA's Fast Track Designation for Chronic Kidney Diseaseï»¿,19390,27-08-2019
GSK Exercises Its Option to License Ionis' Antisense Therapy for Chronic Hepatitis B Virus Infection,19399,27-08-2019
Everyday Health Group to Acquire Johnson and Johnson's BabyCenter a Global Digital Pregnancy and Parenting Resource,19405,27-08-2019
BMS Signs a Research Collaboration with Presage to Evaluate Novel Cancer Therapies In Phase 0 Studies Utilizing CIVO Technology,19422,28-08-2019
Alexion's Soliris (eculizumab) Receives European Commission's Approval for Neuromyelitis Optica Spectrum Disorderï»¿,19432,28-08-2019
AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study for Chronic Obstructive Pulmonary Disease,19444,28-08-2019
BMS's Triple Regimen Receives European Commission Approval for Relapse/Refractory Multiple Myelomaï»¿,19451,28-08-2019
AstraZeneca Receives the US FDA's Orphan Drug Designation for its First Respiratory Biologic Fasenra (benralizumab) to Treat Eosinophilic Esophagitis,19467,28-08-2019
Kyowa Kirin's Nourianz (istradefylline) Receives FDA's Approval as an Adjunctive Therapy in Patients with Parkinson's Disease,19475,28-08-2019
Janssen Collaborates with Arrowhead for the Initiation of REEF-1 P-IIB Study in Patients with Chronic Hepatitis B Infection,19482,28-08-2019
Celgene Signs an Option to License Agreement with Immatics to Develop Novel Adoptive Cell Therapies Targeting Multiple Cancers,19493,29-08-2019
Mitsubishi Tanabe Reports Initiation of P-III BouNDLess Trial in Patients with Fluctuating Parkinson's Disease,19501,29-08-2019
Roche's Tecentriq (atezolizumab) + Abraxane Receive European Commission's Approval for Patients with PD-L1-Positive Metastatic Triple-Negative Breast Cancer,19511,29-08-2019
AstraZeneca Reports Results of Anifrolumab in P-III TULIP 2 Study for Patients with Systemic Lupus Erythematosus,19519,29-08-2019
Roche Reports Launch of First CDx VENTANA PD-L1 (SP142) Assay Identifying TNBC Patients Eligible for Treatment with Tecentriq (atezolizumab),19532,29-08-2019
AbbVie to Discontinue its P-III MERU Trial of Rovalpituzumab Tesirine (Rova-T) as 1L Maintenance Therapy for Patients with Advanced Small-Cell Lung Cancer,19547,29-08-2019
Novartis Reports Results of Ofatumumab (OMB157) in P-III ASCLEPIOS I and II Studies for Multiple Sclerosis,19561,30-08-2019
Sandoz Recalls Losartan Potassium and Ezetimibe Prescription Drug Bottles due to Packaging Issuesï»¿,19570,30-08-2019
Janssen Extends its Research and Licensing Agreement with SVI to Develop Therapies for Alzheimer's Disease,19581,30-08-2019
"Innovent Biologics Reports Results of IBI303 (biosimilar, adalimumab) in P-III Studies for Ankylosing Spondylitisï»¿",19588,30-08-2019
Celltrion and Teva Report Results Updated Results of CT-P6 in P-III Study for Patients Receiving Neoadjuvant Treatment for HER2-Positive Early Breast Cancer,19593,21-08-2019
United Healthcare to Prefer Amgen's Two Anticancer Biosimilars in October 2019,19603,16-08-2019
Philips Collaborates with LindaCare for the Remote Monitoring of Patients with Cardiac Implantable Electronic Devices,19610,30-08-2019
Paratek Reports Results of Nuzyra (omadacycline) in P-III OASIS-2 Study for Skin Infections,19632,30-08-2019
Roche Reports Positive Results of Xofluza (baloxavir marboxil) in Two P-III MINISTONE-2 and BLOCKSTONE Studies for Influenza Infection,19645,02-09-2019
Novartis Reports Results of Entresto (sacubitril/valsartan) in Three P-III PARAGON-HF and P-IV PROVE-HF with EVALUATE-HF Studies for Patients with HFpEF and HFrEF,19658,02-09-2019
UniSA Evaluates Computer Vision Technology to Monitor Premature Babies in Neonatal Units,19668,02-09-2019
AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Study for Coronary Artery Disease and Type-2 Diabetes,19677,02-09-2019
Chugai Files an Application to MHLW for an Additional Indication of Kadcyla (trastuzumab emtansine) as an Adjuvant Therapy for HER2-Positive Early Breast Cancer in Japan,19687,02-09-2019
AstraZeneca Reports Detailed Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failureï»¿,19696,02-09-2019
Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America,19704,03-09-2019
"Federal Circuit to Dismiss Halt Sales of Amgen's Mvasi (biosimilar, bevacizumab-awws) in the US",19714,16-08-2019
Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis,19725,03-09-2019
The European Society of Cardiology Recommends Bayer's Xarelto (rivaroxaban) in Combination with Aspirin for the Management of Diabetes and Chronic Coronary Syndromes,19735,03-09-2019
Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes,19742,03-09-2019
Alytas Therapeutics Signs an Agreement with Velabs Therapeutics to Develop Novel Immune-Based Therapy for Obesity,19754,03-09-2019
Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes,19770,03-09-2019
"Celltrion Enters into a Contract to Manufacture Agreement for its Remsima (biosimilar, infliximab) with Lonzaï»¿",19781,04-09-2019
"STADA to Launch its Movymia (biosimilar, teriparatide) to Treat Osteoporosis in 24 Countries",19789,20-08-2019
AstraZeneca's Tagrisso (osimertinib) Receives NMPA's Approval as a 1L Therapy for EGFR-Mutated Non-Small Cell Lung Cancer in Chinaï»¿,19798,04-09-2019
Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to Expand its KRAS Cancer Program,19814,04-09-2019
Karolinska Institutet Evaluates AsthmaTuner Self-monitoring Mobile App for Managing Uncontrolled Asthmaï»¿,19824,04-09-2019
Merck's Keytruda (pembrolizumab) in Combination with Inlyta (axitinib) Receives European Commission's Approval as a 1L Therapy for Advanced Renal Cell Carcinoma,19832,04-09-2019
Janssen's Investigational Prophylactic Vaccine Receives the US FDA's Breakthrough Therapy Designation to Prevent Respiratory Syncytial Virus,19839,04-09-2019
BMS Signs an Agreement with BioMotiv to Develop Therapies for Patients with Serious Disorder,19849,04-09-2019
Regenxbio Signs an Exclusive Worldwide Option and License Agreement with Clearside Biomedical to Evaluate its Delivery Platform for RGX-314,19857,04-09-2019
Mylan to Make Amendments in its 2018 License Agreement with Revance for Biosimilar of BOTOX,19871,22-08-2019
"Samsung Bioepis Initiates Recruitment of Patients in P-III Study for SB12 (biosimilar, eculizumab) to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH) in India",19881,16-08-2019
Conglomerate of Rheumatology and Spondylitis Organizations Released New Updated Guidelines Against Mandatory Switching to Biosimilars,19889,22-08-2019
AstraZeneca Collaborates with SchrÃ¶dinger to Utilize its Molecule-Modeling Platform for Drug Discovery,19890,05-09-2019
Google Collaborates with Cochlear and GN Hearing to Support Direct Phone Streaming to Hearing Aids for Patients with Hearing Loss,19907,05-09-2019
BioNTech Signs an Agreement with Gates Foundation to Develop Therapies for HIV and Tuberculosis,19928,05-09-2019
Janssen's Stelara (ustekinumab) Receives EC's Approval for its Expanded Use to Treat Moderately to Severely Active Ulcerative Colitis,19937,05-09-2019
AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate Combination Therapy,19949,05-09-2019
Novartis Signs an Exclusive Research and Option to Acquire Agreement with IFM Due to Develop Therapies Targeting cGAS/STING Pathway,19972,05-09-2019
Takeda Recalls Natpara (parathyroid hormone) Injection Formulation in the US,19995,06-09-2019
AstraZeneca Signs a License Agreement with Theragnostics for its PARP Inhibitor,20016,06-09-2019
SpeeDx's ResistancePlus MG FleXible Receives CE-IVD Clearance for Detection of Sexually Transmitted Infection (STI),20025,06-09-2019
BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate-548 Study for Patients Newly Diagnosed with MGMT-Methylated Glioblastoma Multiforme,20038,06-09-2019
Roche's Tecentriq Based Combination Therapy Receives EC's Approval as 1L Treatment for Non-Squamous Non-Small Cell Lung Cancer,20053,06-09-2019
OncoCyte to Acquire Razor Genomics for the Expansion of its Capabilities in Early-Stage Lung Cancer,20075,06-09-2019
Roche's Tecentriq + Chemotherapy Receives EC's Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer,20084,06-09-2019
Sumitomo Dainippon and Roivant Signs a Memorandum of Understanding to Form $3B Alliance,20116,09-09-2019
Eli Lilly Signs an Agreement with Thermo Fisher to Develop CDx for its Selpercatinib (LOXO-292),20132,09-09-2019
AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer,20145,09-09-2019
Abbott to Initiate World's First Study to Evaluate its TriClip Transcatheter Tricuspid Valve Repair System in the USï»¿,20154,09-09-2019
Allergan and Molecular Partners Report Acceptance of FDA's BLA and Validation of EMA's MAA for Abicipar Pegol,20170,09-09-2019
Genmab Signs an Agreement with Tempus to Develop Novel Targets and Biomarkers for Cancer Indications,20178,10-09-2019
Alexion Enters into an Exclusive License Agreement with Eidos to Develop and Commercialize AG10 in Japan,20186,10-09-2019
Medtronic's MiniMed 670G Insulin Pump System Receives Reimbursement for Patients with T1D in Germany,20196,10-09-2019
BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer,20206,10-09-2019
Mallinckrodt to Divest its Subsidiary BioVectra for $250Mï»¿,20215,10-09-2019
Baxter to Acquire Cheetah Medical for ~$230M,20221,10-09-2019
Sanofi Terminates its Four Years Alliance with Lexicon for Zynquista (sotagliflozin)ï»¿,20232,11-09-2019
Xeris' GVOKE (glucagon) Receives FDA's Approval as The First Ready-To-Use Stable Liquid Glucagon for Severe Hypoglycemia,20241,11-09-2019
Google Collaborates with Mayo Clinic for Healthcare Innovation Utilizing AI and Cloud Computingï»¿,20252,11-09-2019
"Samsung Bioepis Reports the Availability of Brenzys (biosimilar, etanercept) in Brazil",20262,11-09-2019
Merck KGaA's Tepotinib Receives FDA's Breakthrough Therapy Designation for Metastatic NSCLC with METex14 Skipping Alterations,20291,11-09-2019
Apple to Launch a Research App for Three Medical Studies Monitoring Health Issues,20314,11-09-2019
GSK to Acquire Sitari Pharmaceuticals for its Celiac Diseases Program,20340,12-09-2019
"Teva Canada's Herzuma (biosimilar, trastuzumab) Receives Health Canada Approval for Multiple Cancer Indicationsï»¿",20347,12-09-2019
Roche Reports Results of Satralizumab in Second P-III Study for Neuromyelitis Optica Spectrum Disorder,20355,12-09-2019
Zentiva to Acquire Sanofi's Ankleshwar Manufacturing Facility in India,20368,12-09-2019
Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis in Adults,20376,12-09-2019
Hansoh Enters into a Collaboration with Atomwise for AI-Based Drug Discovery,20392,12-09-2019
Vertex Signs an Access Agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor),20401,12-09-2019
Aytu BioScience to Acquire Innovus Pharmaceuticals for ~$24M,20423,13-09-2019
Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer,20438,13-09-2019
GSK's Nucala (mepolizumab) Receives the US FDA's Approval as First Biologic for Severe Eosinophilic Asthma in Children Aged 6-11yrs.,20466,13-09-2019
Celgene Reports Results of CC-486 in P-III QUAZAR AML-001 Study as Maintenance Therapy for Acute Myeloid Leukemia,20481,13-09-2019
GE Healthcare's Critical Care Suite AI-Powered X-ray Device Receives FDA's 510(k) Clearance to Identify Pneumothorax,20515,13-09-2019
Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer's Diseaseï»¿,20529,13-09-2019
Lundbeck to Acquire Alder BioPharmaceuticals for $1.95B,20547,16-09-2019
Sanofi and Abbott Collaborate to Assimilate Glucose Sensing and Insulin Delivery Technologies to Manage Diabetes,20558,16-09-2019
Medtronic and Novo Nordisk Collaborate to Deliver Integrated Digital Solutions Easing the Hassles of Diabetes Management,20571,16-09-2019
AstraZeneca's Farxiga (dapagliflozin) Receives FDA's Fast Track Designation to Treat Patients with Heart Failure,20580,16-09-2019
Boehringer Ingelheim Signs an Exclusive Worldwide License Agreement with Oncoheroes Biosciences for Volasertib,20590,16-09-2019
Janssen Reports Submission of sBLA to the US FDA for Tremfya (guselkumab) to Treat Active Psoriatic Arthritis,20602,17-09-2019
Seattle Genetics and Astellas Report Acceptance of BLA for Enfortumab Vedotin to Treat Locally Advanced or Metastatic Urothelial Cancerï»¿,20610,17-09-2019
Medtronic's Envision Pro Continuous Glucose Monitoring System Receives CE Mark in Europe,20619,17-09-2019
Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophyï»¿,20628,17-09-2019
Glenmark's GBR 1342 Receives the US FDA's Orphan Drug Designation for Multiple Myeloma,20635,17-09-2019
Merck Reports Acceptance of BLA to the US FDA for V920 Ebola Virus Vaccine,20640,17-09-2019
Bayer Signs a License Agreement with Informed Data Systems to Utilize its One Drop Digital Therapeutics Platform,20651,17-09-2019
Mylan Launches Generic Faslodex Injection for the Expansion of its Oncology Portfolio in the US,20662,18-09-2019
Generium Launches First Biosimilar of Dornase Alfa Utilizing Selexis' SUREtechnology Platformï»¿,20674,18-09-2019
AstraZeneca Amends its Development and Commercialization Agreement with Ironwood for Linzess (linaclotide) Signed in 2012 ï»¿,20681,18-09-2019
Roche's Gazyva (obinutuzumab) Receives FDA's Breakthrough Therapy Designation for Lupus Nephritis,20690,18-09-2019
Regeneron and Sanofi Launch Educational Campaign Focusing on Patients Living with Moderate-To-Severe Atopic Dermatitis,20698,18-09-2019
The US FDA Initiates its First Step Towards Project Orbis for Concurrent Review of Cancer Therapies,20709,18-09-2019
Merck's Keytruda (pembrolizumab) + Eisai's Lenvima (lenvatinib) Receives FDA's Approval for Certain Types of Endometrial Carcinomaï»¿,20719,18-09-2019
Novigenix Collaborates with BioLizard to Develop AI-Based Diagnostic Algorithm for Detecting Colon Cancer,20729,19-09-2019
Roche Renews its Support to the Phelophepa Healthcare Trains in South Africa Marking the 25th Anniversary,20739,19-09-2019
Novartis Reports Results of Galvus (vildagliptin) Combination Therapy in P-IV VERIFY Study for Type 2 Diabetes Mellitusï»¿,20748,19-09-2019
Biogen to Initiate P-II/III DEVOTE Study Evaluating the Higher Doses of Spinraza (nusinersen) for Spinal Muscular Atrophy,20759,19-09-2019
TB Alliance's Pretomanid Combination Therapy Receives the US FDA's Approval for Highly Drug-Resistant Forms of Tuberculosis,20770,15-08-2019
Harmony Biosciences' Wakix (pitolisant) Receives the US FDA's Approval for Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy,20787,15-08-2019
Novo Nordisk Reports Results of Tresiba (insulin degludec) in CONCLUDE Study for Type 2 Diabetes,20794,19-09-2019
Novartis Reports the Reimbursement of Kisqali as 1L Treatment for Metastatic Breast Cancer in Quebec,20813,19-09-2019
Merck KGaA Signs a License Agreement with Y-Trap to Develop Antibody-Ligand Traps for Immuno-Oncology,20826,20-09-2019
Roche's cobas Babesia Blood Test Receives the US FDA's Approval for Donor Screening,20850,20-09-2019
Takeda and Lundbeck's Trintellix (vortioxetine) Receives MHLW's Approval for Major Depressive Disorder in Japanï»¿,20856,20-09-2019
Eli Lilly's Trulicity (dulaglutide) Receives CHMP Recommendation for Label Update to Include Results from REWIND Study,20876,20-09-2019
Astellas and FibroGen's Evrenzo (roxadustat) Receives MHLW's Approval for Anemia Associated with Chronic Kidney Disease in Dialysis Patients,20886,20-09-2019
Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases,20902,20-09-2019
AstraZeneca's Qtrilmet Receives CHMP's Recommendation for its Approval to Treat Patients with Type-2 Diabetes in Europe,20931,23-09-2019
Novo Nordisk's Rybelsus (semaglutide) Receives FDA's Approval as the First Oral GLP-1 analog for Type 2 Diabetes,20935,23-09-2019
Clovis Oncology Signs a License Agreement with 3B Pharmaceuticals for FAP-Targeted Radiopharmaceutical Program,20944,23-09-2019
Biogen's Plegridy (peginterferon beta-1a) and Avonex (interferon beta-1a) Receive CHMP's Positive Opinion to Use During Pregnancy and Breastfeedingï»¿,20955,23-09-2019
Mallinckrodt Reports Results of StrataGraft Regenerative Tissue in P-III STRATA2016 Study for Deep Partial-thickness Thermal Burnsï»¿,20966,23-09-2019
"Celltrion's CT-P13 (biosimilar, infliximab) Receives CHMP's Positive Opinion for its SC Formulation to Treat Rheumatoid Arthritisï»¿",20977,23-09-2019
MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications,20997,24-09-2019
Bayer's Vitrakvi (larotrectinib) Receives EMA's Approval as the First Tumor Agonist in Europeï»¿,21008,24-09-2019
Sandoz Voluntary Recalls Ranitidine Hydrochloride Capsules Due to Elevated Amount of N-Nitrosodimethylamine in the US,21016,24-09-2019
Bayer Collaborate with Women's Hospital and Massachusetts General Hospital to Launch Joint Lab Targeting Chronic Lung Diseases,21025,24-09-2019
Takeda Collaborates with Evotec to Discover Clinical Candidates for Multiple Therapeutic Areas,21036,24-09-2019
BMS' Opdivo (nivolumab) Receives CHMP Recommendation for Approval of its Four-Week Dosing Scheduleï»¿,21043,24-09-2019
Aldeyra's ADX-2191 Receives FDA's Fast Track Designation to Prevent Proliferative Vitreoretinopathy,21048,24-09-2019
Biocon Biologics Acquires Pfizer's Research Facility to Expand its Research and Development Footprint,21060,25-09-2019
Pfizer Expands its Collaboration with Flatiron Health to Integrate the Use of Real-World Evidence in Oncology,21072,25-09-2019
Amgen Reports Results of Blincyto (blinatumomab) in Two P-III Studies for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patientsï»¿,21082,25-09-2019
Bavarian Nordic's Jynneos Vaccine Receives FDA's Approval to Prevent Smallpox and Monkeypox Disease in Adults,21090,25-09-2019
Achillion's Danicopan (ACH-4471) Receives FDA's Breakthrough Therapy Designation for Paroxysmal Nocturnal Hemoglobinuria,21098,25-09-2019
Ethicon Launches Echelon Circular as the First Powered Circular Stapler for Colorectal Gastric and Thoracic Surgeryï»¿,21107,25-09-2019
Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic Study for Ulcerative Colitis,21115,26-09-2019
Abbott's ARCHITECT STAT High Sensitivity Troponin-I Blood Test Receives FDA Clearance to Detect Heart Attacks Faster and Accurately,21125,26-09-2019
Thermo Fisher to Expand its Clinical Trials Capabilities and Collaborates with Frontier to Develop Therapy for HIV,21143,26-09-2019
Jazz Reports Results of JZP-258 in a P-III Study to Treat Cataplexy and Excessive Daytime Sleepiness in Patients with Narcolepsy,21151,26-09-2019
AstraZeneca and Innate Pharma to Advance Monalizumab in a P-III Study for Head and Neck Cancer,21162,26-09-2019
Medtronic to Initiate Clinical Study Evaluating Infuse Bone Graft in TLIF Spine Procedures,21170,26-09-2019
AbbVie's Mavyret (glecaprevir/pibrentasvir) Receives FDA's Approval for its Expanded Indication in Treatment-NaÃ¯ve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes,21185,27-09-2019
Janssen's Darzalex (daratumumab) Combination Therapy Receives FDA's Approval for Frontline Multiple Myelomaï»¿,21238,27-09-2019
Medtronic Reports Results of Resolute Onyx DES in Onyx ONE Global Study for High-Bleeding Risk Patients with One-Month DAPT ï»¿,21259,27-09-2019
Ieso Launches Eight Billion Minds Digital Initiative Addressing Unmet Mental Health Needs,21267,27-09-2019
Simcere Signs an Exclusive License Agreement with JW Pharmaceutical for an Anti-Gout Drug Candidate URC-102 in Chinaï»¿,21275,27-09-2019
Pfizer Reports Results of Abrocitinib in P-III JADE MONO-2 Study for Moderate to Severe Atopic Dermatitis,21280,27-09-2019
Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma,21296,27-09-2019
Sobi to Acquire Dova Pharmaceuticals for $915Mï»¿,21335,30-09-2019
Roche's Rituxan (rituximab) Receives the US FDA's Approval for Two Rare Blood Vessel Disorders in Pediatric Patients Aged 2yrs. and Aboveï»¿,21344,30-09-2019
GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthmaï»¿,21351,30-09-2019
Merck Reports Results of Recarbrio (imipenem/cilastatin/relebactam) in P-III RESTORE-IMI 2 Study for Patients with HABP/VABP,21358,30-09-2019
Celltrion Signs an Exclusive Co-Marketing Agreement with Juno in Australia,21363,30-09-2019
Fresenius Kabi to Establish R&amp;D Center for Biosimilars in Switzerland,21371,18-09-2019
Vertex Collaborates with Ribometrix to Discover and Develop up to Three RNA Targeted Candidates,21375,30-09-2019
Mochida Receives Marketing Authorization for Teriparatide Biosimilar in Japan,21382,20-09-2019
SymBio Signs Worldwide Exclusive License Agreement with Chimerix to Develop and Commercialize Brincidofovir,21406,01-10-2019
"Dr. Reddy Plans the Onset of P-III trial for DRL_RI (biosimilar, rituximab) in the Korea",21423,17-09-2019
AstraZeneca to Divest Worldwide Commercialization Rights of Losec (omeprazole) to Cheplapharm,21429,01-10-2019
Janssen's Invokana (canagliflozin) Receives the US FDA's Approval for Patients with Type 2 Diabetes and Diabetic Kidney Disease ï»¿,21449,01-10-2019
Roche Reports Result of Tecentriq (atezolizumab) + Platinum-Based CT in P-III IMvigor130 Study for Advanced Bladder Cancer,21460,01-10-2019
"Pfizer to Launch its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019",21470,01-10-2019
Taisho Signs an Exclusive License Agreement with Moberg Pharma to Develop and Commercialize MOB-015 in Japanï»¿,21483,01-10-2019
Eisai Signs a Research and Option Agreement with Numab to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancerï»¿,21495,01-10-2019
Novartis Signs a Multiyear Agreement with Microsoft to Transform Medicine with the Launch of AI Innovation Lab,21510,03-10-2019
"Biocon and Mylan Launch Semglee (biosimilar, Insulin Glargine) in Australia",21522,03-10-2019
Philips Collaborates with Air Ambulance Kent Surrey Sussex to Provide Emergency Services in the UK,21531,03-10-2019
Eli Lilly Reports Results of Taltz (ixekizumab) in Head-to-Head P-IV IXORA-R Study for Moderate to Severe Plaque Psoriasis,21538,03-10-2019
Merck's Keytruda Receives NMPA's Approval as Monotherapy for 1L Treatment of Advanced Non-Small Cell Lung Cancer with PD-L1 Tumor Expression in Chinaï»¿,21547,03-10-2019
Eli Lilly Reports the Availability of Emgality (galcanezumab) to Prevent Migraine in Canada,21565,03-10-2019
Novo Nordisk Collaborates with Noom to Provide Digital Health Solutions Targeting Weight Management in Patients with Obesity,21584,03-10-2019
Takeda Signs a License Agreement with Goldfinch Bio for its GFB-024 to Treat Rare and Metabolic Kidney Diseases,21607,04-10-2019
Gilead's Descovy Receives the US FDA's Approval for HIV Pre-Exposure Prophylaxis ï»¿,21618,04-10-2019
AstraZeneca's Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA's Approval for Severe Eosinophilic Asthmaï»¿,21642,04-10-2019
Silver Cloud Health Partners with Microsoft to Deploy AI for Enhancing its Digital Mental Healthcare,21651,04-10-2019
Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B,21664,04-10-2019
Janssen's Niraparib Receives the US FDA's Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer,21667,04-10-2019
AveXis Reports Results of AVXS-101 (Intrathecal) in P-I/II STRONG Study for Patients with SMA Type 2,21702,07-10-2019
Takeda Signs Multi-Target Strategic Collaboration with Prometheus to Develop Targeted Therapies for Inflammatory Bowel Disease,21711,07-10-2019
Eli Lilly Report Results of Cyramza (ramucirumab) in P-III RELAY Study for 1L Treatment of EGFR-Mutated Non-Small Cell Lung Cancer,21728,07-10-2019
"Alvogen and Pfenex's PF708 (biosimilar, teriparatide) Receives FDA's Approval for the Treatment of Osteoporosisï»¿",21735,07-10-2019
Pfizer Signs an Exclusive Worldwide License Agreement with Akcea for its AKCEA-ANGPTL3-L(Rx),21744,07-10-2019
Biofourmis' Biovitals Analytics Engine Receives FDA's 510(k) Clearance for Ambulatory Physiologic Monitoringï»¿,21748,07-10-2019
Innovate Merging with RDD Pharma to Form New Gastroenterology Company Focusing on Specialty Rare and Orphan Diseases,21776,08-10-2019
Allergan to Launch Three REFRESH RELIEVA Lubricant Eye Drops Expanding its REFRESH Portfolio,21784,08-10-2019
MSD Signs a Research and Option to License Agreement with 4D Pharma to Develop Live Biotherapeutics for Vaccines,21794,08-10-2019
Medtronic Initiates Worldwide Pivotal Study to Evaluate its Extravascular Implantable Cardioverter Defibrillator System,21801,08-10-2019
Novartis' Beovu (brolucizumab) Receives FDA's Approval for the Treatment of Wet Age-Related Macular Degeneration,21813,08-10-2019
Gilead Reports Submission of NDA to MHLW for Filgotinib to Treat Rheumatoid Arthritis in Japan,21818,08-10-2019
GSK Signs a Five Years Collaboration with Lyell to Develop Technologies Improving Cell Therapies for Cancer,21825,09-10-2019
AstraZeneca Canada's Calquence (acalabrutinib) Receives Health Canada Approval for Patients Previously Treated with Mantle Cell Lymphoma (MCL),21833,09-10-2019
Prevail Signs an Agreement with Lonza to Develop and Manufacture AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases,21842,09-10-2019
Amgen Canada's EVENITY (romosozumab) Receives Health Canada Approval to Treat Osteoporosis in Postmenopausal Women at High Risk for Fracture,21850,09-10-2019
GE Healthcare Signs a Worldwide Development and Commercialization Agreement with Theragnostics for Late Stage PSMA Diagnostic for Prostate Cancer,21861,09-10-2019
"Samsung Bioepis Reports Real-World Data of Benepali (biosimilar, etanercept) in Patients with Psoriasis at EADV 2019",21863,09-10-2019
Bluebird Bio Signs a Three-Year Research Collaboration with Novo Nordisk to Develop In-Vivo Genome Editing Therapies for Hemophilia A,21876,09-10-2019
Mitsubishi Tanabe Signs a License Agreement with Viela Bio for its Inebilizumab,21893,10-10-2019
Evotec Signs an Agreement with Celmatix to Develop Pre-Clinical Candidates for Women Health,21903,10-10-2019
Boehringer Ingelheim Reports Results of OFEV (nintedanib) in P-III INBUILD Trial for Patients with Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (1),21914,10-10-2019
Bayer Launches a LifeHub UK for the Development of AI-Enabled Imaging Solutions Enhancing Data-Driven Drug Discovery and Disease Diagnosis,21923,10-10-2019
Sun Pharma Reports Four Years Result of Ilumya (tildrakizumab-asmn) in P-III reSURFACE 1 and 2 Trials in Patients with Moderate-to-Severe Plaque Psoriasis,21933,10-10-2019
UCB to Acquire Ra Pharma to Improve Therapies for Patients with Myasthenia Gravis and Other Rare Diseases,21940,10-10-2019
Reata Regains Exclusive Worldwide Rights of its Nrf2 Activator Product Platform from AbbVie,21949,10-10-2019
Aclaris to Divest its Rhofade (oxymetazoline hydrochloride) with all IPR Rights to EPI Health,21957,11-10-2019
Bayer's G4A Digital Health Partnerships Program Signs an Agreement with Eleven Digital Health Startups Transforming Digital Health Solutions,21971,11-10-2019
Boehringer Ingelheim's Ofev (nintedanib) Receives the US FDA's Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype,21979,11-10-2019
Biocon Biologics Signs an In-License Agreement with Just - Evotec Biologics,21993,11-10-2019
Alexion Signs an Option to Co-Develop and Commercialize Agreement with Stealth for Elamipretide,22005,11-10-2019
OraSure Technologies' Rapid Diagnostic OraQuick Ebola Rapid Antigen Test Receives the US FDA Marketing Approval for Detection of Ebola Virus Antigens,22012,11-10-2019
ï»¿Alnylam Reports Submission of MAA to Brazilian Health Regulatory Agency for Onpattro (patisiran) to Treat Hereditary ATTR Amyloidosis with Polyneuropathy,22013,11-10-2019
ï»¿ImaginAb Collaborates with Three Global Pharmaceutical Companies Focusing on the Development of its CD8 ImmunoPET Technology,22044,14-10-2019
Roche Reports Results of MabThera/Rituxan (rituximab) in P-III PEMPHIX Study for Pemphigus Vulgarisï»¿,22054,14-10-2019
ï»¿Lilly's Reyvow (lasmiditan) Receives FDA's Approval as the First Therapy in a New Class of Acute Treatment for Migraine,22063,14-10-2019
ï»¿Exact Sciences and Mayo Clinic Initiate Voyage Study Evaluating the Real-World Impact of Cologuard,22073,14-10-2019
ï»¿Aytu BioScience to Acquire Cerecor's Prescription Product Portfolio for $17M,22085,14-10-2019
ï»¿Sanofi Launches its First Digital Manufacturing Facility for Delivering Next-Generation Biologics in Massachusetts,22095,15-10-2019
ï»¿Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to Acino for ~$200M in NEMEA Countries,22105,15-10-2019
ï»¿Abbott Collaborates with Omada Health to Provide Integrated Digital Health and Coaching Experience for Patients with Type 2 Diabetes,22116,15-10-2019
ï»¿Bayer and Janssen's Xarelto (rivaroxaban) Receive FDA's Approval to Prevent Venous Thromboembolism in Acutely Ill Patients,22124,15-10-2019
ï»¿Kyowa Kirin Reports the Availability of Nourianz (Istradefylline) to Treat Parkinson's Disease â€œOffâ€ Episodes in the US,22134,15-10-2019
CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights to Facilitate Cell Therapy Programs in Oncologyï»¿,22145,15-10-2019
ï»¿Reata Reports Results of Omaveloxolone in P-II MOXIe Registrational Study for Patients with Friedreich's Ataxia,22152,15-10-2019
ï»¿Abbott and Tandem Collaborate to Explore Integrated Diabetes Solutions Improving Diabetes Management,22165,16-10-2019
ï»¿Sanofi and Kaken to Terminate their Co-Marketing Agreement for Clexane by the Year End 2019,22175,16-10-2019
ï»¿Daiichi Sankyo Acquires Rights for Astellas' Three Therapies to Boost its Presence in Asia,22184,16-10-2019
ï»¿ProQR's Sepofarsen Receives FDA's Rare Pediatric Disease Designation to Treat Leber's Congenital Amaurosis 10,22194,16-10-2019
Alexion to Acquire Achillion for ~$930Mï»¿,22203,16-10-2019
Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study for Metastatic Pancreatic Cancerï»¿,22210,16-10-2019
ï»¿Sandoz Terminates its Prescription Digital Therapies Agreement with Pear Therapeutics,22220,17-10-2019
ï»¿AstraZeneca Collaborates with PetaGene to Deploy PetaSuite in its Core Genomics Initiative,22231,17-10-2019
ï»¿AstraZeneca and Daiichi Report the US FDA's Acceptance of BLA for Trastuzumab deruxtecan (DS-8201) and Granted Priority Review,22241,17-10-2019
Sun Pharma Launches Drizalma Sprinkle (duloxetine delayed-release capsules) for Neuro-Psychiatric and Pain Disorders in the USï»¿,22249,17-10-2019
Ipsen Signs Exclusive Worldwide License Agreement with Blueprint to Develop &amp; Commercialize BLU-782 for Fibrodysplasia Ossificans Progressivaï»¿,22256,17-10-2019
UCB Reports Results of Bimekizumab in P-III BE VIVID Study to Treat Moderate to Severe Chronic Plaque Psoriasisï»¿,22267,17-10-2019
Fitbit Collaborates with BMS-Pfizer Alliance Focusing on Improving Atrial Fibrillation Detectionï»¿,22279,18-10-2019
ï»¿Roche's Xofluza (baloxavir marboxil) Receives the US FDA's Approval for People at High Risk of Developing Influenza-Related Complications,22288,18-10-2019
Amgen and UCB's Evenity (Romosozumab) Receive CHMP Positive Opinion to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fractureï»¿,22297,18-10-2019
Cipla to Acquire Venus Remedies' Elores to Strengthen its Critical Care Footprints in India,22310,18-10-2019
Merck's V920 Ebola Zaire Vaccine Receives CHMP Positive Opinion to Protect Against Ebola Virus Disease,22319,18-10-2019
AbbVie's Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritisï»¿,22327,18-10-2019
Johnson &amp; Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US,22335,18-10-2019
Roche Reports Result of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study for Unresectable Hepatocellular Carcinoma,22357,21-10-2019
GSK to Divest its Rabipur and Encepur Vaccines to Bavarian Nordic for ~1B,22369,21-10-2019
ï»¿AstraZeneca's Farxiga (dapagliflozin) Receives the US FDA's Approval for Reducing the Risk of Hospitalization for Heart Failure in Patients with Type-2 Diabetes,22378,21-10-2019
ï»¿Sartorius to Acquire Danaher's Life Science Portfolio for $750M,22384,21-10-2019
ï»¿Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for Moderately to Severely Active Ulcerative Colitis,22392,21-10-2019
ï»¿Humana and Microsoft Collaborate to Reimagine Health Leveraging Azure Cloud and AI with Voice Technologies,22404,22-10-2019
ï»¿Bayer to Terminate its JV Agreement with CRISPR Therapeutics,22412,22-10-2019
ï»¿Takeda Acquires Exclusive Worldwide License Rights for COUR's CNP-101 to Treat Celiac Disease,22421,22-10-2019
ï»¿Pfizer and OPKO Reports Results of Somatrogon in P-III Study for Children with Growth Hormone Deficiency,22430,22-10-2019
ï»¿Vertex's Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Receives the US FDA's Approval to Treat the Underlying Cause of Cystic Fibrosis,22440,22-10-2019
ï»¿BMS Reports Result of Opdivo (nivolumab) + Yervoy (ipilimumab) + CT in P-III CheckMate-9LA Study as 1L Therapy for Lung Cancer,22448,22-10-2019
"ï»¿Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies for PF708 (biosimilar, teriparatide)",22455,23-10-2019
ï»¿Novo Nordisk's Fiasp (insulin aspart injection) Receives the FDA's Approval for use in Insulin Infusion Pumps to Treat Type 1 or Type 2 Diabetes,22462,23-10-2019
ï»¿Biogen and Eisai Plan to File BLA to the US FDA for Aducanumab to Treat Alzheimer's Disease,22474,23-10-2019
ï»¿BerGenBio's Bemcentinib Receives the US FDA's Fast Track Designation for Relapsed Acute Myeloid Leukemia,22482,23-10-2019
ï»¿Brii Biosciences Collaborates with Qpex to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China,22493,23-10-2019
ï»¿Biomica Signs an Agreement with Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic-Resistant Bacteria,22501,23-10-2019
Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases,22512,24-10-2019
ï»¿GSK's Zejula (niraparib) Receives FDA's Approval for Late-line Treatment in Women with Recurrent Ovarian Cancer,22520,24-10-2019
Bausch Health In-Licenses Clearside's Xipere (triamcinolone acetonide suprachoroidal injectable suspension) For Macular Edema Associated with Uveitisï»¿,22526,24-10-2019
ï»¿NovoCodex Collaborates with Ambrx to Develop and Commercialize its ARX305 in China,22531,24-10-2019
ï»¿WHO Signs MoU with IGBA for Promoting the Access to Biosimilars and Generics,22538,24-10-2019
ï»¿AbbVie Collaborate with Cystic Fibrosis Foundation to Advance CFTR Potentiator,22555,25-10-2019
ï»¿Allergan's BOTOX (onabotulinumtoxinA) Receives the US FDA's Approval for Pediatric Patients with Lower Limb Spasticity Excluding Spasticity Caused by Cerebral Palsy,22563,25-10-2019
ï»¿Astellas' Xospata (gilteritinib) Receives EC's Approval as Monotherapy for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation,22571,25-10-2019
ï»¿Zentiva to Acquire Alvogen's Generics and OTC Business in Central and Eastern Europe,22583,25-10-2019
ï»¿NHS England Signs an Agreement with Vertex to Access All Licensed Cystic Fibrosis Therapies,22594,25-10-2019
ï»¿Urology San Antonio Collaborates with Anixa Biosciences on Ccheck Prostate Cancer Study,22601,25-10-2019
ï»¿Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program,22610,29-10-2019
ï»¿AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer,22619,29-10-2019
ï»¿Pfizer's Bavencio (avelumab) + Axitinib Dual Regimen Receive EC's Approval as 1L Treatment for Advanced Renal Cell Carcinoma,22630,29-10-2019
GSK Reports Results of M72/AS01E in P-IIb Study for the Prevention of Pulmonary Tuberculosis Disease,22640,29-10-2019
MorphoSys and Galapagos in Collaboration with Novartis Terminate Clinical Development of MOR106 in Atopic Dermatitis,22646,29-10-2019
ï»¿Astellas' ASP1128 Receives the US FDA's Fast Track Designation for Patients at High Risk of Acute Kidney Injury,22655,29-10-2019
Boehringer Ingelheim Collaborates with The Defeat-NCD Partnership to Tackle the Impacts of Non-Communicable Diseases,22667,30-10-2019
"GSK's Benlysta (belimumab, IV) Receives EC's Approvals as the First Biologic to Treat Lupus in Children",22678,30-10-2019
AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm in Europe and Russia,22688,30-10-2019
Roche Reports EMA and FDA's Acceptance of Marketing Application for Satralizumab to Treat Neuromyelitis Optica Spectrum Disorder,22701,30-10-2019
Novartis Reports FDA's Hold on P-I/II Intrathecal Study Evaluating Zolgensma/AVXS-101 (onasemnogene abeparvovec-xioi) for Spinal Muscular Atrophy Type 2,22709,30-10-2019
LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies,22715,30-10-2019
Biogen and Alkermes' Vumerity (diroximel fumarate) Receive FDA's Approval for Multiple Sclerosis,22724,30-10-2019
Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription Digital Therapeutics for GI Indications,22735,31-10-2019
Astellas Signs an Exclusive License Agreement with Pandion to Deliver Immunomodulators for Autoimmune Diseases of the Pancreas,22743,31-10-2019
Johnson &amp; Johnson Vision Launches TECNIS Eyhance Monofocal Intraocular Lens for Post Cataract Surgery Patients in India,22752,31-10-2019
AliveCor and Huami Collaborate to Bring the Next Generation ECG Wearables Devices,22758,31-10-2019
Roche Signs a Development and Commercialization Agreement with Dicerna for its DCR-HBVS to Treat Chronic Hepatitis B Virus Infection,22769,31-10-2019
Janssen's Darzalex (daratumumab) Combination Regimen Receives Health Canada Approval for Transplant Ineligible Patients with Multiple Myeloma,22776,31-10-2019
Amgen Acquires Stake in BeiGene to Expand its Oncology Portfolio in China,22789,01-11-2019
Pfizer Reports Launch Date for its Two Anticancer Biosimilars,22796,29-10-2019
"Formycon Reports Initiation of P-I Trial for FYB202 (biosimilar, ustekinumab)",22807,28-10-2019
"Pfenex Reports Results of Human Factors Study for its PF708 Candidate (biosimilar, teriparatide)",22816,14-10-2019
"NeuClone Reports Dosing of NeuLara (proposed biosimilar, ustekinumab) in P-I Trial",22823,01-11-2019
Novartis Reports Results of Cosentyx (secukinumab) in Head to Head P-III EXCEED Study for Psoriatic Arthritis,22827,01-11-2019
AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2 Study for Psoriatic Arthritis,22839,01-11-2019
Vertex Reports Results of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Two P-III Studies for Cystic Fibrosis,22844,01-11-2019
"Mundipharma's Pegfilgrastim Mundipharma (biosimilar, pegfilgrastim) Receives CHMP Positive Opinion for MAA in EU",22852,18-10-2019
Beam Therapeutics Signs Exclusive License Agreement with Prime Medicine for Prime Editing Technology,22860,01-11-2019
Medtronic Reports MHLW's Shonin Approval and Launches Valiant Navion Thoracic Stent Graft System in Japan,22872,01-11-2019
Google to Acquire Fitbit for ~$2.1B,22897,04-11-2019
Sanofi Reports Results of Toujeo (insulin glargine 300 Units/mL) in P-III EDITION JUNIOR Study in Children and Adolescents with Type 1 Diabetes,22910,04-11-2019
Janssen Collaborates with Vifor Pharma to Co-commercialize Invokana (canagliflozin) for the Treatment of Diabetic Kidney Disease in the US,22916,04-11-2019
Yas Holding to Acquire Stake in Alvotech and Signs an Exclusive Agreement for its Three Biosimilar Candidates,22925,04-11-2019
Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer,22932,04-11-2019
Boehringer Ingelheim and Lilly Restructure their Alliance to Emphasis Full Expertise and Investment on Jardiance,22940,05-11-2019
"Sandoz's Ziextenzo (biosimilar, pegfilgrastim) Receives the US FDA's Approval to Decrease the Incidence of Febrile Neutropenia",22949,05-11-2019
Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to STADA for ~$660M,22957,05-11-2019
Sanofi's Fluzone High-Dose Quadrivalent (Influenza Vaccine) Receives the FDA's Approval for Adults Agedâ‰¥ 65yrs.,22965,05-11-2019
Henlius and Ascentage Pharma Collaborate to Evaluate the Combination Therapy for Chronic Lymphocytic Leukemia in China,22972,05-11-2019
Stryker to Acquire Wright Medical for $5.4B,22980,05-11-2019
BeiGene Signs an Exclusive Worldwide License Agreement with Seattle Genetics to Advance Preclinical Candidates Treating Cancer,22986,06-11-2019
Takeda Signs an Exclusive License and Research Agreement with MD Anderson for CAR NK Cell Therapies,22997,06-11-2019
BioLineRx Reports Results of BL-8040 in Combination with Keytruda (pembrolizumab) in P-IIb Trial for Patients with Metastatic Pancreatic Cancer,23005,06-11-2019
Vela Diagnostics' Sentosa SQ HIV-1 Genotyping Assay Receives the US FDA's DE Novo Authorization for Detection of HIV-1 Genomic Drug Resistance Mutations (DRMs),23014,06-11-2019
Evotec Collaborates with Vifor Pharma to Launch a Joint Venture to Discover and Develop Therapies for Nephrology,23023,06-11-2019
Eisai to Transfer Royalty Rights for Tazemetostat to Royalty Pharma Outside Japan,23029,06-11-2019
Regeneron Signs a Research and Option to License Agreement with Vyriad for Oncolytic Virus-Based Therapies,23037,06-11-2019
Biogen Signs an Exclusive Commercialization Agreement with Samsung Bioepis to Expand its Biosimilars Portfolio,23057,07-11-2019
Coherus Signs an Exclusive License Agreement with Bioeq for Biosimilar of Lucentis (ranibizumab) in the US,23071,07-11-2019
Promega Signs a Worldwide Agreement with Merck to Develop MSI Technology as CDx for Keytruda,23076,07-11-2019
Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE Industries for its UD-014,23085,07-11-2019
STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe,23093,07-11-2019
AstraZeneca to Invest $1B for the Transformation of Healthcare in China,23103,07-11-2019
"Bio Thera's QLETLI (biosimilar, adalimumab) Receives NMPA's Approval for Auto-Immune Diseases in China",23109,07-11-2019
"Teva and Celltrion Reports the Availability of Truxima (biosimilar, Rituxan) in the US",23117,07-11-2019
AstraZeneca Reports Results of Roxadustat in P-III OLYMPUS and ROCKIES Studies for Chronic Kidney Disease Patients with Anaemia,23125,08-11-2019
Sierra Oncology Amends its Asset Purchase Agreement with Gilead for Momelotinib Signed in 2018,23135,08-11-2019
Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM4 Study as 1L Treatment for Multiple Myeloma Patients Not Treated with Stem Cell Transplantation,23144,08-11-2019
Yuhan Pharmaceutical Collaborates with Cyclica to Enhance Drug Development Utilizing AI-Integrated Drug Discovery Platform,23153,08-11-2019
Triumvira's TAC01-CD19 Receives FDA's Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma,23158,08-11-2019
Janssen Reports Submission of MAA to EMA for its Investigational Ebola Vaccine Regimen to Prevent Ebola Virus Disease,23161,08-11-2019
Sandoz to Acquire Aspen's Japanese Operations and Associated Assets for ~$440M,23182,11-11-2019
AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia,23191,11-11-2019
Roche Reports Results of Risdiplam in Pivotal SUNFISH Study for Patients with Type 2 or 3 Spinal Muscular Atrophy,23203,11-11-2019
Celgene's Reblozyl (luspaterceptâ€“aamt) Receives FDA's Approval as the First Therapy to Treat Patients with Rare Blood Disorder,23209,11-11-2019
Roche Reports Results of Gazyva (obinutuzumab) in P-II NOBILITY Study for Lupus Nephritis,23216,11-11-2019
Medtronic Reports Results of World's Smallest Pacemaker in MARVEL 2 Study for Patients with Atrioventricular Block,23227,12-11-2019
Merck's Ervebo [Ebola Zaire Vaccine (rVSVÎ”G-ZEBOV-GP) live] Receives EC's Conditional Approval to Prevent Ebola Virus Disease,23233,12-11-2019
Lupin to Divest its Stake in Kyowa to Unison for ~$525M,23242,12-11-2019
BMS Reports Acceptance of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) for Patients with Previously Treated Advanced Hepatocellular Carcinoma,23250,12-11-2019
Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER Studies for Active Psoriatic Arthritis,23258,12-11-2019
Bluebird Bio Collaborates with Forty Seven to Evaluate Antibody Conditioning Regimen in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy,23265,12-11-2019
Mylan and Pfizer Names Viatris as the New Company for Mylan-Upjohn's Combination,23273,13-11-2019
Celgene Amends its Existing Collaboration with Editas to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for Cancer and Autoimmune Diseases,23279,13-11-2019
Celgene Signs an Exclusive Worldwide License Agreement with Skyhawk to Develop Therapies Modulating RNA Splicing,23287,13-11-2019
AbbVie Reports Results of Rinvoq (upadacitinib) in P-II/III SELECT-AXIS 1 Study for Patients with Ankylosing Spondylitis,23298,13-11-2019
Boehringer Ingelheim and Lilly Commence P-III EMPULSE Study to Evaluate Jardiance in People Hospitalized for Acute Heart Failure Who Have Been Stabilized,23305,13-11-2019
GSK Reports Results of Nucala (mepolizumab) in P-III Study for Hypereosinophilic Syndrome,23313,13-11-2019
Merck Acquires Calporta Therapeutics for ~$576M,23332,14-11-2019
Pfizer Collaborates with Centogene to Access its Rare Disease Data,23340,14-11-2019
Shreis Scalene's Cytotron Receives the US FDA's Breakthrough Device Designation for the Treatment of Multiple Cancer Indications,23348,31-10-2019
Boehringer Ingelheim and Lilly Report FDA's EMDAC Outcomes for Empagliflozin (2.5mg) as Adjunct to Insulin for T1D Patients,23352,14-11-2019
Takeda Expands its Collaboration with Finch Therapeutics to Develop Microbiome Therapies Utilizing Human-First Discovery Platform,23359,14-11-2019
Zambon Signs a License Agreement with Aquestive to Develop and Commercialize Riluzole Oral Film for Amyotrophic Lateral Sclerosis in EU,23366,14-11-2019
Clinuvel's Scenesse Receives the US FDA's Approval for Erythropoietic Protoporphyria (EPP),23371,08-10-2019
Bayer Collaborates with Dewpoint to Develop New Therapies Targeting Cardiovascular and Gynecological Diseases,23377,14-11-2019
Galderma's Aklief (trifarotene) Receives the US FDA's Approval for the Treatment of Acne in 20 Years,23385,04-10-2019
Ardelyx's Ibsrela (tenapanor) Receives the US FDA's Approval for Irritable Bowel Syndrome with Constipation (ISB-C) for Adults,23393,12-09-2019
Foamix's Amzeeq (topical minocycline) Receives the US FDA's Approval for Moderate to Severe Acne,23401,18-10-2019
Allergan Signs an Exclusive Option and License Agreement with Exicure to Discover and Develop SNA-based Therapies for Hair Loss Disorders,23407,15-11-2019
Metacel Pharmaceuticals' Ozobax (baclofen) Receives the US FDA's Approval for Spasticity Due to Multiple Sclerosis,23414,18-09-2019
AstraZeneca and MSD Report FDA's Acceptance of NDA for Selumetinib in Patients with Neurofibromatosis Type 1,23428,15-11-2019
BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Accelerated Approval for Patients with Mantle Cell Lymphoma Who Received At least One Prior Therapy,23440,15-11-2019
Shionogi's Fetroja (cefiderocol) Receives the US FDA's Approval for the Treatment of Complicated Urinary Tract Infections,23446,15-11-2019
Sarepta Signs a License Agreement with Stride Bio to Develop In vivo AAV-Based Gene Therapies,23455,15-11-2019
Stanford Medicine Reports Results of Apple Heart Study for Detecting Atrial Fibrillation,23466,15-11-2019
Roche's Kadcyla (trastuzumab emtansine) Receives CHMP's Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treatment,23473,15-11-2019
Roche to Acquire Promedior for $1.39B,23489,18-11-2019
"Pfizer's Abrilada (biosimilar, adalimumab) Receives the US FDA's Approval for Rheumatoid Arthritis",23498,18-11-2019
Novartis' Adakveo (crizanlizumab) Receives the US FDA's Approval for Reducing the Frequency of VOCs in Sickle Cell Disease,23506,18-11-2019
Novo Nordisk Collaborates with Dicerna to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases,23514,18-11-2019
Aerie Pharmaceuticals to Acquire Avizorex Pharma to Expand its Footprint in Ophthalmology,23521,18-11-2019
Merck and Bayer Report Results of Vericiguat in P-III VICTORIA Study for Patients with Worsening Chronic Heart Failure,23529,18-11-2019
Novartis Collaborates with Biofourmis To Offer Digital Therapeutics for Managing Heart Failures,23544,19-11-2019
Alkermes to Acquire Rodin Therapeutics for $950M,23551,19-11-2019
Santhera Reports Results of Idebenone in SYROS Study for Duchenne Muscular Dystrophy,23558,19-11-2019
Janssen Redefines Clinical Trial Design by Leveraging Wearable Technology,23563,19-11-2019
Vertex Collaborates with Molecular Templates to Discover and Develop Conditioning Regimens Enhancing Hematopoietic Stem Cell Transplants,23571,19-11-2019
"Samsung Bioepis Reports FDA's Acceptance of BLA for SB8 (biosimilar, bevacizumab)",23580,19-11-2019
Merck KGaA Collaborates with Personalis to Develop Novel Biomarkers for Cancer Therapies,23592,20-11-2019
CRISPR Therapeutics and Vertex Report Results of CTX001 from First Two Patients with Severe Hemoglobinopathies,23603,20-11-2019
Myovant Sciences Reports Results of Relugolix in P-III HERO Study for Men with Advanced Prostate Cancer,23615,20-11-2019
Janssen's Darzalex (daratumumab) Combination Regimen Receives EC's Approval for Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma,23620,20-11-2019
BioVentrix's Revivent TC Transcatheter Ventricular Enhancement System Receives FDA's Breakthrough Device Designation for Heart Failure,23624,20-11-2019
Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma,23632,20-11-2019
BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -915 Study for Patients with Resected High-Risk Melanoma and PD-L1,23641,20-11-2019
AbbVie Collaborates with Dragonfly Therapeutics to Develop Therapies for Autoimmune and Oncology Indications,23650,21-11-2019
Alnylam's Givlaari (givosiran) Receives the US FDA's Approval as the First Therapy for Acute Hepatic Porphyria,23661,21-11-2019
Novartis Collaborates with Mila to Transform Therapies with Artificial Intelligence in Canada,23668,21-11-2019
Sanofi Collaborates with Aetion to Leverage its Evidence Platform for Advancing Regulatory Submissions,23679,21-11-2019
Astellas Signs a License Agreement with Welldoc to Develop and Commercialize Digital Therapies,23685,21-11-2019
"Aerie's Rhokiinsa (netarsudil ophthalmic solution, 0.02%) Receives EC's Approval for Patients with Open-Angle Glaucoma or Ocular Hypertension",23692,21-11-2019
AbbVie Enters into an Exclusive Option and License Agreement for HPN217 and Expands its Existing Collaboration with Harpoon Therapeutics,23700,21-11-2019
Knight Therapeutics Signs an Exclusive License Agreement with Onconova for Rigosertib in Canada,23714,22-11-2019
AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Approval for Chronic Lymphocytic Leukemia Under the Project Orbis,23723,22-11-2019
GSK and ViiV Healthcare Sign an Exclusive License Agreement with NIH for its Investigational bNAb to Treat and Prevent HIV,23732,22-11-2019
Medtronic's IN.PACT AV Drug-Coated Balloon Receives the US FDA's Approval for the Treatment of Arteriovenous Fistula Lesions,23740,22-11-2019
BioMarin Reports Submission of MAA to EMA for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A,23748,22-11-2019
Lupin Launches Smart Device for Metered-Dose Inhalers to Support Treatment of Respiratory Diseases in India,23753,22-11-2019
Novartis to Acquire The Medicines Company for $9.7B,23766,25-11-2019
Roche Reports the US FDA's Acceptance of NDA for Risdiplam and Granted Priority Review to Treat Spinal Muscular Atrophy,23775,25-11-2019
Takeda's Takhzyro (lanadelumab injection) Receives CADTH's CDEC Positive Opinion for the Routine Prevention of Hereditary Angioedema Attacks,23782,25-11-2019
Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carcinoma at ESMO Congress 2019,23792,25-11-2019
Takeda Reports Results of Alunbrig (brigatinib) in P-III ALTA-1L Study for Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer,23797,25-11-2019
Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on the Development of Gene Therapy for Bladder Cancer,23809,26-11-2019
Zogenix Reports the US FDA Acceptance of NDA and Granted Priority Review for Fintepla (fenfluramine) to Treat Dravet Syndrome,23817,26-11-2019
Bayer Reports Submission of MAA to EMA for Rivaroxaban to Treat Venous Thromboembolism in Children,23825,26-11-2019
Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its Existing Partnership,23832,26-11-2019
Yas Holding Collaborates with Alvogen to Commercialize its Generic Portfolio in MENA Region,23839,26-11-2019
Merck's Keytruda (pembrolizumab) + CT Receives NMPA's approval as 1L Treatment for Metastatic Squamous Non-Small Cell Lung Cancer,23848,26-11-2019
Novoheart Collaborates with AstraZeneca to Develop World's First Heart-in-a-Jar Model of Heart Failure,23857,27-11-2019
"Biocon Report the US FDA's Approval of sBLA for Fulphila (biosimilar, pegfilgrastim) Manufactured at its New Facility in Bengaluru",23864,27-11-2019
"Celltrion's Remsima SC (biosimilar, infliximab) Receives EC's Approval for Rheumatoid Arthritis",23871,27-11-2019
Elsevier Acquires 3D4Medical for ~$50M,23880,27-11-2019
Amazon's Alexa Launches Medication Management Feature for Giant Eagle's Clients,23888,27-11-2019
Astellas' Xtandi (enzalutamide) Receives NMPA's Approval for Metastatic Castration-Resistant Prostate Cancer in Men,23894,27-11-2019
Incyte Reports Acceptance and Priority Review of NDA for Pemigatinib to Treat Patients with Cholangiocarcinoma,23900,27-11-2019
AbbVie UK Collaborates with NorthWest EHealth to Generate Real World Evidence for Exploring Autoimmune Conditions,23912,28-11-2019
Mochida Launches Teriparatide Biosimilar for the Treatment of Osteoporosis in Japan,23920,28-11-2019
Boehringer Ingelheim's Ofev (nintedanib) Receives Health Canada's Approval as the First Therapy to Treat SSc-ILD in Canada,23924,28-11-2019
Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Japan,23927,28-11-2019
JW Pharma Acquires C&amp;C Research Laboratories a Joint Venture with Chugai,23942,28-11-2019
Simcere Signs an Exclusive Regional Licensing Agreement with GI Innovation for its GI-101 Candidate,23953,28-11-2019
Avion Signs an Exclusive License Agreement with ImmuPharma to Develop and Commercialize Lupuzor,23990,29-11-2019
Roche's Kadcyla (trastuzumab emtansine) Receives Health Canada's Approval for The Treatment of HER2-Positive Early Breast Cancer After Surgery,23998,29-11-2019
WuXi ATU and GeneMedicine Collaborate to Develop and Manufacture Oncolytic Virus Products,24004,29-11-2019
AstraZeneca Reports the US FDA Acceptance of sBLA and Granted Priority Review for Imfinzi (durvalumab) to Treat Patients with Extensive-Stage Small Cell Lung Cancer,24014,29-11-2019
AstraZeneca Collaborates with JVP to Invest in Digital Health Program in Israel,24048,29-11-2019
ONO Reports Submission of MAA to MHLW for Tirabrutinib Hydrochloride to Treat Waldenstrom Macroglobulinemia and Lymphoplasmacytic Lymphoma,24070,29-11-2019
Roche Reports Results of Satralizumab in P-III SAkuraSky Study to Treat Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD),24084,02-12-2019
Y-mAbs Reports Initiation of Rolling Review of BLA for Naxitamab to the US FDA to Treat Neuroblastoma,24093,02-12-2019
Fosun Pharma's FN-1501 Receives the US FDA's Orphan Drug Designation for Leukemia,24102,02-12-2019
Chipscreen Bioscience's Epidaza (chidamide) Receives NMPA Approval for Breast Cancer Indication,24114,02-12-2019
Merck's Keytruda (pembrolizumab) Receives FDA's Priority Review for sBLA to Treat High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC),24123,02-12-2019
"Mylan and Biocon Launch Ogivri (biosimilar, trastuzumab) in the US",24131,02-12-2019
Neurocrine Signs a License Agreement with Xenon to Develop Therapies for Epilepsy,24137,02-12-2019
Baxter to Acquire Seprafilm Adhesion Barriers from Sanofi for $350M,24145,02-12-2019
Astellas to Acquire Audentes Therapeutics for $3B,24156,03-12-2019
STADA to Acquire Biopharma's Pharmaceutical Prescription and Consumer Health Business to Expand Its Footprint in Ukraine,24163,03-12-2019
AstraZeneca Divests Commercial Rights of Seroquel and Seroquel XR to Cheplapharm in the US and Canada,24172,03-12-2019
Gene Techno Science Signs an Agreement with Kishi Kasei to Co-Develop Biosimilar of Aflibercept,24181,03-12-2019
Seattle Genetics and Astellas Collaborate with Merck to Evaluate Enfortumab Vedotin + Keytruda (pembrolizumab) for Metastatic Urothelial Cancer,24189,03-12-2019
GE Healthcare Signs an Agreement with Affidea to Deploy Digital Imaging Technologies,24198,03-12-2019
Kamada Collaborates with Alvotech to Commercialize its Six Biosimilar Products in Israel,24206,03-12-2019
StemoniX Collaborates with Atomwise to Form a Joint Venture Targeting Rett Syndrome,24211,03-12-2019
Ethicon Launches VISTASEAL Fibrin Sealant (Human) for Sealing Off Bleeds During Surgery,24220,04-12-2019
Lupin Plans to Launch Two of its Biosimilars in the US,24228,28-11-2019
"Qilu Reports Initiation of P-III Trial for QL1206 (biosimilar, denosumab) in China",24236,22-11-2019
Merck KGaA and Ping An Good Doctor Collaborate to Support Health Management in China,24242,04-12-2019
Roche's Tecentriq + CT (abraxane and carboplatin) Receive the US FDA's Approval for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer,24256,04-12-2019
Johnson &amp; Johnson Vision Launches TECNIS Toric II 1-Piece IOL as a New Monofocal Option for Cataract Patients with Astigmatism in the US,24263,04-12-2019
Veracyte Signs an Exclusive License Agreement with NanoString for its nCounter FLEX System,24273,04-12-2019
Eris Lifesciences Acquires Novartis' Zomelis (vildagliptin) in India for $13M,24281,04-12-2019
BMS' Orencia (abatacept) Receive the FDA's Breakthrough Therapy Designation to Prevent Acute Graft-Versus-Host Disease After Stem Cell Transplant,24291,04-12-2019
LEO Pharma Collaborates with Portal Instruments to Develop Needle-Free Drug Delivery Device,24299,04-12-2019
Lannett Reports Results of Biosimilar Insulin Glargine in Human Clinical Study to Treat Patients with Type 2 Diabetes,24307,04-12-2019
Novartis Collaborates with Amazon to Leverage Cloud Services for its Business Operations,24316,05-12-2019
Novartis Highlights its Blockbuster Portfolio at R&amp;D Day 2019,24325,05-12-2019
Takeda Collaborates with Enzyre to Develop Diagnostic Device to Regulate Coagulation Status in Patients with Hemophilia at Home,24333,05-12-2019
AstraZeneca and MSD's Lynparza (olaparib) Receive NMPA's Approval as 1L Maintenance Therapy for BRCA-Mutated Advanced Ovarian Cancer,24343,05-12-2019
Philips Collaborates with Humana to Deliver Remote Monitoring Capabilities to Select Medicare Advantage Members,24348,05-12-2019
Bayer Collaborates with Children's Hospital of Philadelphia to Develop Oral Non-Replacement Therapy for the Treatment of Hemophilia,24357,05-12-2019
AstraZeneca Signs an Agreement with Gatehouse Bio to Identify New Therapies Targeting Respiratory and Cardiovascular Diseases,24366,05-12-2019
Cerecor to Acquire Aevi Genomic Medicine for ~$22.6M,24382,06-12-2019
FDA and NIH Launch CURE ID Crowdsourcing App for Patients with Infectious Diseases,24392,06-12-2019
The US FDA Draft New Guidelines for Proposed Biosimilars and Interchangeable Insulins,24403,25-11-2019
Novartis Reports Results of QMF149 in P-III PALLADIUM Study for Patients with Uncontrolled Asthma,24404,06-12-2019
Y-mAbs Reports EMA's Acceptance of Pediatric Investigation Plan for Omburtamab,24419,06-12-2019
Bayer And Simulations Plus Collaborate to Advance ADMET Predictor for Improving Data Integrity in Drug Discovery,24431,06-12-2019
Bio-Thera Reports NMPA's Acceptance of IND for BAT2206 Proposed Biosimilar of Stelara (ustekinumab),24442,06-12-2019
Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders,24458,06-12-2019
Sanofi to Acquire Synthorx for $2.5B,24488,09-12-2019
Janssen to Acquire XBiotech's Bermekimab for $750M,24495,09-12-2019
Sobi's Dova Pharmaceutical Reports Results of an Online Survey Highlighting Disease Burden and Impact for Patients with Immune Thrombocytopenia,24502,09-12-2019
Boehringer Ingelheim Collaborates with Healx to Identify New Treatments for Rare Neurological Diseases,24511,09-12-2019
"Amgen's Avsola (biosimilar, infliximab) Receives the US FDA's Approval for the Same Indications as Remicade (infliximab)",24518,09-12-2019
AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE TN Study for Previously Untreated Chronic Lymphocytic Leukemia,24527,09-12-2019
Merck to Acquire ArQule for $2.7B,24538,09-12-2019
AstraZeneca Collaborates with DeepMatter for Optimization of Compound Synthesis Leveraging AI and Machine Learning,24547,10-12-2019
Roche's Accu-Chek SugarView App Receives CE Mark Approval for Non-Insulin-Dependent Patients with Type 2 Diabetes or Pre-Diabetes,24556,10-12-2019
AbbVie Signs an Exclusive Agreement with Scripps Research to Develop New Therapies Targeting Multiple Therapeutic Areas,24561,10-12-2019
Merck Collaborates with Seven and Eight BioPharmaceuticals to Evaluate the BDB001 + Keytruda (pembrolizumab) for Advanced Solid Tumors,24568,10-12-2019
AbbVie to Deploy Adaptive's clonoSEQ Assay to Assess MRD Status Across Multiple Myeloma Studies,24578,10-12-2019
Engitix and Morphic Collaborate to Detect ECM-Related Targets in Fibrostenotic Inflammatory Bowel Disease,24584,10-12-2019
Sanofi Divulges its Strategic Framework to Drive Innovation and Growth,24589,10-12-2019
Sanofi and Regeneron to Restructure its Collaboration for Kevzara (sarilumab) and Praluent (alirocumab),24602,11-12-2019
Roche and Novartis Report the US FDA's Acceptance of sBLA for Xolair (omalizumab) to Treat Nasal Polyps,24611,11-12-2019
"AffaMed Therapeutics' AMT901 (biosimilar, trastuzumab) Receives NMPA's Approval to Initiate P-III Clinical Study in China",24616,11-12-2019
Vertex's Kalydeco (ivacaftor) Receives EC's Approval for Infants with Cystic Fibrosis with CFTR Gene Mutation Aged 6 to,24620,11-12-2019
Amgen Reports Results of KYPROLIS (carfilzomib) and DARZALEX (daratumumab) in P-III CANDOR study for Patients with Relapsed or Refractory Multiple Myeloma,24632,11-12-2019
Dermiraâ€˜s Lebrikizumab Receives the US FDA's Fast Track Designation to Treat Atopic Dermatitis,24638,11-12-2019
Kite and Kiniksa Collaborate to Evaluate the Combination of Yescarta (axicabtagene ciloleucel) and Mavrilimumab for R/R Large B-Cell Lymphoma,24653,12-12-2019
Kite Reports Submission of BLA to the US FDA for its Second CAR T Cell Therapy,24666,12-12-2019
Novartis Signs Worldwide License Agreement with Forendo Pharma to Discover Therapies Targeting Chronic Liver Diseases,24673,12-12-2019
Almirall to Accelerate Drug Discovery Process Utilizing Iktos' AI Technology,24680,12-12-2019
Roche Reports Results of Fixed-Dose SC Combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) in P-III FeDeriCa Study for HER2-Positive Breast Cancer,24685,12-12-2019
Amgen and UCB's Evenity (romosozumab) Receive EC's Approval to Treat Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture,24694,12-12-2019
AstraZeneca and Daiichi Sankyo Report Result of Trastuzumab Deruxtecan in P-II DESTINY-Breast01 Study for HER2 Positive Metastatic Breast Cancer,24699,12-12-2019
AstraZeneca's Imfinzi (durvalumab) Receives NMPA's Approval for Unresectable Stage III Non-Small Cell Lung Cancer,24702,12-12-2019
Alvogen to Acquire Assertio's Gralise (gabapentin) for $127.5M,24709,12-12-2019
iTeos Therapeutics Collaborates with Merck to Evaluate EOS100850 + Keytruda (pembrolizumab) for Solid Tumors,24721,13-12-2019
PerkinElmer's Screening Kit Receives the FDA's Approval as the First Test to Aid in Newborn Screening for Duchenne Muscular Dystrophy,24728,13-12-2019
Roche Reports Results of Triple Combination Regimen in P-III IMspire150 Study for Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma,24735,13-12-2019
Equillium Expands its Exclusive Licensing Agreement with Biocon for Itolizumab,24743,13-12-2019
Pfizer's Xeljanz XR (tofacitinib) Receives the US FDA's Approval for Ulcerative Colitis,24750,13-12-2019
SK Life Sciences' XCOPRI (cenobamate tablets) Receives the US FDA's Approval for Partial-Onset Seizures in Adults,24757,21-11-2019
Global Blood's Oxbryta (Voxelotor) Receives the US FDA's Accelerated Approval for Treatment of Sickle Cell Disease,24774,25-11-2019
RedHill Biopharma's Talicia Received the US FDA's Approval for H. pylori in Adults,24783,04-11-2019
ViiV Healthcare Reports Regulatory Submission to the US FDA and EMA for Dispersible Formulation of Tivicay (dolutegravir),24786,13-12-2019
Sun Pharmaceuticals' Absorica Received the US FDA's Approval for Severe Recalcitrant Nodular Acne,24793,05-11-2019
Aquestive Therapeutics' Exservan (riluzole) Receives the US FDA Approval to Treat Amyotrophic Lateral Sclerosis (ALS),24803,13-11-2019
Cumberland Pharmaceuticals' RediTrex (methotrexate) Injection Receives the US FDA's Approval for Rheumatoid Arthritis and Psoriasis,24813,13-12-2019
Janssen's Darzalex (daratumumab) Combination Regimen Receives CHMP's Positive Opinion for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma,24821,13-12-2019
"Pfizer's Amsparity (biosimilar, adalimumab) Receives CHMP's Positive Opinion for Inflammatory and Autoimmune Disorders",24825,13-12-2019
Roche Launches cobas Zika Blood Screening Test to Detect Zika Virus RNA,24857,16-12-2019
Tandem's Predictive Insulin Pump Software Receives the US FDA's Approval to Deliver Accurate Doses of Insulin in Patients Utilizing t:slim X2 Insulin Pump,24869,16-12-2019
Novartis Terminates Clinical Development of Fevipiprant (AW039) in P-III LUSTER Studies for Patients with Uncontrolled GINA 4/5 Asthma,24876,16-12-2019
Boehringer Ingelheim and Lilly Report Results of Jardiance (empagliflozin) in P-III EMPERIAL Studies for Chronic Heart Failure,24883,16-12-2019
SanBio and Sumitomo Dainippon Pharma Terminate Joint Development and License Agreement for SB623 in North America,24888,16-12-2019
Lilly Collaborates with DexCom to Utilize Dexcom CGM in its Personalized Diabetes Management System,24897,16-12-2019
Charles River to Acquire HemaCare Corporation for $380M,24903,16-12-2019
Medtronic and ChristianaCare Collaborate to Deploy Value-Based Healthcare Initiatives in Delaware,24914,17-12-2019
Alexion Exercises its Option to License Dicerna's Two Additional GalXC RNAi Programs,24923,17-12-2019
Eagle Pharmaceuticals' Ryanodex (dantrolene sodium) Receives the US FDA's ODD for the Treatment of Organophosphate Exposure,24930,17-12-2019
BeiGene Report Results of Brukinsa (zanubrutinib) in P-III ASPEN Study for WaldenstrÃ¶m's Macroglobulinemia,24938,17-12-2019
Janssen's Erleada (apalutamide) Receives Health Canada's Approval for Metastatic Castration-Sensitive Prostate Cancer,24943,17-12-2019
Xiangxue Signs an Exclusive License Agreement with Athenex to Expand their Existing Partnership,24951,17-12-2019
Sangamo Highlights its Genomic Medicine Pipeline at R&amp;D Day 2019,24956,17-12-2019
Medtronic Acquires Klue to Bolster its Personalized Closed Loop Technology for Diabetes Management,24966,18-12-2019
Merck Receives the US FDA Advisory Committee's Recommendation on Approval of Keytruda (pembrolizumab) for Patients with High-Risk Non-Muscle Invasive Bladder Cancer,24976,18-12-2019
Takeda Collaborates with Cerevance to Develop New Therapies for Gastrointestinal Disorders,24988,18-12-2019
BioInvent Collaborates with MSD to Evaluate BI-1206 in Combination with Keytruda (pembrolizumab) for Advanced Solid Tumors,25007,18-12-2019
AstraZeneca and Merck &amp; Co Receive the US FDA Advisory Committee's Recommendation on Approval of Lynparza (olaparib) as 1L Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer,25014,18-12-2019
Eisai Signs a Research Collaboration with BioArctic to Characterize BAN2401's Mechanism of Action,25026,18-12-2019
Chondrial Therapeutics Signs a Reverse Merger Agreement with Zafgen,25031,18-12-2019
Genentech Signs a Clinical Trial Collaboration with Arcus for Colorectal and Pancreatic Cancers,25049,19-12-2019
"GSK Reports Results of Benlysta (belimumab, IV) in P-III BLISS-LN Study for Patients with Active Lupus Nephritis",25056,19-12-2019
Specialised Therapeutics Signs an Exclusive License Agreement with Onconova Therapeutics for Rigosertib,25063,19-12-2019
AbbVie's RINVOQ (upadacitinib) Receives the EC's Approval for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis,25071,19-12-2019
Novartis Terminates its Agreement with Akcea for AKCEA-APOCIII-LRx,25080,19-12-2019
Biogen Signs an Exclusive License Agreement with Ionis for IONIS-MAPTRx,25088,19-12-2019
Exelixis Signs a Clinical Trial Collaboration with Roche for Patients with Solid Tumors,25096,19-12-2019
Genmab and CureVac Collaborate to Develop mRNA-based Antibody Therapeutics,25133,20-12-2019
"Amgen and Allergan Report Submission of BLA to the US FDA for its ABP 798 (biosimilar, rituximab)",25141,20-12-2019
Smith Medical Recalls Medfusion 4000 Syringe Pump Due to its Software Failure,25150,20-12-2019
Merck's Ervebo Vaccine Receives the US FDA's Approval for Prevention of Ebola Virus,25159,20-12-2019
Gilead Reports Submission of Filgotinib's NDA Under Priority Review to the US FDA for Rheumatoid Arthritis Treatment,25166,20-12-2019
Novo Nordisk Signs a Five-Year Agreement with UVA Center for Diabetes Technology for Type 2 Diabetes,25171,20-12-2019
AstraZeneca to Sell Commercialization Rights of its Two Oncology Candidates to Juvise Pharmaceuticals,25179,20-12-2019
Roche Signs an Exclusive Worldwide Option and License Agreement with Rheos Medicines to Develop and Commercialize Therapies for Immunometabolism,25217,23-12-2019
Roche Signs a License Agreement with Sarepta for its Gene Therapy Candidate SRP-9001,25222,23-12-2019
BMS' Revlimid + Rituximab Receives EC's Approval to Treat Adults Previously Treated Follicular Lymphoma (Grade 1-3a),25231,23-12-2019
Johnson &amp; Johnson to Acquire TARIS Biomedical for its Drug Delivery Technology to Treat Bladder Cancer,25238,23-12-2019
"Gilead's Vosevi (sofosbuvir, velpatasvir and voxilaprevir) Receives NMPA's Approval for Chronic Hepatitis C Infection Who Require Re-Treatment",25247,23-12-2019
Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for its Pan-JAK Inhibitor Program,25261,26-12-2019
Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan,25271,26-12-2019
Allergan's Ubrelvy (ubrogepant) Receives the US FDA's Approval for Acute Treatment of Migraine with or without Aura in Adults,25282,26-12-2019
AstraZeneca's Triple Combination Regimen Receives NMPA's Approval as the Maintenance Treatment for COPD in China,25289,26-12-2019
Pfizer Extends its Research and License Agreement with BioInvent to Develop Ab Targeting Tumor-Associated Myeloid Cells,25294,26-12-2019
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) Receive the FDA's Accelerated Approval for HER-2 Positive Unresectable/ Metastatic Breast Cancer,25306,26-12-2019
OBI Pharma's OBI-999 Receives the US FDA's Orphan Drug Designation for Pancreatic Cancer,25311,26-12-2019
Astellas Acquires Xyphos Biosciences for ~$665M,25322,27-12-2019
Kadmon and Meiji Collaborate to Form JV for the Development and Commercialization of KD025 in Japan,25332,27-12-2019
ONO and BMS Report Submission of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) in Japan,25344,27-12-2019
Chugai Receives MHLW's Approval for the Expanded Use of FoundationOne CDx as a Companion Diagnostic of Rozlytrek (entrectinib),25350,27-12-2019
Immunomedics Reports the US FDA's Acceptance of BLA for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer,25357,27-12-2019
Luye Pharma Reports Submission of NDA to the US FDA for LY03005,25363,27-12-2019
Pharming to Reacquire Exclusive Commercialization Rights for its Ruconest from Sobi,25377,30-12-2019
Eisai Reports Results of DAYVIGO (lemborexant) in P-III SUNRISE 1 Study in Patients with Insomnia Disorder,25387,30-12-2019
Zai Lab's Zejula (niraparib) Receives NMPA's Approval as Maintenance Therapy for Patients with Recurrent Ovarian Cancer in China,25400,30-12-2019
AstraZeneca and Merck &amp; Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer,25409,30-12-2019
Eli Lilly Opens its P-III LIBRETTO-531 Clinical Trial for LOXO-292 (selpercatinib) to Treat RET-Mutant Medullary Thyroid Cancer (MTC) Patients,25418,30-12-2019
BeiGene's Tislelizumab Receives NMPA's Approval for the Treatment of 2L Classical Hodgkin's Lymphoma (cHL),25429,31-12-2019
Acceleron Signs a License Agreement with Fulcrum for the Identification of Therapies to Treat Pulmonary Diseases,25436,31-12-2019
GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology,25446,31-12-2019
"Clover Reports First Patient Dosing in P-III Trial with SCB-808 (biosimilar, etanercept) in China",25456,31-12-2019
MorphoSys Reports Submission of Tafasitamab's BLA to the US FDA to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL),25468,31-12-2019
Axsome Therapeutics Reports Results of AXS-07 in MOMENTUM P-III Migraine Trial in Patients with History of Inadequate Response,25479,02-01-2020
MappBio Collaborates with Aridis Pharmaceuticals to Develop Therapies Utilizing APEX Technology,25490,02-01-2020
Roche Signs an AI-Based Research Agreement with Sensyne Health,25499,02-01-2020
Sol-Gel Reports Results of Twyneo in Two P-III Trials for Acne Vulgaris,25508,02-01-2020
Amgen Signs an Agreement with BeiGene for the Expansion of its Oncology Footprints in China,25516,03-01-2020
Johnson &amp; Johnson Signs a License Agreement with Pulmatrix to Develop Therapies for Lung Cancer,25531,03-01-2020
Arena Signs a Multi-Year Agreement with Beacon Discovery to Develop Therapies for Immune and Inflammatory Diseases,25542,03-01-2020
Incyte Reports Results of Itacitinib in GRAVITAS-301 P-III Study for Patients with Treatment-Naive Acute Graft-Versus-Host Disease,25550,03-01-2020
Innate's Lumoxiti (moxetumomab pasudotox-tdfk) Receives EMA's MAA to Treat Patients with Relapsed or Refractory Hairy Cell Leukemia,25559,03-01-2020
RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106,25572,03-01-2020
BeiGene Signs an Exclusive Option and License Agreement with Leap Therapeutics for DKN-01,25597,06-01-2020
AstraZeneca's Farxiga (dapagliflozin) Receives the US FDA's Priority Review Voucher for the Reduction of CV Risks and Death in Patients with Type-2 Diabetes,25614,06-01-2020
Kyowa Kirin's Istradefylline (KW-6002) Receives EMA's MAA as an Adjunctive Treatment to Levodopa-Based Regimens in Adult with Parkinson's disease Experiencing â€œOffâ€ Time,25620,06-01-2020
AstraZeneca's Lokelma (sodium zirconium cyclosilicate) Receives NMPA's Approval for Patients with Hyperkalaemia,25632,06-01-2020
I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients with Relapsed or Refractory Multiple Myeloma,25642,06-01-2020
Merck &amp; Co. Signs an Exclusive Worldwide License Agreement with Taiho and Astex to Develop Targeted Therapies,25653,06-01-2020
InxMed Signs a Clinical Trial Collaboration with Merck &amp; Co for Patients with Pancreatic Cancer,25669,07-01-2020
Sorrento's Partner Mabpharm Files NDA to the NMPA for Infliximab Biosimilar in China,25678,07-01-2020
Merck &amp; Co Reports Results of Keytruda in P-III KEYNOTE-604 Trial in 1L Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC),25686,07-01-2020
Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution in South Korea,25695,07-01-2020
Merck KGaA and Pfizer Report Results of Bavencio (avelumab) in P-III JAVELIN Bladder 100 Study for Patients with Locally Advanced or Metastatic Urothelial Carcinoma,25712,07-01-2020
Mithra Signs a License Agreement with Alvogen for its Estelle in Hong Kong and Taiwan,25722,07-01-2020
Evotec Expands its 2016 Agreement with Bristol-Myers Squibb,25730,07-01-2020
Bicycle Therapeutics Signs Clinical Development Partnership with Cancer Research UK for BT7401,25746,08-01-2020
MiNA Therapeutics Signs a Research Collaboration with AstraZeneca to Evaluate Therapies for Metabolic Diseases,25756,08-01-2020
Eagle Signs a Co-Promotion Agreement with Tyme for SM-88 to Treat Cancer,25765,08-01-2020
Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat Cancer and Fibrotic Diseases in the US,25772,08-01-2020
Abbott's HeartMate 3 Heart Pump Receives the US FDA's Approval for Patients to Avoid Open Heart Surgery,25782,08-01-2020
PhoreMost Signs a Multi-Project Drug Discovery Agreement with Boehringer Ingelheim,25795,08-01-2020
Gilead Signs a License Agreement with Xencor for its GS-9722 to Treat HIV,25808,08-01-2020
Veracyte Signs a Multi-Year Agreement with AstraZeneca,25817,09-01-2020
Merck &amp; Co's Keytruda (pembrolizumab) Receives the US FDA's Approval for Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer,25825,09-01-2020
Almirall Signs an In-License Agreement with 23andMe for Multiple Inflammatory Diseases,25837,09-01-2020
Mylan Voluntarily Recalls Nationwide Three Lots of Nizatidine Capsules USP Due to Trace Amounts of NDMA (N-Nitrosodimethylamine),25844,09-01-2020
Evotec Signs a Five-Year Collaboration with Bayer to Develop Therapies for Polycystic Ovary Syndrome,25850,09-01-2020
BioMed Collaborates with Merck &amp; Co for Autoimmune Diseases,25861,09-01-2020
Gilead Signs an Exclusive License Agreement with Rockefeller University for its Portfolio of HIV Abs,25869,10-01-2020
Kaleido Signs a Collaboration with Janssen for Microbiome Metabolic Therapies (MMT),25877,10-01-2020
Pfizer Signs an Exclusive Worldwide License Agreement with eFFECTOR to Develop Therapies for Cancer Indications,25883,10-01-2020
Immunic Exercises its Worldwide Exclusive Option to License for IMU-856 with Daiichi Sankyo,25896,10-01-2020
Bayer Signs a Three Year Multi Target AI-based Agreement with Exscientia to Treat Cardiovascular and Oncology Diseases,25906,10-01-2020
Eli Lilly to Acquire Dermira for $1.1B,25915,10-01-2020
Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb,25938,10-01-2020
Iovance Signs a License Agreement with Novartis to Develop and Commercialize IOV-3001,25959,13-01-2020
AstraZeneca's Lynparza (olaparib) + Bevacizumab Receive the US FDA's Priority Review for 1L Treatment of Advanced Ovarian Cancers,25968,13-01-2020
Incyte Signs a Worldwide License Agreement with MorphoSys for Tafasitamab,25982,13-01-2020
Roche Signs a Technology License Agreement with Amunix Pharmaceutical to Develop Non-Oncology Therapies,25992,13-01-2020
Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates in Hong Kong and Taiwan,25999,13-01-2020
Biogen to Acquire Pfizer's PF-05251749 to Bolster its Neurological Pipeline,26007,13-01-2020
BeiGene Collaborates with EUSA Pharma to Develop and Commercialize Sylvant (siltuximab) and Qarziba (dinutuximab beta) in Greater China,26017,13-01-2020
Coherus Signs a License Agreement with Innovent Biologics to Commercialize Biosimilar of Avastin (bevacizumab) in the US and Canada,26026,14-01-2020
MSD Signs a Multiyear Agreement with Just â€“ Evotec Biologics for Gaining Access to J.POD Facility,26035,14-01-2020
Roche Collaborates with Illumina to Expand the Adoption of NGS Based Testing in Oncology,26043,14-01-2020
Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell Platform and Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies,26051,14-01-2020
Amgen Collaborates with Guardant Health and Qiagen to Expand Molecular Testing for Patients with Non-Small Cell Lung Cancer,26060,14-01-2020
Axsome In-Licenses Pfizer's Reboxetine and Esreboxetine in the US,26067,14-01-2020
Bayer Signs an Exclusive Option to License Agreement with Dare Biosciences to Commercialize Ovaprene in the US,26076,14-01-2020
Takeda Collaborates with Charles River to Identify and Develop Preclinical Candidates,26080,14-01-2020
Genome &amp; Company Signs a Clinical Trial Agreement with Merck KGaA and Pfizer to Evaluate the Combination Therapy,26093,15-01-2020
Astellas' Xospata (gilteritinib) Receives Health Canada Approval for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation,26104,15-01-2020
ViiV Healthcare's Dovato (dolutegravir/lamivudine) Receives MHLW's Approval to Treat HIV 1 Infection,26112,15-01-2020
Insilico Collaborates with Pfizer to Explore Novel Data and AI System for Target Discovery,26117,15-01-2020
JAMP Signs an Agreement with Alvotech to Commercialize Five Biosimilars in Canada,26124,15-01-2020
Alexion to Initiate P-III CHAMPION-ALS Study Evaluating Ultomiris (ravulizumab) in Amyotrophic Lateral Sclerosis,26134,15-01-2020
Kymera Signs a DNA-Encoded Library Based Drug Discovery Research Agreement with HitGen,26141,15-01-2020
BioLineRx's Motixafortide (BL-8040) Receives EC's ODD to Treat Pancreatic Cancer in Europe,26146,15-01-2020
Galapagos Signs an Exclusive Option to License Agreement with Fibrocor to Expand their Existing 2019 Partnership for Fibrosis,26154,16-01-2020
JT Signs an Exclusive License Agreement with Dermavant to Develop and Commercialize Tapinarof in Japan,26162,16-01-2020
Livongo to Integrate Dexcom's G6 CGM System into its Applied Health Signals Platform,26172,16-01-2020
Wuxi Biologic to Acquire Bayer's Production Facility in Germany,26182,16-01-2020
UCB's Cimzia (certolizumab pegol) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis,26189,16-01-2020
BMS Reports the US FDA Acceptance of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) as 1L Treatment for Non-Small Cell Lung Cancer,26198,16-01-2020
Sun Pharma Signs a License Agreement with Rockwell Medical for Triferic in India,26203,16-01-2020
"Meiji and Dong-A Socio Initiate P-I Trial for DMB-3115 (biosimilar, ustekinumab)",26212,16-12-2019
Boehringer Ingelheim Report Results of BI 695501 in P-III Trial for Patients with Crohn's Disease,26222,17-12-2019
BioNTech To Acquire Neon to Bolster its Immunotherapy Pipeline,26229,17-01-2020
"Celltrion Reports Results of Truxima (biosimilar, rituximab) in P-III Study for Advanced Follicular Lymphoma in the US",26233,12-12-2019
"Clover Reports Dosing of SCB-808 (biosimilar, etanercept) in P-III Trial in China",26241,30-12-2019
"Neuclone Reports Dosing of NeuLara (biosimilar, ustekinumab) in P-I Trial",26252,30-12-2019
Samsung Bioepis Initiates P-III Trial for Ontruzant in China,26263,20-12-2019
Novo Nordisk's Ozempic (semaglutide) Receives the US FDA's Approval for Reduction in MACE in Patients with Type 2 Diabetes,26270,17-01-2020
Just â€“ Evotec Signs a Development and Manufacturing Agreement with OncoResponse for OR2805,26294,17-01-2020
Healthy.io Launches Digital Wound Management Solution to Treat Chronic Wounds,26300,17-01-2020
Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment,26312,17-01-2020
Arena's APD418 Receives FDA's Fast Track Designation to Treat Patients with Decompensated Heart Failure,26328,17-01-2020
AstraZeneca's Lynparza (olaparib) Receives the US FDA's Priority Review for HRR-Mutated Metastatic Castration-Resistant Prostate Cancer,26354,20-01-2020
AstraZeneca's Imfinzi (durvalumab) + Tremelimumab Receive the US FDA's Orphan Drug Designation for Liver Cancer,26365,20-01-2020
Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies Under Project Nexus,26370,20-01-2020
CMS Signs a License Agreement with Zydus for Desidustat in Greater China,26381,20-01-2020
Astellas to Establish a New Manufacturing Facility for API of Prograf in Toyama Technology Center,26386,20-01-2020
TB Alliance Collaborates with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China,26391,20-01-2020
Novartis' Mayzent (siponimod) Receives EC's Approval to Treat Patients with Secondary Progressive Multiple Sclerosis with Active Disease,26399,21-01-2020
Roche's Polivy (polatuzumab vedotin) Based Combination Regimen Receives EC's Approval for Patients with R/R Diffuse Large B-Cell Lymphoma,26408,21-01-2020
Pharming Receive EMA's Approval to Establish New Facility for Manufacturing Ruconest (conestat alfa),26417,21-01-2020
Jazz Pharmaceuticals' Sunosi (solriamfetol) Receives EMA's MAA for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea,26423,21-01-2020
Inotrem Signs a Worldwide License agreement with Roche Diagnostic for CDx Test in Septic Shock,26433,21-01-2020
PhoreMost Signs Multi-Project Drug Discovery Collaboration with Otsuka Pharmaceutical to Identify Novel Targets,26439,21-01-2020
Janssen's Darzalex (daratumumab) Combination Regimen Receives EC's Approval for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma,26450,21-01-2020
OBI Pharma's OBI-999 Receives the US FDA's Orphan Drug Designation to Treat Gastric Cancer,26457,21-01-2020
MD Anderson to Acquire Bellicum's Manufacturing Facility for $15M,26467,22-01-2020
Fresenius Kabi Forms a Joint Venture in Collaboration with Bio-Techne and Wilson Wolf to Advance Cell and Gene Therapies,26473,22-01-2020
Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease,26482,22-01-2020
Medtronic's Micra AV Receives the US FDA's Approval as the World's Smallest Pacemaker to Treat AV Block,26492,22-01-2020
Theramex to Acquire Commercial Rights of MSD's Zoely to Expand its Footprints,26498,22-01-2020
GSK's Belantamab Mafodotin Receives FDA's Priority Review for Relapsed or Refractory Multiple Myeloma,26504,22-01-2020
Genialis Collaborates with Oncologie on Precision Medicine Initiative in Gastric Cancer,26513,23-01-2020
Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy,26521,23-01-2020
Bayer's Nubeqa (darolutamide) Receives MHLW's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer,26532,23-01-2020
Bayer Reports Submission of MAA to the EMA for Pre-Filled Syringe to Administer Eylea (aflibercept solution for intravitreal injection),26541,23-01-2020
Evotec and Indivumed Collaborate to Develop Therapies for Patients with Non-Small Cell Lung Cancer,26548,23-01-2020
Merck & Co's Keytruda (pembrolizumab) Receives Health Canada's Approval as 1L Treatment for Advanced Renal Cell Carcinoma,26553,23-01-2020
Janssen Receives EC's Approval for the Expanded Use of Stelara (Ustekinumab) to Treat Pediatric Patients with Moderate to Severe Plaque Psoriasis,26563,24-01-2020
Roche Reports Results of Tecentriq (atezolizumab) in P-III IMvigor010 Study for Patients with Muscle-Invasive Urothelial Cancer,26571,24-01-2020
Pfizer to Launch Two Oncology Biosimilars at Lowest Wholesale Acquisition Cost in the US,26580,24-01-2020
Evarsana Signs an Agreement with Evoke Pharma to Commercialize Gimoti in the US,26589,24-01-2020
Epizyme's Tazverik (tazemetostat) Receives the US FDA's Accelerated Approval as the First Therapy for Epithelioid Sarcoma,26604,24-01-2020
AbbVie to Divest Allergan's Brazikumab and Zenpep (pancrelipase) to Gain the US FTC and EC's Approval on Pending Allergan Acquisition,26624,27-01-2020
AstraZeneca to Divest its Hypertension Therapies to Atnahs Pharma,26632,27-01-2020
Roche Reports Submission of sBLA to the US FDA for Tecentriq (atezolizumab) + Avastin (bevacizumab) to Treat Unresectable Hepatocellular Carcinoma,26644,27-01-2020
AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THALES Study for Patients with Minor Acute Ischemic Stroke or High-Risk Transient Ischemic Attack,26653,27-01-2020
Merck & Co's Dificid (fidaxomicin) Receives FDA's Approval to Treat Clostridioides difficile in Children Aged Six Months and Older,26661,27-01-2020
Sanofi and Regeneron Receive the US FDA's Priority Review Acceptance for Dupixent's sBLA to Treat Moderate-to-Severe Atopic Dermatitis in Children Aged 6 to 11 Years,26670,28-01-2020
GSK Out Licenses its Tuberculosis Vaccine (M72/AS01E ) to Bill &amp; Melinda Gates Medical Research Institute,26681,28-01-2020
Eli Lilly and Boehringer Ingelheim's Triple Regimen Receive the US FDA's Approval for Type 2 Diabetes,26687,28-01-2020
Bausch + Lomb Collaborates with TerraCycle to Launch First Contact Lens Recycling Program in Canada,26694,28-01-2020
Ningbo NewBay Medical Technology Signs an Exclusive License Agreement with Genentech to Develop and Commercialize GDC-0570,26702,28-01-2020
Alkermes Reports the US FDA Acceptance of NDA for ALKS 3831 to Treat Schizophrenia and Bipolar I Disorder,26708,28-01-2020
Timber Pharmaceuticals Signs a Reverse Merger Agreement with BioPharmX,26717,29-01-2020
Takeda Report Submission of NDA to MHLW for Cabometyx (cabozantinib) to Treat Advanced Hepatocellular Carcinoma in Japan,26726,29-01-2020
Kite Reports the Validation of EMA's MAA for KTE-X19 to Treat Relapsed or Refractory Mantle Cell Lymphoma,26731,29-01-2020
Eli Lilly's Selpercatinib (LOXO-292) Receives Priority Review Status for the Treatment of RET-Driven Cancer Indications,26740,29-01-2020
Verastem Reports Dosing of Copiktra (duvelisib) in CPSC's Chinese Study for Relapsed or Refractory Follicular Lymphoma,26746,29-01-2020
Akcea and Ionis Report Results of AKCEA-ANGPTL3-LRx in P-II Study for Patients with Cardiovascular and Metabolic Diseases,26752,29-01-2020
Johnson &Johnson Initiates the Development of Vaccines Against Coronavirus,26765,30-01-2020
Sanofi Reports Results of Olipudase alfa in Two Studies for Acid Sphingomyelinase Deficiency in Adults and Pediatric Patients,26776,30-01-2020
Astellas Reports Submission of sNDA to MHLW for Evrenzo (roxadustat) to Treat Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan,26784,30-01-2020
Sorrento Collaborates with Celularity to Initiate the Development of Emergency Allogeneic Natural Killer Cell Therapy for Coronavirus Infection,26790,30-01-2020
Janssen Receives EC's Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer,26797,30-01-2020
Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III ARAMIS Study for Non-Metastatic Castration-Resistant Prostate Cancer,26804,30-01-2020
Spring Bank Discontinues the Development of Inarigivir to Treat Patients with Chronic Hepatitis B Virus,26810,30-01-2020
Inovio Collaborates with Beijing Advaccine to Advance the Development of INO-4800 Vaccine Targeting Coronavirus in China,26822,31-01-2020
Abbott's Tendyne Receives CE Mark as the World's First Transcatheter Mitral Valve Implantation System in Europe,26831,31-01-2020
Microsoft Launches $40M AI Program to Accelerate Health Initiatives Globally,26836,31-01-2020
Accenture Collaborates with Google Cloud to Support Life Sciences Companies Advancing Research and Development of Innovative Therapies,26843,31-01-2020
ProQR's QR-421a Receives FDA's Rare Pediatric Disease Designation for Retinitis Pigmentosa,26850,31-01-2020
Alnylam's Givlaari (givosiran) Receives CHMP's Positive Opinion to Treat Acute Hepatic Porphyria in Adults and Adolescents,26853,31-01-2020
Eli Lilly's Fast-Acting Insulin Lispro Receives CHMP's Positive Opinion in Patients with Diabetes,26866,31-01-2020
GSK Collaborates with CEPI to Develop Vaccine Against Corona Virus,26881,03-02-2020
Eli Lilly Launches Reyvow (lasmiditan) C-V for the Treatment of Migraine in the US,26891,03-02-2020
Teva Reports Results of Ajovy (fremanezumab) in Two P-II/III Clinical Studies for the Treatment of Migraine in Japan,26900,03-02-2020
"Pfizer's Ruxience (biosimilar, rituximab) Receives CHMP's Positive Opinion for Cancer and Autoimmune Diseases",26905,03-02-2020
"Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Inflammatory Diseases in Brazil",26917,03-02-2020
Danaher Receives S.Korean FTC's Conditional Approval for its $21.4B GE Biopharma Acquisition,26928,04-02-2020
IMIDomics Collaborates with Gossamer Bio to Develop Therapies for Treating Immune-Mediated Inflammatory Diseases,26934,04-02-2020
"Bio-Thera Reports Results of BAT1706 (biosimilar, bevacizumab) in P-III Trial for Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",26949,04-02-2020
Kyowa Kirin Terminates its Agreement with Zeria Pharmaceuticals for ASACOL (mesalazine),26957,04-02-2020
CELLINK Expands its Multi-Target Collaboration with AstraZeneca for Drug Discovery,26969,04-02-2020
Boehringer Ingelheim Reports Real-World Data for Spiriva Respimat (tiotropium bromide) Inhalation Spray 1.25mcg in Patients with Asthma,26981,04-02-2020
GSK Reports EMA's Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma,26990,04-02-2020
Regeneron Expands its Existing Collaboration with HHS'BARDA to Develop Antibody Therapies for Coronavirus,27002,05-02-2020
BioMotiv and BMS to Launch Anteros Pharmaceuticals,27008,05-02-2020
AbbVie's Rinvoq (upadacitinib) Receives ANVISA's Approval for Rheumatoid Arthritis,27015,05-02-2020
The US FDA Grants Emergency Use Authorization for Coronavirus Diagnostic Test,27020,05-02-2020
Merck &amp; Co. to Spin-Off its Non-Core Business into a New Company to Focus on its Core Therapy Areas,27028,05-02-2020
Seqirus' Audenz Receives the US FDA's Approval as the First Adjuvanted Cell-Based Pandemic Influenza A (H5N1) Vaccine,27032,05-02-2020
Navrogen and Levena Collaborate to Develop ADCs for Humoral Immuno-Suppressed Cancers,27042,05-02-2020
Alector's AL101 Receives FDA's Fast Track Designation to Treat Frontotemporal Dementia,27045,05-02-2020
Merck &amp; Co. Collaborates with Atreca to Identify Novel Antibody Targets in Oncology,27054,06-02-2020
Sanofi Reports Results of SAR442168 in P-IIb Study for Relapsing Multiple Sclerosis,27059,06-02-2020
Fresenius Kabi Reports the Availability of Glucagon Emergency Medicine Kit to Treat Hypoglycemia in the US,27066,06-02-2020
Roche Reports Results of Risdiplam in SUNFISH Part 2 Study for Patients with Type 2 Or 3 Spinal Muscular Atrophy,27075,06-02-2020
Nestle Health Science Signs a Worldwide Exclusive Agreement with VALBIOTIS to Develop and Commercialize TOTUM-63 for Reducing the Risk of T2D,27079,06-02-2020
Bridge Biotherapeutics Signs a License Agreement with Konkuk University for its Back-Eye Disease Therapy,27085,06-02-2020
Almirall Collaborates with Plug and Play to Offer Digital Solutions in Dermatology,27097,07-02-2020
Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study in Chinese Patients with Hepatocellular Carcinoma,27113,07-02-2020
Merck &amp; Co. to Initiate P-II Study of MK-5890 for Non-Small Cell Lung Cancer,27122,07-02-2020
Collegium to Acquire US Rights of Assertio's Nucynta Franchise for $375M,27129,07-02-2020
Novo Nordisk to Invest ~$117.4M in Expansion of its Production Facilities in Denmark,27141,07-02-2020
Curis Amends its Existing Collaboration with Aurigene for the Development and Commercialization of CA-170,27149,07-02-2020
Â­WHO to Accelerate Global Research and Innovation Against Corona Virus,27158,07-02-2020
Eli Lilly Reports Results of Solanezumab in P-II/III DIAN-TU Study for Dominantly Inherited Alzheimer's Disease,27175,10-02-2020
Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Study for Patients with Diabetic Retinopathy,27183,10-02-2020
Zealand Pharma to Acquire Valeritas' Business and Retain its Employees,27194,10-02-2020
Bayer Plans Two P-III Studies to Evaluate Aflibercept 8mg Formulation,27214,10-02-2020
Roche Reports Results of Gantenerumab in P-II/III DIAN-TU-001 Study for Autosomal Dominant Alzheimer's Disease,27233,10-02-2020
BioIntelliSense's BioSticker Receives FDA's 510 (k) Clearance for Month-Long Vitals Monitoring,27243,11-02-2020
Sapphire Biotech Collaborates with Arizona State University to Develop Metastatic Cancer Inhibitor,27251,11-02-2020
Kite's KTE-X19 Receives the US FDA's Priority Review for Relapsed or Refractory Mantle Cell Lymphoma,27257,11-02-2020
Bayer and Nuvisan Collaborate to Establish a New Research Entity in Berlin,27265,11-02-2020
Eagle's Pemfexy (pemetrexed for injection) Receives Final FDA's Approval to Treat Nonsquamous Non-Small Cell Lung Cancer,27277,11-02-2020
Novartis' Capmatinib (INC280) Receives FDA's Priority Review for METex14 Mutated Advanced Non-Small Cell Lung Cancer,27312,11-02-2020
Janssen Reports Submission of sBLA to the US FDA for Darzalex (daratumumab) based Combination Regimen for Relapsed/Refractory Multiple Myeloma,27325,11-02-2020
Caption Health's Caption Guidance Receives FDA's Marketing Authorization as the First AI-Guided Image Acquisition System,27329,11-02-2020
Janssen Collaborates with BARDA to Facilitate the Development of Corona Virus Vaccine,27343,12-02-2020
Pfizer Terminates its License Agreement with GlycoMimetics Signed in 2011,27355,12-02-2020
"Novo Nordisk Launches Esperoct [antihemophilic factor (recombinant), glycopegylated-exei] to Treat Hemophilia A in the US",27372,12-02-2020
Eli Lilly's Taltz (ixekizumab) Receives Health Canada's Approval for Active Ankylosing Spondylitis,27386,12-02-2020
Cognoa Collaborates with Autism Learning Partners for Screening App to Accelerate Early Diagnosis of Autism,27400,12-02-2020
Astellas and Pfizer Report Results of Xtandi (enzalutamide) in P-III PROSPER Study for Non-Metastatic Castration-Resistant Prostate Cancer,27415,12-02-2020
Merck &amp; Co. Reports Results of Keytruda (pembrolizumab) + CT in P-III KEYNOTE-355 Study as 1L Treatment for Metastatic Triple-Negative Breast Cancer,27426,12-02-2020
Dr. Reddy's to Acquire Wockhardt's Select Business Divisions for ~$259M in India,27442,13-02-2020
Deciphera Reports the US FDA's Acceptance of NDA and Priority Review for Ripretinib to Treat Patients with Advanced Gastrointestinal Stromal Tumors,27459,13-02-2020
Vizient Submits Response to the US FDA for Draft Guidance on Biosimilars Development,27477,28-01-2020
Alvotech Signs an Exclusive Commercialization Agreement with JAMP Pharma for Biosimilars in Canada,27486,14-01-2020
Medtronic Recalls its MiniMed 600 Series Insulin Pumps Due to Incorrect Insulin Dosing,27496,13-02-2020
BenevolentAI Collaborates with UC San Diego to Develop Non-Invasive Therapies for Cerebral Cavernous Malformations,27506,13-02-2020
Medtronic to Acquire Digital Surgery to Bolster its Robotic-Assisted Surgery Platform and AI Capabilities,27519,13-02-2020
Amgen Receives Health Canada's Marketing Authorization Transfer of Otezla for Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis,27527,13-02-2020
BMS Receives FDA's Priority Review Acceptance of Lisocabtagene Maraleucel's BLA for Patients with Relapsed or Refractory Large B-Cell Lymphoma,27534,13-02-2020
Thermo Fisher Collaborates with NanoPin to Facilitate Infectious Diseases Diagnosis,27544,14-02-2020
Roche's Tecentriq (atezolizumab) + CT Receive NMPA's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer,27554,14-02-2020
Orthofix's STIM onTrack 2.1 Mobile App Receives the US FDA's Approval for Bone Growth Stimulators,27563,14-02-2020
Codagenix Collaborates with Serum Institute of India to Co-Develop a Live-Attenuated Vaccine Against Coronavirus (COVID-19),27576,14-02-2020
Soligenix's RiVax Receives the US FDA's Fast Track Designation for the Prevention of Ricin Poisoning,27584,14-02-2020
Epizyme Reports the US FDA Acceptance of NDA for Tazverik (tazemetostat) to Treat Follicular Lymphoma,27589,14-02-2020
Teva Collaborates with Global HOPE and Direct Relief for Providing Access to Medications in Africa,27614,17-02-2020
"Merck & Co's Ervebo (Ebola Zaire Vaccine, Live) Receives Approval in Four African Countries",27621,17-02-2020
PharmaMar and Jazz Receive the US FDA's Priority Review Acceptance of Lurbinectedin's NDA for Patients with Relapsed Small Cell Lung Cancer,27629,17-02-2020
"Celltrion Reports Results of Remsima SC (biosimilar, infliximab) in a Clinical Study for Active Crohn's Disease and Ulcerative Colitis #ECCO2020",27637,17-02-2020
Novartis' Beovu (brolucizumab) Receives EC's Approval for Wet Age-Related Macular Degeneration,27644,17-02-2020
Zydus Cadila Launches a Research Program to Develop Vaccine Against Coronavirus,27651,17-02-2020
Chugai and Sanofi to Terminate their Licensing Agreement for Tofogliflozin Hydrate in Japan,27661,18-02-2020
GSK's Voltaren Arthritis Pain Receives the US FDA's Approval as an OTC Medication,27671,18-02-2020
Noxopharm Collaborates with GenesisCare to Bring Combination Regimen of Veyonda (idronoxil) and Lu-PSMA in Australia,27678,18-02-2020
MVC Collaborates with the US NIH to Develop Vaccine Against Corona Virus,27685,18-02-2020
Â­WAT Medical Reports Results of HeadaTerm TENS Therapy in a Clinical Study to Treat Acute Migraine,27693,18-02-2020
"Pfizer's Vyndaqel (tafamidis, 61mg) Receives EC's Approval as the First Therapy to Treat Transthyretin Amyloid Cardiomyopathy in the EU",27706,18-02-2020
Chugai's RG6042 Receives MHLW's Orphan Drug Designation for Huntington's Disease in Japan,27711,18-02-2020
Sanofi Collaborates with BARDA to Facilitate the Development of Coronavirus Vaccine,27723,19-02-2020
Roche Reports the US FDA Acceptance of sBLA and Granted Priority Review for Tecentriq (atezolizumab) as 1L Monotherapy for Advanced Non-Small Cell Lung Cancer,27734,19-02-2020
Hyperfine Research Receives the US FDA's 510(k) Clearance for its World's First Bedside MRI system,27741,19-02-2020
Abbott's Gallant ICD and CRT-D Device Receives CE Mark in the EU,27746,19-02-2020
Janssen Expands its Collaboration with BARDA to Expedite the Discovery of COVID-19 Therapies,27753,19-02-2020
Sarepta Receives the US FDA's Approval for VYONDYS 53 (golodirsen) Injection to Treat Duchenne Muscular Dystrophy (DMD) in Patients with Amenable to Skipping Exon 53,27758,12-12-2019
Abbott Collaborates with Insulet to Integrate Glucose Sensing Technology with Automated Insulin Delivery System for Seamless Diabetes Care,27762,19-02-2020
Astellas and Seattle Genetics' PADCEV (enfortumab vedotin-ejfv) Receives the US FDA's Approval for Locally Advanced or Metastatic Urothelial Cancer in Adults,27766,18-12-2019
WuXi Vaccines Signs Twenty Years Manufacturing Agreement with Global Vaccine Leaders for $3B,27779,19-02-2020
Merck KGaA to Divest its Allergopharma to Dermapharm,27789,20-02-2020
Astellas and Seattle Genetics' Padcev (enfortumab vedotin-ejfv) + Keytruda Receive FDA's Breakthrough Therapy Designation as 1L Treatment for Advanced Bladder Cancer,27796,20-02-2020
Intra-Cellular's CAPLYTA (lumateperone) Receives the US FDA's Approval for the Treatment of Schizophrenia in Adults,27826,23-01-2020
Blueprint Medicines' Ayvakit (avapritinib) Receives FDA's Approval to Treat Patients with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor,27834,09-01-2020
Vifor Pharma and Fresenius Kabi Collaborate to Establish Joint Venture in China,27836,20-02-2020
Eisai's Dayvigo (lemborexant) Receives the US FDA's Approval to Treat Insomnia in Adults,27859,23-12-2019
Abbott to Recall Coronary Dilatation Catheters Due to Failure of Balloon Deflation,27875,20-02-2020
Genentech Signs an Agreement with Nimble to Discover and Develop Novel Peptide-Based Therapies,27891,20-02-2020
Roche Introduces RocheDiabetes InsulinStart to Facilitate the Access to Insulin Therapy for T2D Patients,27902,20-02-2020
GSK Signs an Agreement with Immatics to Develop Adoptive Cell Therapies for Multiple Cancer Indications,27922,21-02-2020
BioMarin Receives the US FDA's Priority Review Acceptance of Valoctocogene Roxaparvovec's BLA for Patients with Hemophilia A,27926,21-02-2020
VBL Therapeutics to Initiate P-II Study Evaluating VB-111 (ofranergene obadenovec) + Nivolumab in Patients with Metastatic Colorectal Cancer,27930,21-02-2020
Teva Reports Results of Austedo (deutetrabenazine) in Two Clinical Studies for Tourette Syndrome,27934,21-02-2020
Chugai's Rozlytrek Receives MHLW's Approval for ROS1 Fusion-Positive Non-Small Cell Lung Cancer,27949,21-02-2020
Esperion's NEXLETOL (bempedoic acid) Tablet Receives the US FDA's Approval for Lowering Cholesterol Level,27966,24-02-2020
Novartis Reports Acceptance of Ofatumumab's (OMB157) sBLA from the US FDA and EMA to Treat Relapsing Forms of Multiple Sclerosis (RMS),27977,24-02-2020
Eli Lilly's Trulicity (dulaglutide) Receives the US FDA's Approval to Reduce MACE in T2D Adults,27985,24-02-2020
Lundbeck's Vyepti (eptinezumab-jjmr) Receives the US FDA's Approval to Prevent Migraine in Adults,27993,24-02-2020
Asuragen's AmplideX Fragile X Dx and Carrier Screen Kit Receives the US FDA's Approval for Detecting Fragile X Syndrome (FXS),28003,24-02-2020
Paratek Signs an Exclusive License Agreement with Almirall for SEYSARA (sarecycline),28017,24-02-2020
GSK Signs a Research Collaboration with Clover for the Evaluation of Coronavirus (COVID-19) Vaccine,28022,24-02-2020
Sanofi to Establish New Company to Provide Active Pharmaceutical Ingredients in the EU,28039,25-02-2020
Roche Reports Acceptance of BLA for Fixed-Dose SC Combination of Perjeta and Herceptin to Treat HER2-Positive Breast Cancer,28047,25-02-2020
AstraZeneca to Divest Global Rights of Movantik (naloxegol) to RedHill Biopharma,28055,25-02-2020
STADA Acquires GSK's Consumer Healthcare Portfolio to Expand its OTC Business,28063,25-02-2020
Takeda's Alunbrig (brigatinib) Receives the US FDA's Priority Review to Treat ALK + Metastatic Non-Small Cell Lung Cancer,28070,25-02-2020
FMCNA's Novalung ECMO System Receives the US FDA's Approval for Acute Respiratory and Cardiopulmonary Failure,28078,25-02-2020
Genentech Collaborates with Bicycle Therapeutics to Develop and Commercialize Bicycle-Based Immuno-Oncology Therapies,28093,25-02-2020
Novartis Collaborates with DNDi to Develop LXE408 for Visceral Leishmaniasis,28100,26-02-2020
WuXi Biologics and Vir Biotechnology Collaborate for the Global Development of Antibodies Against COVID-19,28110,26-02-2020
Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M,28117,26-02-2020
Johnson & Johnson in Collaboration with Apple Launch Heartline Study App in the US,28134,26-02-2020
The US FDA Upgrades the Purple Book to Assist the Transparency in Biosimilars,28139,26-02-2020
Eisai Signs a License Agreement with FUJI YAKUHIN for Dotinurad to Treat Hyperuricemia and Gout in China,28147,26-02-2020
Gilead Reports the Initiation of Two P-III Studies of Remdesivir to Treat COVID-19,28155,27-02-2020
Gemini Therapeutics Signs a Research Agreement with SERI to Identify New Therapies for Age-related Macular Degeneration,28161,27-02-2020
Hikma Signs an Exclusive License Agreement with Glenmark to Commercialize Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) in the US,28172,27-02-2020
Esperion Receives the US FDA's Approval for Nexlizet (Non-Statin LDL-Cholesterol Lowering Therapy),28180,27-02-2020
GSK Reports the Acceptance of EMA's MAA for Zejula (niraparib) as 1L Maintenance Treatment for Platinum-Responsive Advanced Ovarian Cancer,28187,27-02-2020
Co-Diagnostics Receives CE Mark for its Logix Smart Coronavirus PCR Test,28193,27-02-2020
"Celltrion's Remsima SC (biosimilar, infliximab) Receives KFDA's Approval for Rheumatoid Arthritis",28201,28-02-2020
Biogen Signs an Exclusive Worldwide License Agreement with Sangamo to Develop Gene Therapies for Multiple Neurological Diseases,28211,28-02-2020
Boehringer Ingelheim Collaborates with Trutino Biosciences to Develop New Therapies Utilizing On-Demand-Cytokine Platform,28230,28-02-2020
Fujifilm's CAD EYE Receives CE Mark to Support the Detection of Colonic Polyp Utilizing AI in the EU,28245,28-02-2020
Gates Foundation Forms an Alliance with Global Pharma Companies to Develop PAN-TB Drug Regimen for Tuberculosis,28253,28-02-2020
Takeda's Vedolizumab SC Receives CHMP's Positive Opinion as a Maintenance Therapy for Moderately to Severely Active UC or CD,28261,28-02-2020
Companion Medical's InPen Diabetes Management System Receives the US FDA's Approval for Fixed Dosing and Meal Estimation,28272,28-02-2020
Merck KGaA's ERBITUX (cetuximab) Receives NMPA's Approval as a 1L treatment for Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck,28298,02-03-2020
Boehringer Ingelheim's Nintedanib Receives CHMP's Positive Opinion to Treat Systemic Sclerosis-Associated Interstitial Lung Disease,28306,02-03-2020
Medexus Acquires Aptevo BioTherapeutics for its Hematology Asset IXINITY,28314,02-03-2020
Gilead to Acquire Forty Seven for $4.9B,28321,02-03-2020
Takeda to Divest a Portfolio of Select OTC and Non-Core Assets to Hypera Pharma in Latin America for $825M,28328,02-03-2020
Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthritis,28335,02-03-2020
uniQure Signs an Exclusive Research and License Agreement with Gen-X to Develop Novel Synthetic Promoters,28344,03-03-2020
Sanofi's Sarclisa (isatuximab-irfc) Receives the US FDA's Approval for Relapsed Refractory Multiple Myeloma,28350,03-03-2020
Thermo Fisher Scientific to Acquire QIAGEN for ~$11.5B,28363,03-03-2020
Insulet to Halt Study of Omnipod Horizon Due to Software Anomaly,28371,03-03-2020
Genentech's Esbriet (pirfenidone) Receives FDA's Breakthrough Therapy Designation for Unclassifiable Interstitial Lung Disease,28380,03-03-2020
Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate EsoCheck in Patients with Eosinophilic Esophagitis,28391,03-03-2020
Novartis' Mayzent Receives Health Canada's Approval for Secondary Progressive Multiple Sclerosis with Active Disease,28397,03-03-2020
BMS Collaborates with Voluntis to Co-Develop Digital Therapies to Treat Cancer Indications,28406,04-03-2020
Roche's Elecsys GALAD scores Receive the US FDA's Breakthrough Device Designation for Earlier Diagnosis of Hepatocellular Carcinoma,28416,04-03-2020
Takeda to Initiate the Development of Plasma-Derived Therapy to Treat Corona Virus (COVID-19),28438,04-03-2020
Alnylam's Givlaari (givosiran) Receives EC's Approval for Acute Hepatic Porphyria in Adults and Adolescents,28449,04-03-2020
Iktos and SRI Collaborate to Accelerate Discovery and Development of Novel Anti-Viral Therapies,28454,04-03-2020
Janssen Reports Submission of Ponesimod's MAA to EMA for the Treatment of Relapsing Multiple Sclerosis,28460,04-03-2020
Vir and Alnylam Expand their 2017 License Agreement to Target COVID-19,28474,05-03-2020
Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10,28481,05-03-2020
The US FDA and FTC Sign Agreement to Support the Development of Biosimilars,28488,03-02-2020
The US FDA Released Draft Guidelines for Proposed Biosimilar or Proposed Interchangeable Biosimilars,28489,07-02-2020
Alopexx Signs an Exclusive License Agreement with Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia,28503,05-03-2020
Roche's Actemra (tocilizumab) Receives Approval to Combat Coronavirus Complications in China,28515,05-03-2020
Insud's mAbxience Inaugurates New Biosimilar Plant Facility in Argentina,28526,24-02-2020
Zuellig Pharma Acquires Alliance Pharma (Cambodge) to Bolster its Presence in Indochina,28528,05-03-2020
The US FDA Informs About Cybersecurity Vulnerabilities in Medical Devices with Bluetooth Low Energy,28535,05-03-2020
Heat Biologics Signs a Research Collaboration with University of Miami to Develop Vaccine Against COVID-19,28553,06-03-2020
Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market,28558,28-02-2020
Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets,28573,06-03-2020
Zydus' Saroglitazar Receives DCGI's Approval as the World's First Therapy for Non-Cirrhotic NASH in India,28582,06-03-2020
Allergan's Durysta (bimatoprost implant) Receives the US FDA's Approval as the First Intracameral Biodegradable Sustained-Release Implant for Patients with OAG and OHT,28594,06-03-2020
AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV Bladder Cancer,28609,06-03-2020
Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19,28620,06-03-2020
Tetra Therapeutics and Shionogi Expand their Existing 2018 Collaboration to Develop and Commercialize BPN14770,28638,09-03-2020
Novartis' Isturisa (osilodrostat) Receives the US FDA's Approval for Cushing's Disease,28653,09-03-2020
AbbVie's Maviret (glecaprevir/pibrentasvir) Receives EC's Marketing Authorization as Eight-Week Regimen for Treatment-NaÃ¯ve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis,28663,09-03-2020
Zydus Signs a License Agreement with XOMA to Advance IL-2- Based Immuno-Oncology Therapy,28670,09-03-2020
BMS Reports Results of Triple Regimen in P-III ELOQUENT-1 Study for Patients with Newly Diagnosed Untreated Multiple Myeloma,28677,09-03-2020
Biocon and Mylan Report the US FDA Acceptance of BLA for Proposed Biosimilar of Avastin (bevacizumab),28684,09-03-2020
AbbVie Collaborates with Global Health Authorities to Investigate its Kaletra/Aluvia (lopinavir/ritonavir) Against COVID-19,28691,10-03-2020
"Celltrion Reports Submission of MAA to EMA for CT-P17 (biosimilar, adalimumab)",28698,10-03-2020
ViiV Healthcare Renews its 2015 Collaboration with UNC-Chapel Hill to Discover a Cure for HIV,28706,10-03-2020
Boehringer Ingelheim's Ofev (nintedanib) as the First Treatment for Chronic Fibrosing ILDs with Progressive Phenotype,28715,10-03-2020
Novo Nordisk's Fiasp (insulin aspart injection) Receives Health Canada's Approval for Children with Diabetes,28721,10-03-2020
Â­Bora Pharmaceuticals to Acquire GSK's Facility in Canada,28731,10-03-2020
CEPI Expands its Investment in the Development of Vaccine Against COVID-19,28741,11-03-2020
Roche's CINtec PLUS Cytology Receives the US FDA's Approval as the First Biomarker-Based Triage Test to Improve the Prevention of Cervical Cancer,28747,11-03-2020
Bridge Biotherapeutics Signs an AI-Based Research Agreement with Atomwise to Expand its Pellino Inhibitor Portfolio,28758,11-03-2020
Janssen's JNJ-6372 Receives the US FDA's Breakthrough Therapy Designation for Non-Small Cell Lung Cancer,28766,11-03-2020
Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study for Transplant Ineligible Patients with Multiple Myeloma,28775,11-03-2020
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive the US FDA's Approval for Patients with Hepatocellular Carcinoma Prior Treated with Sorafenib,28784,11-03-2020
Vir Biotechnology Collaborates with NIH Vaccine Research Center to Advance the Development of mAbs Against Coronavirus,28795,12-03-2020
"Henlius Reports the NMPA's Acceptance of IND for HLX14 (biosimilar, denosumab)",28802,12-03-2020
Teva's Ajovy (fremanezumab) Receives NICE Positive Recommendation for Prevention of Migraine in Adults,28809,12-03-2020
AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation to Treat Chronic Lymphocytic Leukaemia (CLL) in Adults,28815,14-08-2019
Novavax and Serum Institute of India Collaborate to Develop and Commercialize Vaccines for Malaria,28822,12-03-2020
AstraZeneca's Selumetinib Receives the US FDA's Breakthrough Therapy Designation for Neurofibromatosis Type 1,28826,01-04-2019
F2G's Olorofim Receives the US FDA's Breakthrough Therapy Designation to Treat Invasive Mold Infections in Patients with Limited or No Treatment Options,28831,11-11-2019
AbbVie's Dual Regimen Receives EC's Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia,28834,12-03-2020
Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for Multiple Cancer Indications,28848,12-03-2020
Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults,28849,29-05-2019
Merck and Eisai's Dual Regimen Receives the US FDA's Breakthrough Therapy Designation as 1L Treatment for Advanced Unresectable Hepatocellular Carcinoma,28857,23-07-2019
Novartis's Capmatinib (INC280) Receives the US FDA's Breakthrough Therapy Designation for MET-Mutated Advanced Non-Small Cell Lung Cancer,28858,06-09-2019
Chugai's Nemolizumab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis,28866,09-12-2019
Agios' Tibsovo (ivosidenib) Receives the US FDA's Breakthrough Therapy Designation for Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation,28874,16-12-2019
AbCellera and Eli Lilly Collaborate to Co-develop Antibody Therapies Targeting COVID-19,28879,13-03-2020
Roche's cobas SARS-CoV-2 Test Receives the US FDA's Emergency Use Authorization to Identify Corona Virus,28888,13-03-2020
Usona Institute's Psilocybin Receives the US FDA Breakthrough Therapy Designation for Major Depressive Disorder,28895,22-11-2019
AstraZeneca and MSD Report Results of Cediranib + Lynparza in P-III GY004 Study for Patients with Platinum-Sensitive Relapsed Ovarian Cancer,28908,13-03-2020
Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) Receives the US FDA's Fast Track Designation for Chronic Kidney Disease,28919,13-03-2020
EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head and Neck,28933,13-03-2020
I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19,28946,13-03-2020
Johnson &amp; Johnson Collaborates with the Beth Israel Deaconess Medical Center to Accelerate the Development of Vaccine Against COVID-19,28973,16-03-2020
Fosun Pharma Signs an Agreement with BioNTech to Develop and Commercialize BNT162 for COVID-19,28980,16-03-2020
Eli Lilly and Incyte's Olumiant (baricitinib) Receives the US FDA's Breakthrough Therapy Designation for Alopecia Areata,28987,16-03-2020
Biogen Collaborates with Vir Biotechnology to Develop Antibodies Against COVID-19,28994,16-03-2020
Sanofi and Regeneron to Initiate the Clinical Program Evaluating Kevzara (sarilumab) in Patients with Severe COVID-19,29003,16-03-2020
"Teva and Celltrion Launch Herzuma (biosimilar, trastuzumab) in the US",29014,17-03-2020
Pfizer and BioNTech Collaborate to Co-Develop BNT162 Against COVID-19,29022,17-03-2020
Novo Nordisk Halts Clinical Studies Evaluating Concizumab (anti-TFPI mAb) for Hemophilia A and B With or Without Inhibitors,29033,17-03-2020
AcelRx to Acquire Tetraphase Pharmaceuticals to Expand its Product Portfolio,29038,17-03-2020
AstraZeneca Reports Results of Imfinzi + Tremelimumab in P-III CASPIAN Study as 1L Treatment for Extensive-Stage Small Cell Lung Cancer,29048,17-03-2020
Alphabet's Verily Launched its COVID-19 Screening Site in Collaboration with California's Government,29058,17-03-2020
GSK's Nucala Receives Health Canada's Approval for Severe Eosinophilic Asthma in Children and Adolescents,29064,17-03-2020
NIH Initiates its P-I Trial for COVID-19 at KPWHRI in Seattle,29070,17-03-2020
Moleculin Collaborates with UTMB to Evaluate WP1122 for Multiple Viruses Including Coronavirus,29081,18-03-2020
Merck &amp; Co. Reports Results of Gefapixant (MK-7264) in Two P-III Studies for Refractory or Unexplained Chronic Cough,29089,18-03-2020
NuProbe Collaborates with QIAGEN to Develop Diagnostics Tests for Cancer Indications,29099,18-03-2020
Regeneron to Initiate COVID-19 Antibody Program in Early Summer,29108,18-03-2020
IDEAYA and Pfizer Collaborate to Evaluate IDE196 + Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations,29115,18-03-2020
Samsung Biologics Collaborates with APRINOIA Therapeutics to Expand its Presence in Greater China,29120,18-03-2020
Juno Therapeutics Signs License and Clinical Supply Agreement with Oxford Biomedica for LentiVector Platform,29131,19-03-2020
Roche to Initiate P-III COVACTA Study of Actemra/RoActemra in Hospitalized Patients with Severe Covid-19 Pneumonia in Collaboration with BARDA,29142,19-03-2020
Novartis' Zolgensma (onasemnogene abeparvovec) Receives MHLW's Approval for Spinal Muscular Atrophy,29156,19-03-2020
Eli Lilly and ISDH Collaborate to Accelerate the Testing for COVID-19,29189,19-03-2020
AstraZeneca's Lynparza (olaparib) Receives MHLW's Orphan Drug Designation for BRCA-Mutated Metastatic Pancreatic Cancer,29217,19-03-2020
FDA Divulges Guidance for Conducting Clinical Studies During COVID-19 Pandemic,29228,19-03-2020
Janssen Reports Submission of Ponesimod's NDA to the US FDA for the Treatment of Relapsing Multiple Sclerosis,29231,19-03-2020
CEPI Collaborates with University of Hong Kong to Develop Vaccine for COVID-19,29247,20-03-2020
Gilead's Epclusa (Sofosbuvir/Velpatasvir) Receives the US FDA's Approval for Children with Chronic Hepatitis C Infection,29271,20-03-2020
Abbott Launches its Molecular Test to Detect COVID-19 and Receives the US FDA's Emergency Use Authorization,29278,20-03-2020
FDA Recommends Avoiding the Use of NSAIDs for COVID-19 Symptoms,29285,20-03-2020
BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US,29294,20-03-2020
Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform,29336,20-03-2020
Takeda's Entyvio (vedolizumab) Receives NMPA's Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn's Disease,29455,23-03-2020
Bayer Signs a Research and License Agreement with Curadev to Develop Novel STING Antagonists Across Multiple Indications,29464,23-03-2020
Microsoft and Adaptive Biotechnologies Expand Their Collaboration for Mapping the Immune Response to COVID-19,29474,23-03-2020
Sorrento Develops STI-4398 (COVIDTRAP Protein) to Prevent and Treat COVID-19,29480,23-03-2020
Celltrion to Launch Rapid Self-Testing Kit and Accelerates the Development of Treatment Against COVID-19,29487,23-03-2020
Takeda Collaborates with Codexis to Advance Novel Gene Therapies for Rare Genetic Disorders,29497,23-03-2020
Amgen and its Foundation Grant $12.5M to Support COVID-19 Relief Efforts Globally,29517,24-03-2020
Roche Highlights its Response to COVID-19 Pandemic,29533,24-03-2020
Sorrento and SmartPharm To Develop Novel Gene-Encoded Antibody Vaccine for COVID-19,29540,24-03-2020
Genentech Receives the US FDA's Approval for P-III Clinical Study Evaluating Actemra to Treat Hospitalized Patients with Severe COVID-19 Pneumonia,29547,24-03-2020
QIAGEN Releases QIAstat-Dx Test Kit as the First Syndromic Test to Detect COVID-19 Under New FDA Policy,29562,24-03-2020
Astellas Collaborates with CytomX Therapeutics to Develop Probody T-Cell Engaging Bispecific Therapies for Cancer Indications,29569,24-03-2020
Sorrento Signs an Exclusive License Agreement with Mabpharm for ACE-MAB to Treat COVID-19,29578,25-03-2020
Elevar Therapeutics Acquires Worldwide Development and Commercialization Rights for Oasmia's Apealea,29589,25-03-2020
"Alvotech Signs an Exclusive License Agreement with DKSH for AVT02 (biosimilar, adalimumab) in Asia",29593,25-03-2020
Horizon's Procysbi (Cysteamine Bitartrate) Receives the US FDA's Approval for Delayed Release Oral Tablets,29598,18-02-2020
"Samsung Bioepis Receives the US FDA's Approval for Multi-Dose Vial of Ontruzant (biosimilar, trastuzumab)",29618,25-03-2020
Merck KGaA's Tepmetko (tepotinib) Receives the Japanese MHLW's Approval for Advanced NSCLC with METex14 Skipping Alterations,29637,25-03-2020
AstraZeneca Collaborates with Silence Therapeutics to Develop siRNA Therapeutics Targeting Multiple Diseases,29650,25-03-2020
Agile Therapeutics Receives the US FDA's Approval for Twirla (levonorgestrel and ethinyl estradiol) Transdermal System,29666,14-02-2020
Biohaven's Nurtec Receives the US FDA's Approval for Treatment of Migraine in Adults,29673,27-02-2020
Sorrento to Initiate the Novel Decoy Cellular Vaccine Program for COVID-19,29674,26-03-2020
Baudax Bio's Anjeso Receives the US FDA's Approval to Manage Moderate to Severe Pain,29689,20-02-2020
Esperion's Nexlizet (bempedoic acid and ezetimibe) Tablet Receives the US FDA's Approval as LDL-Cholesterol Lowering Medicine,29704,26-02-2020
GSK's Advil Dual Action in Combination with Acetaminophen Receives the US FDA's Approval for Pain Relief,29709,28-02-2020
Vir Biotechnology Signs a License Agreement with Xencor to Utilize Xtend Fc Technology in Antibodies Targeting COVID-19,29714,26-03-2020
Acacia's Barhemsys (amisulpride) Receives the US FDA's Approval for the Prevention of Postoperative Nausea and Vomiting,29716,27-02-2020
AstraZeneca's Lokelma (sodium zirconium cyclosilicate) Receives MHLW's Approval for the Treatment of Hyperkalemia in Japan,29739,26-03-2020
Gates Foundation Collaborates with the Consortium of Life Sciences Companies to Address Challenges Against the Pandemic COVID-19,29758,26-03-2020
PRA Health Sciences Launches COVID-19 Monitoring App to Track Symptoms,29769,26-03-2020
Boehringer Ingelheim Signs a Second Research Collaboration with Saniona to Develop Therapies Targeting Schizophrenia,29814,27-03-2020
BMS' Zeposia (ozanimod) Receives the US FDA's Approval as New Oral Treatment for Relapsing Forms of Multiple Sclerosis,29821,27-03-2020
Sanofi's Sarclisa (isatuximab) Receives CHMP's Positive Opinion for Relapsed and Refractory Multiple Myeloma,29832,27-03-2020
Quidel's Lyra SARS-CoV-2 Assay Receives the US FDA's Expanded Emergency Use Authorization for Molecular Detection of COVID-19,29842,27-03-2020
Medopad Provides its Remote Patient Monitoring Platform to Support Global COVID-19 Pandemic,29862,27-03-2020
Mylan Delays its Merger with Upjohn Due to COVID-19 Pandemic,29869,27-03-2020
Sanofi Collaborates with Translate Bio to Develop Novel mRNA Vaccine Against COVID-19,29894,30-03-2020
Sanofi and Regeneron Expand Clinical Program of Kevzara (sarilumab) for the Treatment of COVID-19 Outside the US,29908,30-03-2020
"Mylan and Lupin Receive CHMP's Positive Opinion for Nepexton (biosimilar, etanercept)",29918,30-03-2020
AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Approval for Extensive-Stage Small Cell Lung Cancer,29926,30-03-2020
Eli Lilly's Taltz (ixekizumab) Receives the US FDA's Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis,29937,30-03-2020
BMS's Zeposia (ozanimod) Receives the CHMP's Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Active Disease,29942,30-03-2020
Johnson &amp; Johnson and BARDA to Fund ~$1B in Research and Development of Novel COVID-19 Vaccines,29964,31-03-2020
Abbott Receives FDA's Emergency Use Authorization for its Point-Of-Care Test to Detect Novel COVID-19 in Five Minutes,29979,31-03-2020
Bayer's Nubeqa (darolutamide) Receives the EC's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer,29985,31-03-2020
The US FDA Authorizes the Emergency Use of Antimalarial Drugs to Combat COVID-19,29994,31-03-2020
AstraZeneca's Lokelma Receives CHMP's Recommendation for Approval for Patients with Hyperkalemia on Stable Hemodialysis,30019,31-03-2020
Lilly Signs a Worldwide License and Research Agreement with Sitryx to Develop New Immunometabolic Therapies,30035,31-03-2020
Sorrento and the University of Texas Medical Branch Collaborate for the Preclinical Testing of COVID-19 Therapeutic Candidates,30046,01-04-2020
Amgen Provides Update on its Clinical Activities and Medicine Supply Amid COVID-19 Pandemic,30055,01-04-2020
VIVUS Expedites the Launch of Telemedicine and Remote Monitoring Modules for Effective Patient Care During COVID-19,30064,01-04-2020
Amgen Repurchases Astellas' Stakes in Amgen Astellas JV to Strengthen its Footprints in Japan,30081,01-04-2020
Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for Gene Therapy Manufacturing Technology,30087,01-04-2020
QIAGEN's QIAstat-Dx Test Kit Receives the US FDA's EUA as the First Syndromic Test to Detect COVID-19,30097,01-04-2020
BD and BioMedomics Launch Rapid Serology Test to Detect Exposure to COVID-19 in 15 Minutes,30106,01-04-2020
Three Global Pharmaceutical Companies Launch Worker Volunteer Programs to Combat COVID-19,30118,02-04-2020
Y-mAbs Reports the Submission of Naxitamab's BLA to the US FDA for Relapsed/Refractory High-Risk Neuroblastoma,30129,02-04-2020
FDA Launches Emergency Program to Expedite the Development of COVID-19 Treatments,30142,02-04-2020
Gilead Initiates Two P-III Studies Evaluating Remdesivir (GS-5734) for COVID-19 in the UK,30160,02-04-2020
Merck &amp; Co. Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 Study for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer,30172,02-04-2020
Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19,30185,02-04-2020
"Pfizer's Ruxience (biosimilar, rituximab) Receives EC's Approval for Cancer Indications and Autoimmune Diseases",30208,03-04-2020
Celularity's New Cell Therapy Receives the US FDA's IND Approval for COVID-19,30220,03-04-2020
Amgen and Adaptive Biotechnologies Collaborate to Develop Therapies Targeting COVID-19,30225,03-04-2020
Novartis and Incyte Intend to Initiate the P-III RUXCOVID Study of Jakavi (ruxolitinib) as a Treatment for Patients with COVID-19 Associated Cytokine Storm,30234,03-04-2020
Celltrion Enters the Next Phase of Development for its Antiviral Therapy to Combat COVID-19 Pandemic,30244,03-04-2020
Sorrento Initiates the Next Phase of its Collaboration with Celularity,30258,03-04-2020
GSK Collaborates with Innovax to Evaluate a Vaccine Against COVID-19 Pandemic,30280,06-04-2020
EMA's CHMP Recommends Compassionate Use of Gilead's Remdesivir for COVID-19,30291,06-04-2020
Janssen Signs a Worldwide Collaboration with Fate Therapeutics for Novel iPSC-Derived Cell-Based Cancer Immunotherapies,30301,06-04-2020
Gilead Sciences and Second Genome Signs a Four-Year Collaboration to Identify Biomarkers and Therapies Targeting Inflammatory Bowel Disease,30306,06-04-2020
Takeda Signs a Multi-Year Research Collaboration with Evotec to Expedite Research Program Across its Core Therapeutic Areas,30329,06-04-2020
Sanofi and Regeneron Finalizes the Restructuring of Their Collaboration on Praluent (alirocumab),30351,07-04-2020
Alnylam and Dicerna Collaborate to Develop and Commercialize RNAi Therapeutics for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease,30361,07-04-2020
GSK Collaborates with Vir to Develop Treatment for COVID-19,30368,07-04-2020
Takeda's Alunbrig (brigatinib) Receives EC's Approval as a 1L Treatment for ALK+ Advanced Non-Small Cell Lung Cancer,30400,07-04-2020
CytoDyn Collaborates with UK's Department of Health to Provide Emergency Access to Leronlimab (PRO 140) for Patients with COVID-19,30411,07-04-2020
Merck Receives the US FDA's Priority Review for Keytruda's (pembrolizumab) sBLA Based on Biomarker Regardless of Tumor Type,30426,07-04-2020
The US FDA Delays its Decision on Roche's Risdiplam for the Treatment of Spinal Muscular Atrophy,30439,08-04-2020
Oxford Biomedica Joins Consortium to Develop ChAdOx1 nCov-19 for COVID-19,30448,08-04-2020
BMS Expands its Existing Patient Support Programs to Aid Uninsured Patients in the US Amid COVID-19,30471,08-04-2020
Bayer Launches Eylea (aflibercept) Pre-Filled Syringe in Europe,30484,08-04-2020
Zai Lab Signs a Development and Commercialization Agreement with Regeneron for REGN1979 in Oncology,30499,08-04-2020
The US FDA will Approve a New Pathway for Biosimilars,30505,23-03-2020
Biocad with its Partner ICM Received the Registration Certificate for two of its Biosimilar in EU,30506,30-03-2020
Roche Signs a License Agreement with Arrakis Therapeutics for the Discovery of RNA-Targeted Small Molecule Therapies,30538,08-04-2020
AstraZeneca Focuses on the Discovery of Monoclonal Antibodies Neutralizing SARS-CoV-2 Virus,30549,09-04-2020
Chugai Initiates P-III Clinical Study of Actemra for COVID-19 Pneumonia in Japan,30580,09-04-2020
Novavax Accelerates the Initiation of Clinical Study for NVX-CoV2373 to Mid-May 2020,30586,09-04-2020
The US FDA to Waive Interchangeability Standard for Insulin Biosimilars,30596,09-04-2020
EMD Serono and Pfizer's Bavencio (avelumab) Receive the US FDA's Breakthrough Therapy Designation as 1L Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,30609,09-04-2020
Global Pharmaceuticals and the University of Cambridge Collaborate to Launch a Laboratory for COVID-19 Testing,30620,09-04-2020
Pfizer and BioNTech Provide Updates on its Collaboration for Global COVID-19 Vaccine,30633,09-04-2020
Astellas Reports NMPA's Acceptance of NDA for XOSPATA (gilteritinib) to Treat R/R AML with a FLT3 Mutation in Adults,30646,10-04-2020
BMS Signs a Clinical Trial Collaboration with NeoImmune to Evaluate Opdivo (nivolumab) in Combination with NT-I7 (Hyleukin-7),30655,10-04-2020
Cipla Receives FDA's ANDA Approval for its HFA Inhalation Aerosol to Treat Acute Episodes of Bronchospasm or to Prevent Asthmatic Symptoms,30664,10-04-2020
Abbott's TriClip Transcatheter Tricuspid Valve Repair System Receives the CE Mark for Minimally Invasive Tricuspid Valve Repair,30673,10-04-2020
Samsung Biologics Signs an Agreement with Vir Biotechnology to Develop Abs for COVID-19,30679,10-04-2020
Amgen Signs a Partnership with Adaptive Biotechnologies to Develop Abs for COVID-19,30691,10-04-2020
Revance and Mylan Provide Updates on Development BOTOX (onabotulinumtoxinA) Biosimilar,30701,30-03-2020
Apple and Google Collaborate on Contact Tracing Technology to Combat COVID-19,30737,13-04-2020
Eli Lilly Signs a Clinical Trial Collaboration with NIH to Evaluate Baricitinib Against COVID-19,30744,13-04-2020
Terumo BCT and Marker Therapeutics Receive the US FDA's Emergency Use Authorization for their Purification Device to Treat COVID-19,30753,13-04-2020
AstraZeneca and MSD's Koselugo (selumetinib) Receives the US FDA's Approval as the First Therapy for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas,30760,13-04-2020
"Bausch Health to Initiate Clinical Study Evaluating Virazole (Ribavirin for Inhalation Solution, USP) in Patients with COVID-19 in Canada",30780,13-04-2020
Blackstone and Alnylam Enter into a Collaboration to Accelerate the Advancement of RNAi Therapeutics,30812,14-04-2020
"Biocon and Mylan Launch Fulphila (biosimilar, Pegfilgrastim) in Australia",30821,14-04-2020
Celltrion Anticipates the Initiation of its First-in-Human Clinical Studies Targeting COVID-19 in July,30833,14-04-2020
BD Receives Second FDA's Emergency Use Authorization for its New Molecular Diagnostic Test to Detect COVID-19,30840,14-04-2020
Sanofi and GSK Collaborate to Develop Adjuvanted COVID-19 Vaccine,30852,14-04-2020
B. Braun Receives the US FDA's EUA for the Use of Infusion Pumps with Nebulizers to Treat COVID-19,30868,14-04-2020
Alnylam's Vutrisiran Receives the US FDA's Fast Track Designation to Treat Polyneuropathy of hATTR Amyloidosis,30886,14-04-2020
AstraZeneca Initiates CALAVI Study Evaluating Calquence (acalabrutinib) Against COVID-19,30897,15-04-2020
Boehringer Ingelheim Collaborates with Insilico on AI-Based Drug Discovery,30907,15-04-2020
Sosei Heptares to Utilize its Structure-Based Drug Design Expertise in New COVID-19 R&amp;D Program,30912,15-04-2020
"Merck Launches Ontruzant (biosimilar, trastuzumab) in the US",30919,15-04-2020
Ortho Clinical Diagnostics' Total Antibody Test Receives the US FDA's Emergency Use Authorization for COVID-19,30927,15-04-2020
Abbott Launches its Third Test to Detect COVID-19,30934,15-04-2020
GE Healthcare and Microsoft Exploit Remote Patient Data Monitoring Technology to Support Clinicians for the Treatment of COVID-19,30944,16-04-2020
Vanda Signs a Collaboration with UW Medicine to Initiate CALYPSO Program for Evaluating the Role of Genetic Variation in COVID-19,30959,16-04-2020
QIAGEN Launches Therascreen BRAF Test as CDx to a BraftovI Regimen for Metastatic Colorectal Cancer,30968,16-04-2020
Novavax Signs a Clinical Trial Agreement with Nucleus Network to Initiate the Clinical Study Evaluating NVX-CoV2373 Against COVID-19,30976,16-04-2020
Dynavax Signs an Agreement with Sinovac to Develop a Vaccine for COVID-19,30985,16-04-2020
Regeneron Reports the US FDA's Acceptance of Priority Review for REGN-EB3's BLA to Treat Ebola,30997,16-04-2020
Sanofi and Luminostics Collaborate to Develop Smartphone-Based Self-Testing Solution for COVID-19,31044,17-04-2020
Roche Develops Elecsys Anti-SARS-CoV-2 Serology Test to Detect Ab Against COVID-19,31058,17-04-2020
BARDA Grants ~ $483M to Moderna for Accelerating the Development of mRNA-1273 Against COVID-19,31079,17-04-2020
Chi-Med's Surufatinib Receives the US FDA's Fast Track Designations for Pancreatic and Non-Pancreatic Neuroendocrine Tumors,31125,17-04-2020
1Health.io Launches Self-Collection Kits to Detect COVID-19,31165,17-04-2020
Sinovac Initiates the P-I Clinical Study for Vaccine Candidate Against COVID-19,31182,17-04-2020
Novartis Signs an Agreement with the US FDA to Evaluate Hydroxychloroquine in Patients with COVID-19,31229,20-04-2020
Roche Reports the FDA and EMA's Acceptance of sBLA for Ocrevus Shorter 2-Hour Infusion Time,31240,20-04-2020
Incyte Initiates P-III RUXCOVID Study Evaluating Jakafi (ruxolitinib) to Treat Patients with COVID-19 Associated Cytokine Storm,31246,20-04-2020
Fosun Pharma Receives the US FDA's EUA for its COVID-19 RT-PCR Detection Kit,31278,20-04-2020
Otsuka Signs a Development and Commercialization Agreement with Esperion for Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Japan,31295,20-07-2020
Alexion to Initiate P-III Study of Ultomiris (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19,31303,20-04-2020
"RedHill Biopharma Collaborates with NIAID to Investigate RHB-107 (upamostat, WX-671) Against COVID-19",31347,21-04-2020
Cue Biopharma Signs Clinical Trial Collaboration with Merck to Evaluate CUE-101 + Keytruda (pembrolizumab) as 1L Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer,31355,21-04-2020
Roche's cobas HPV Test Receives the US FDA's Approval for cobas 6800/8800 System to Identify Women at Risk for Cervical Cancer,31362,21-04-2020
Noxopharm Anticipates the US FDA's Approval for Evaluating Veyonda in a Clinical Study for COVID-19,31369,21-04-2020
Sangamo Signs an Exclusive License Agreement with Mogrify for iPSC and ESC-Derived Regulatory T-Cells,31378,21-04-2020
Novartis Reports Results of Mayzent (siponimod) in P-III EXPAND Study for Secondary Progressive Multiple Sclerosis,31397,21-04-2020
Bayer Collaborates with the Population Health Research Institute to Identify Treatment for COVID-19,31421,22-04-2020
Gilead and Kite Sign a Three Years Agreement with oNKo-innate to Discover Cancer Immunotherapies,31431,22-04-2020
Novartis' Kymriah (tisagenlecleucel) Receives the US FDA's Regenerative Medicine Advanced Therapy Designation for Follicular Lymphoma,31440,22-04-2020
Hope Biosciences Reports its Third US FDA's Approval for Clinical Trial in COVID-19,31446,22-04-2020
Pfizer and BioNTech to Commence Clinical Study for COVID-19 in Germany,31475,22-04-2020
Sobi's Affiliate Florio GmbH Launches a Digital Platform to Improve the Lives of Patients with Hemophilia,31491,22-04-2020
Valneva and Dynavax Collaborate to Advance the Development of Vaccine Against COVID-19,31505,23-04-2020
The European Commission Approves the Merger of Mylan and Upjohn with Conditions,31514,23-04-2020
AstraZeneca and Saint Luke's Mid America Heart Institute to Initiate P-III DARE-19 Evaluating Farxiga Against COVID-19,31523,23-04-2020
LabCorp Receives the US FDA's Emergency Use Authorization for its COVID-19 At-Home Test Kit,31531,23-04-2020
Mobidiag Receives Emergency Use Authorization for its Automated COVID-19 Test in Finland,31539,23-04-2020
Theravance Reports First Patient Dosing in P-I Study with TD-0903 to Treat Patients with Acute Lung Injury Associated with COVID-19,31573,23-04-2020
Janssen Collaborates with Emergent BioSolutions to Accelerate the Manufacturing of its Vaccine Against COVID-19,31630,24-04-2020
Merck &amp; Co. Reports the Resubmission of sBLA to the US FDA for Keytruda (pembrolizumab) Six-Week Dosing Schedule,31645,24-04-2020
AstraZeneca and MSD Report Results of Lynparza in P-III PROfound Study for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer,31653,24-04-2020
Takeda to Divest Select OTC and Non-Core Assets in Europe to Orifarm for $670M,31665,24-04-2020
Sanofi Receives the US FDA's Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine,31687,24-04-2020
Santhera Signs a Clinical Trial Agreement with Cold Spring Harbor Laboratory to Evaluate Lonodelestat (POL6014) Against Acute Respiratory Distress Syndrome Associated with COVID-19,31803,27-04-2020
Janssen Reports Submission of Two sBLA to the US FDA for SIMPONI ARIA (golimumab) to Treat Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis,31831,27-04-2020
Chugai Reports Results of P-III SAkuraStar Study of Satralizumab for Neuromyelitis Optica Spectrum Disorder,31841,27-04-2020
Regeneron and Sanofi Provide Update of P-II/III Adaptive-Designed Trial of Kevzara in Hospitalized Patients with COVID-19 in the US,31855,27-04-2020
Capital Health Launches Antibody Testing Initiative for COVID-19,31862,27-04-2020
Merck Collaborates with ISB to Evaluate the Mechanism of COVID-19 and to Identify Potential Prognostic Biomarkers,31876,28-04-2020
Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy,31899,28-04-2020
CEPI Collaborates with Clover to Support the Development of Vaccine Against COVID-19 in Australia ,31919,28-04-2020
Takeda's Mobocertinib (TAK-788) Receives the US FDA's Breakthrough Therapy Designation for NSCLC Patients with EGFR Exon 20 Insertion Mutations,31928,28-04-2020
Abbott's Freestyle Libre System Receives Health Canada Authorization Under Interim Order for Hospitalized Patients During COVID-19,31949,28-04-2020
Moderna to Initiate P-II Study of mRNA-1273 Against Novel COVID-19,31956,28-04-2020
"Biocon and Mylan Launch Fulphila (biosimilar, pegfilgrastim) in Canada",31970,28-04-2020
Sarepta Signs a Research Agreement with the US Department of Defense to Identify Antisense Oligonucleotides Against COVID-19,31981,29-04-2020
Novartis' Cosentyx (secukinumab) Receives EC's Approval for Axial Spondyloarthritis Spectrum Marking its Fourth Indication in EU,32007,29-04-2020
BioNTech and Pfizer Complete Dosing of BNT162 in First Cohort of P-I/II Study in Germany,32018,29-04-2020
Astellas Signs a Three-Year Research Alliance with Harvard University Across Multiple Therapeutic Areas,32026,29-04-2020
Novartis Plans to Commence P-III Clinical Study Evaluating Canakinumab for Patients with COVID-19 Pneumonia,32033,29-04-2020
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Indications,32036,29-04-2020
Johnson &amp; Johnson Signs a Manufacturing Agreement with the Catalent to Bolster the Capacity of COVID-19 Vaccine in the US,32059,30-04-2020
Gilead Reports Results of Remdesivir in P-III SIMPLE Studies for Patients with Severe COVID-19,32066,30-04-2020
AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19,32078,30-04-2020
GSK's Zejula (niraparib) Receives the US FDA's Approval as 1L Monotherapy Maintenance Treatment for Women with Advanced Ovarian Cancer Regardless of Biomarker Status,32103,30-04-2020
Curium's Pulmotech MAA Receives the US FDA's Approval for Lung Imaging,32110,24-03-2020
Bergenbio's Bemcentinib Selected to be Fast-Tracked Under UK's ACCORD Program Targeting COVID-19,32134,30-04-2020
Rockwell's Triferic AVNU Receives the US FDA's Approval to Replace Iron and Maintain Hemoglobin Hemodialysis Patients,32135,27-03-2020
MSD Signs a Two-Year Research Agreement with Almac to Discover DUB Therapeutic Targets for Neurodegenerative Diseases,32145,30-04-2020
Pfizer Signs a Development and Commercialization Agreement with Valneva for Lyme Disease Vaccine,32177,01-05-2020
Moderna Signs a Ten-Year Worldwide Agreement with Lonza to Manufacture mRNA-1273 Against COVID-19,32186,01-05-2020
"Novartis' Enerzair Breezhaler (QVM149, IND/GLY/MF) Receives CHMP's Recommendation for Approval as a Treatment for Uncontrolled Asthma",32228,01-05-2020
WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis,32277,01-05-2020
Gilead's Remdesivir Receives the US FDA's Emergency Use Authorization for the Treatment of COVID-19,32395,04-05-2020
"Revance and Mylan to Extend Biosimilar to BOTOX Program Decision Beyond April 30, 2020",32405,04-05-2020
MHLW Expedites the Reviews of Gilead's Remdesivir to Treat Patients with COVID-19 in Japan,32413,04-05-2020
Roche Receives FDA's Emergency Use Authorization for its Elecsys to Detect COVID-19,32456,04-05-2020
"Teva and Celltrion Launch Truxima (biosimilar, rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US",32482,05-05-2020
Lilly and Junshi Collaborate to Co-Develop Antibody Therapies for the Treatment of COVID-19,32490,05-05-2020
Vir and Alnylam Anticipate the Initiation of Clinical Study Assessing VIR-2703 By the Year End,32498,05-05-2020
Alexion to Acquire Portola for ~$1.41B,32518,05-05-2020
Bio-Rad Receives the US FDA's Emergency Use Authorization for its Droplet Digital PCR Test Kit to Detect COVID-19,32532,05-05-2020
Pfizer and BioNTech Report First Patient Dosing with BNT162 in P-I/II Study for COVID-19 in the US,32544,06-05-2020
NeoGenomics Collaborates with Bayer to Provide NTRK Testing for Patients with Colorectal and Thyroid Cancer,32555,06-05-2020
Regeneron Anticipates the Initiation of Clinical Study for its COVID-19 Antibody Cocktail in June,32578,06-05-2020
Bavarian Nordic Collaborates with AdaptVac to Advance COVID-19 Vaccine Program,32590,06-05-2020
Sanofi and Regeneron Report Results of Libtayo (cemiplimab) in a P-II Study as 2L Treatment for Advanced Basal Cell Carcinoma,32597,06-05-2020
iBio Supports AzarGen's Development of a Biosimilar to Rituximab,32605,26-03-2020
PTC Therapeutics to Acquire Censa Pharmaceuticals to Bolster its Rare Disease Portfolio,32612,07-05-2020
"Novartis and Incyte's Tabrecta (capmatinib, INC280) Receives the US FDA's Approval for Metastatic Non-Small Cell Lung Cancer with METex14",32622,07-05-2020
"Bausch + Lomb Signs an Exclusive License Agreement with STADA and Xbrane for Xlucane (biosimilar, ranibizumab) in the US and Canada",32643,07-05-2020
Amgen Reports Results of Otezla (apremilast) in P-III ADVANCE Study for Mild-To-Moderate Plaque Psoriasis,32652,07-05-2020
Laurent Receives Health Canada's Approval to Initiate P-II RESOLUTION Study Evaluating LAU-7b for COVID-19,32662,07-05-2020
Gedeon Richter Signs an Asset Purchase Agreement with Mycenax for Biosimilar Tocilizumab to Treat Rheumatoid Arthritis,32666,29-04-2020
Henlius HLX02 (Trastuzumab for Injection) Receives EU GMP Certificates,32680,23-04-2020
"Henlius Receives NMPA's IND Approval for its HLX13 (biosimilar, ipilimumab)",32685,08-04-2020
"Xbrane Biopharma Reports Update on the Ongoing P-III Xplore Study of Xlucane (biosimilar, ranibizumab)",32690,02-04-2020
Gilead's Veklury (remdesivir) Receives MHLW's Approval for Patients with Severe COVID-19 in Japan,32700,08-05-2020
Sanofi's Insulin Aspart Biosimilar Receives CHMP's Positive Recommendation for Approval in the EU,32708,30-04-2020
Moderna Anticipates the Initiation of P-III Study of mRNA-1273 for COVID-19 by Early Summer,32723,08-05-2020
CoVIg-19 Plasma Alliance to Initiate Clinical Study Evaluating Hyperimmune Therapy for COVID-19 by Summer 2020,32740,08-05-2020
GSK to Evaluate Otilimab for Treating Pulmonary Disease Associated with COVID-19,32787,08-05-2020
"Celltrion Launches Remsima SC (biosimilar, infliximab) for the Treatment of Autoimmune Diseases in the Netherlands",32799,08-05-2020
Fitbit Launches Heart Study to Validate its Wearable Technology for Identifying Atrial Fibrillation,32810,08-05-2020
AstraZeneca Terminates Their License Agreement with Allergan for Brazikumab Signed in 2016,32830,11-05-2020
Sorrento Collaborates with Mount Sinai Health System to Develop COVI-SHIELD Antibody Cocktail Targeting COVID-19,32837,11-05-2020
Regeneron's RGC Signs a Research Collaboration with Colorado Center to Advance the Drug Discovery for Personalized Medicine,32845,11-05-2020
Eli Lilly's Retevmo (selpercatinib) Receives the US FDA's Approval as the First Therapy to Treat Advanced RET-Driven Lung and Thyroid Cancers,32854,11-05-2020
Sanofi Reports Results of Sarclisa (isatuximab) in P-III IKEMA trial in Patients with Relapsed Multiple Myeloma,32871,12-05-2020
Neurocrine Biosciences Exercises its Option with Idorsia for ACT-709478,32880,12-05-2020
PharmaMar Signs an Exclusive License Agreement with MegaPharm for Lurbinectedin,32889,12-05-2020
Novartis Signs an Agreement with Dyno to Develop Novel AVV Therapies Utilizing AI Technology for Ocular Diseases,32905,12-05-2020
Abbott Receives FDA's Emergency Use Authorization for its Fourth Ab Blood Test to Detect COVID-19,32915,12-05-2020
GRYT Health and BMS Sign an Agreement to Launch Virtual Platform COVID Advocacy Exchange,32921,12-05-2020
Gilead Collaborates with Generics Makers to Supply Remdesivir in 127 Countries,32945,13-05-2020
Moderna's mRNA-1273 Receives the US FDA's Fast Track Designation to Treat COVID-19,32976,13-05-2020
Alvotech Reports Results of AVT02 (a proposed biosimilar to adalimumab) in Two Clinical Studies for Autoimmune Diseases,32986,13-05-2020
Skyhawk Therapeutics Expands its Agreement with Merck to Develop Novel Small Molecules Modulating RNA Splicing,32998,13-05-2020
LifeScan Collaborates with Noom to Launch Digital Diabetes and Weight Loss Management Program,33008,13-05-2020
"BMS and bluebird bio to Resubmit the BLA for Idecabtagene Vicleucel (ide-cel, bb2121) to Treat Patients with Multiple Myeloma",33018,14-05-2020
Sanofi's Sutimlimab Receives the US FDA's Priority Review to Treat Hemolysis Patients with Cold Agglutinin Disease,33024,14-05-2020